

10-24-00

A



MPG-8



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE


Applicants : Luis Angel Pardo-Fernández, et al.
For : NOVEL HUMAN K⁺ ION CHANNEL AND THERAPEUTIC
APPLICATIONS THEREOF

EXPRESS MAIL CERTIFICATION

"Express Mail" mailing label number EK170574511US

Date of Deposit October 23, 2000

I hereby certify that this transmittal letter and the other papers and fees identified in this transmittal letter as being transmitted herewith are being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and are addressed to the Hon. Assistant Commissioner for Patents, Washington, D.C. 20231.




CLARE J. SANTO

Hon. Assistant Commissioner
for Patents
Washington, D.C. 20231

TRANSMITTAL LETTER FOR RULE 53(b)
CONTINUING PATENT APPLICATION

Sir:

This is a request for filing a continuation application of pending international application PCT/EP99/02695, filed April 21, 1999, which designated the United States.



Transmitted herewith for filing are the following: [X] specification (51 pages); [X] claims (32); [X] abstract; [X] unexecuted Declaration and Power of Attorney; [X] Preliminary Amendment; [X] Statement Under 37 C.F.R. §§ 1.97 and 1.56; [X] Form PTO-1449 and documents cited therein; [X] Sequence Listing (pages 1 - 13); for the above-identified patent application.

[X] The enclosed declaration is:

Unexecuted.

[X] Also transmitted herewith are:

37 sheets of:

Informal drawings. Formal drawings will be filed during the pendency of this application.

The filing fee has been calculated as shown below for a small entity*:

FOR	NUMBER FILED	NUMBER EXTRA	RATE	FEE
BASIC FEE				\$355.00
TOTAL CLAIMS	50	- 20 = 30	x \$9	= \$270.00
INDEPENDENT CLAIMS	1	- 3 = 0	x \$40	= \$0
A MULTIPLE DEPENDENT CLAIM			+ \$135	= \$135.00
TOTAL				<u>\$760.00</u>

* Fee calculation based on claims pending after Preliminary Amendment.

[X] This application is being filed unaccompanied by a filing fee. The appropriate filing fee will be paid in response to a Notice to File Missing Parts, pursuant to 37 C.F.R. § 1.53(f).

- [X] The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. § 1.16 in connection with the paper(s) transmitted herewith, or credit any overpayment of same, to Deposit Account No. 06-1075. A duplicate copy of this transmittal letter is transmitted herewith.

JC841 U.S. PRO
09/694777
10/23/00

Respectfully submitted,



Jane A. Massaro (Reg. No. 34,218)
Attorney for Applicants
Elinor K. Shin (Reg. No. 43,117)
Agent for Applicants
c/o Fish & Neave (Customer No. 1473)
1251 Avenue of the Americas
New York, New York 10020-1104
Tel.: (212) 596-9000
Fax.: (212) 596-9090

**STATEMENT CLAIMING SMALL ENTITY STATUS
(37 CFR 1.9(f) & 1.27(d))--NONPROFIT ORGANIZATION**

Docket No. MPG-8

Applicant, Patentee, or Identifier: PARDO-FERNÁNDEZ, Luis Angel et al.
Application No.:
Application Filed:
International Application No.: PCT/EP99/02695
International Filing Date: 21 April 1999
Title: Novel human K⁺ ion channel and therapeutic applications thereof

I hereby state that I am an official empowered to act on behalf of the nonprofit organization identified below:

NAME OF NONPROFIT ORGANIZATION: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.
ADDRESS OF NONPROFIT ORGANIZATION: Berlin, Germany

TYPE OF NONPROFIT ORGANIZATION:

- ☐ UNIVERSITY OR OTHER INSTITUTION OF HIGHER EDUCATION
☐ TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3))
☐ NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)
☒ WOULD QUALIFY AS TAX EXEMPT UNDER INTERNAL REVENUE SERVICE CODE (26 U.S.C. 501(a) and 501(c)(3))
IF LOCATED IN THE UNITED STATES OF AMERICA
☐ WOULD QUALIFY AS NONPROFIT SCIENTIFIC OR EDUCATIONAL UNDER STATUTE OF STATE OF THE UNITED
STATES OF AMERICA IF LOCATED IN THE UNITED STATES OF AMERICA
(NAME OF STATE _____)
(CITATION OF STATUTE _____)

I hereby state that the nonprofit organization identified above qualifies as a nonprofit organization as defined in 37 CFR 1.9(e) for purposes of paying reduced fees to the United States Patent and Trademark Office regarding the invention described in:

- ☒ the specification filed herewith with title as listed above.
☐ the application identified above.
☐ the patent identified above.

I hereby state that rights under contract or law have been conveyed to and remain with the nonprofit organization regarding the above identified invention. If the rights held by the nonprofit organization are not exclusive, each individual, concern, or organization having rights in the invention must file separate statements as to their status as small entities and that no rights to the invention are held by any person, other than the inventor, who would not qualify as an independent inventor under 37CFR 1.9(c) if that person made the invention, or by any concern which would not qualify as a small business concern under 37 CFR 1.9(d) or a nonprofit organization under 37 CFR 1.9(e).

Each person, concern, or organization having any rights in the invention is listed below:

- ☒ no such person, concern, or organization exists.
☐ each such person, concern, or organization is listed below.

I acknowledge the duty to file, in this application or patent, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of the issue fee or any maintenance fee due after the date on which status as a small entity is no longer appropriate. (37 CFR 1.28(b))

NAME OF PERSON SIGNING Christa Herzog
TITLE IN ORGANIZATION OF PERSON SIGNING Head of patent department
ADDRESS OF PERSON SIGNING: Hofgartenstr, 8, 80539 München

SIGNATURE Christa Herzog DATE 6.9.2000
Christa Herzog
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

EXPRESS MAIL
EK170574511US

INVENTOR INFORMATION

Inventor One Given Name:: Luis A
Family Name:: Pardo-Fernandez
Postal Address Line One:: Dustere-Eichen-Weg 14a
City:: Gottingen
Country:: Germany
Postal or Zip Code:: 37073
Citizenship Country:: Spain
Inventor Two Given Name:: Walter
Family Name:: Stuhmer
Postal Address Line One:: Stiegbreite 13
City:: Gottingen
Country:: Germany
Postal or Zip Code:: 37077
Citizenship Country:: Germany
Inventor Three Given Name:: Synnove
Family Name:: Beckh
Postal Address Line One:: Steigbreite 13
City:: Gottingen
Country:: Germany
Postal or Zip Code:: 37077
Citizenship Country:: Germany
Inventor Four Given Name:: Andrea
Family Name:: Bruggemann
Postal Address Line One:: Hoechst-Marion-Roussel, DG Cardiovascular,
Postal Address Line Two:: H821
City:: Frankfurt
Country:: Germany
Postal or Zip Code:: 65926
Citizenship Country:: Germany
Inventor Five Given Name:: Donato Del Camino
Family Name:: Fernandez-Miranda
Postal Address Line One:: Neurobiology Department
Postal Address Line Two:: Harvard Medical School
City:: Boston
State or Province:: Massachusetts
Country:: USA
Postal or Zip Code:: 02115
Citizenship Country:: Spain
Inventor Six Given Name:: Araceli S
Family Name:: Perez
Postal Address Line One:: Dustere-Eichen-Weg 14a
City:: Gottingen
Country:: Germany
Postal or Zip Code:: 37073
Citizenship Country:: Spain
Inventor Seven Given Name:: Rudiger
Family Name:: Weseloh
Postal Address Line One:: Immanuel-Kant-Strasse 32

City:: Gottingen
Country:: Germany
Postal or Zip Code:: 37083
Citizenship Country:: Germany

CORRESPONDENCE INFORMATION

Correspondence Customer Number:: 1473
Fax One:: 212.596.9090
Electronic Mail One:: JMassaro@fishneave.com
Fax Two:: 212.596.9090
Electronic Mail Two:: EShin@fishneave.com

APPLICATION INFORMATION

Title Line One:: NOVEL HUMAN K+ ION CHANNEL AND THERAPEUT
Title Line Two:: IC APPLICATIONS THEREOF
Total Drawing Sheets:: 37
Formal Drawings?:: No
Application Type:: Utility
Docket Number:: MPG-8
Secrecy Order in Parent Appl.?:: No

REPRESENTATIVE INFORMATION

Representative Customer Number:: 1473
Registration Number One:: 34218
Registration Number Two:: 4117

CONTINUITY INFORMATION

This application is a:: CONTINUATION OF
> Application One:: PCT/EP99/02695
Filing Date:: 04-21-1999

PRIOR FOREIGN APPLICATIONS

Foreign Application One:: EP 98 10 7268.9
Filing Date:: 04-21-1998
Country:: EPO
Priority Claimed:: Yes

Source:: PrintEFS Version 1.0.1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : Not yet assigned
Group : Not yet assigned
Applicants : Luis Angel Pardo-Fernández, et al.
Serial No. : Not yet assigned
Filed : Concurrently herewith
For : NOVEL HUMAN K⁺ ION CHANNEL AND THERAPEUTIC
APPLICATIONS THEREOF

New York, New York
October 23, 2000

Honorable Assistant Commissioner for Patents
Washington, D.C. 20231

PRELIMINARY AMENDMENT

Prior to the issuance of the first Office Action on the merits, amend the application
as follows:

IN THE SPECIFICATION

Under the title of the application, add

- - This application is a continuation of copending international application

PCT/EP99/02695, which designated the United States. - - .

EXPRESS MAIL
EK170574511US

IN THE CLAIMS

Under the title heading "Claims," add the words - - We claim: - - .

Amend claims 1, as follows:

1. (Amended) A nucleic acid molecule comprising a nucleic acid [molecule] sequence encoding a (poly)peptide having a function of the human K⁺ ion eag [channel which is] channel, wherein the nucleic acid sequence is selected from the group consisting of:

- (a) a nucleic acid [molecule] sequence comprising a nucleic acid molecule encoding the polypeptide having the amino acid sequence [of SEQ ID: No] SEQ ID NO:3 or SEQ ID NO:4;
- (b) [a nucleic acid molecule comprising the nucleic acid molecule having the DNA sequence of SEQ ID: No] the nucleic acid sequence SEQ ID NO:13 or SEQ ID NO:14;
- (c) a nucleic acid [molecule hybridizing] sequence that hybridizes to the complementary strand of a nucleic acid molecule of (a) or (b); [or] and
- (d) a nucleic acid molecule being degenerate to the sequence of the nucleic acid molecule of (c).

2. (Amended) [A] The nucleic acid molecule that specifically [hybridizing] hybridizes to the nucleic acid molecule of claim 1 [which] and comprises the nucleic acid sequence 5'-GGGAGGATGACCATGGCT-3'.

3. (Amended) The nucleic acid molecule of claim 1 or [2 which] 2, wherein the nucleic acid molecule is DNA.

4. (Amended) The nucleic acid molecule of claim 1 or [2 which] 2, wherein the nucleic acid molecule is RNA.

5. (Amended) The nucleic acid molecule of [any one of claims 1 to 4 encoding] claim1 or claim 2, wherein the nucleic acid sequence encodes a fusion protein.

6. (Amended) A vector comprising the nucleic acid molecule of [any one of claims 1 to 5] claim 1 or claim 2.

7. (Amended) The vector of [claim 6 which is] claim 6, wherein the vector is selected from the group consisting of an expression [vector and/or] vector, a gene targeting vector [or] and a gene transfer vector.

8. (Amended) A host transformed with [a] the vector of claim 6 [or 7].

9. (Amended) The host of [claim 8 which is] claim 8, wherein the host is selected from the group consisting of a mammalian cell, a fungal cell, a plant cell, an insect cell [or] and a bacterial cell.

10. (Amended) A method of producing the (poly)peptide encoded by the nucleic acid molecule of [any one of claims] claim 1 [or 3 to 5] comprising the steps of culturing the host [of claim 8 or 9] comprising said nucleic acid molecule and isolating the produced (poly)peptide.

11. (Amended) A (poly)peptide encoded by the nucleic acid of [any one of claims 1 or 3 to 5 or produced by the method of claim 10] claim 1.

In claim 12, delete "to," and substitute therefor - - against - -.

13. (Amended) The antibody of [claim 12 which] claim 12, wherein the antibody is a monoclonal antibody.

14. (Amended) A [pharmaceutical] composition comprising the nucleic acid molecule of claim [2, the vector of claim 6, the polypeptide of claim 11] 1 or claim 2, a vector nucleic acid molecule, a polypeptide encoded by said nucleic acid molecule, and/or the antibody [of claim 12 or 13 and] specifically directed against said polypeptide, wherein the composition additionally comprises a pharmaceutically acceptable carrier and/or diluent and/or excipient.

15. (Amended) A diagnostic composition comprising the nucleic acid molecule of [any one of claims 1 to 5, the vector of claim 6, the polypeptide of claim 11 and/or the antibody of claim 12 or 13] claim 1 or claim 2, a vector comprising said nucleic acid molecule, a polypeptide

encoded by said nucleic acid molecule and/or antibody specifically directed against said polypeptide.

16. (Amended) A method for preventing or treating a disease which is caused by the undesired expression or overexpression of the nucleic acid molecule of [any one of claims] claim 1 [or 3 to 5], comprising the step of introducing an inhibitor of the expression of [the] said nucleic acid molecule [of any one of claims 1 or 3 to 5] or an inhibitor of the function of the (poly)peptide [of claim 11] encoded by said nucleic acid molecule into a mammal affected by said disease or being suspected of being susceptible to said disease.

17. (Amended) A method for preventing or treating a disease which is caused by the malfunction of the (poly)peptide [of claim 11 comprising introducing an inhibitor of the expression of] encoded by the nucleic acid molecule of [any one of claims 1 or 3 to 5] claim 1 comprising the step of introducing into a mammal affected by said disease or being suspected of being susceptible to said disease, an inhibitor of the expression of said nucleic acid molecule or an inhibitor or modifying agent of the malfunction of [the] said (poly)peptide [of claim 11] or [the] said nucleic acid molecule [of any one of claims 1 or 3 to 5] encoding heag or [the] said polypeptide [of claim 11] having heag activity [into a mammal affected by said disease or being suspected of being susceptible to said disease].

18. (Amended) The method of claim 16 wherein said inhibitor of the expression or overexpression of said nucleic acid molecule is [a nucleic acid molecule of claim 2] the nucleic

acid molecule according to claim 1 that comprises the nucleic acid sequence 5'-
GGGAGGATGACCATGGCT-3'.

In claim 20, after the phrase "effected into said cells," add the word - - and - -.

31. (Amended) [Use of] A method of gene therapy comprising the step of using
the nucleic acid molecule of any one of claims 1 to 5 [in gene therapy].

32. (Amended) [Kit] A kit comprising the nucleic acid molecule of claim 2, [the
vector of claim 6] a vector comprising the nucleic acid molecule, the polypeptide of claim 11
and/or the antibody of claim 12 or 13.

Add:


33. A (poly)peptide produced by the method of claim 10.

REMARKS

Applicants have amended the claims to improve their form and to remove
improper multiple dependent claims. Applicants have added claim 33. Support for this
amendment may be found, e.g., in claim 11 as originally filed.

No new matter has been added. Entry of the amendments is requested.

Respectfully submitted,



Jane A. Massaro (Reg. No. 34,218)

Attorney for Applicants

Elinor K. Shin (Reg. No. 43,117)

Agent for Applicants

c/o Fish & Neave (Customer No. 1473)

1251 Avenue of the Americas

New York, New York 10020-1104

Tel.: (212) 596-9000

Fax.: (212) 596-9090

Novel human K⁺ ion channel and therapeutic applications thereof

The present invention relates to a novel human K⁺ ion channel, to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to antibodies specifically directed to the novel K⁺ ion channel and to pharmaceutical compositions and diagnostic kits containing at least one of the above-mentioned components. Furthermore, the present invention relates to methods of treating a disease caused by malfunction of the polypeptide of the present invention or by the (over)expression of the nucleic acid molecule of the invention comprising administering an inhibitor of said (over)expression or of ion channel function or an inhibitor abolishing said malfunction to a patient in need thereof. Methods of devising drugs for treating or preventing the above-mentioned disease, methods of inhibiting cell proliferation and methods of prognosing cancer are additional embodiments comprised by the present invention. The invention also envisages specific antisense or gene therapies on the basis of the nucleic acid molecule of the invention for inhibiting undesired cellular proliferation, for example, in connection with cancer or in neurodegenerative diseases.

Potassium channels are a relevant factor in the regulation of the resting potential of cells, and this has been regarded as their major role in excitable and non-excitable tissues. On the other hand, the explanation for their ubiquitous presence and the impressive variability in their properties remains elusive. A reasonable hypothesis is that potassium channels are present in all cell types because they have in addition some "housekeeping" role, for example in cell proliferation¹. Their implication in the regulation of the cell division cycle has been tested repeatedly, and some experimental evidence has been presented^{2,3}. However, especially since both depolarization and hyperpolarization of the membrane potential during cell cycle have been reported as depending on cell type^{1,4}, there is no general model to explain the function of potassium

EXPRESS MAIL
EK170574511US

channels in cell cycle. Two mechanisms have been proposed to explain the role of K^+ channels: they either influence the intracellular Ca^{2+} concentration, or control cell volume (17, 18). Both mechanisms would indirectly influence cell proliferation. A member of the *eag* family has also been proposed to be preferentially expressed in cancer cells (19). Several potassium channel blockers have been tested for their capability to block cancer cell proliferation, and some of them have even been used as coadjuvants for tumor chemotherapy, specially in multidrug-resistant tumors. Nevertheless, the lack of identification of a particular potassium channel directly involved in the control of cell proliferation has, up to date, precluded the description of more specific and effective treatment protocols.

Thus, the technical problem underlying the present invention was to identify a biological component within the conglomerate of potassium channels with their various effects on cell cycle division that allows an unambiguous assignment to cellular proliferation, with a specific view to human cellular proliferation. The solution to said technical problem is achieved by providing the embodiments characterized in the claims.

Accordingly, the present invention relates to a nucleic acid molecule comprising a nucleic acid molecule encoding a (poly)peptide having a function of the human K^+ ion *eag* channel which is

- (a) a nucleic acid molecule comprising a nucleic acid molecule encoding the polypeptide having the amino acid sequence of SEQ ID: No 3 or 4;
- (b) a nucleic acid molecule comprising the nucleic acid molecule having the DNA sequence of SEQ ID: No 13 or 14;
- (c) a nucleic acid molecule hybridizing to the complementary strand of a nucleic acid molecule of (a) or (b); or
- (d) a nucleic acid molecule being degenerate to the sequence of the nucleic acid molecule of (c).

The nucleic acid molecule of the invention encodes a (poly)peptide which is or comprises the human homologues of the rat *eag* channel. In this regard the term "a nucleic acid molecule comprising a nucleic acid molecule encoding a (poly)peptide having a function of the human K^+ ion *eag* channel" may mean that said first mentioned

nucleic acid molecule solely encodes said (poly)peptide. Thus, it may be identical to said second mentioned nucleic acid molecule. Alternatively, it may comprise regulatory regions or other untranslated regions. In a further embodiment, said first mentioned nucleic acid may comprise heterologous nucleic acid which may encode heterologous proteinaceous material thus giving rise, e.g., to fusion proteins. It is further to be noted that the DNA sequences of SEQ ID NO: 13 and 14 are splice variants of the nucleic acid sequence encoding the (poly)peptide of the invention. The corresponding amino acid sequences are depicted in SEQ ID NO: 3 and 4.

The term "having a function of a human K^+ ion *eag* channel", as used in connection with the present invention, has the following meaning: The channel has a single channel conductance in asymmetrical potassium, at 0mV of about 6 pS. This value clearly distinguishes the human channel from the rat channel for which a value of about 7 pS was measured. In addition or in the alternative, the above term may have the following meaning: The channel has a IC₅₀ of about 1mM to quinidine when expressed in *Xenopus laevis* oocytes, as compared to 400μM for *reag*. Further, when measuring voltage-dependence of activation in high extracellular potassium using a two-electrode voltage-clamp it was found that in a conductance-voltage plot, the voltage for half-activation is shifted by about 40mV or more to the right in the *heag* channel with respect to the *reag* channel (see Figure 13). On the basis of the above features, either alone or in combination, a differentiation based on function between the human ion channel of the invention and the prior art channels, in particular of the rat ion channel, is possible for the person skilled in the art without further ado. Preferably, the channel has all recited functions. The above values refer to values that are obtainable with the experimental set-up described in this specification. Alterations of experimental parameters such as the employment of a different expression system may, as is well known to the person skilled in the art, also change the above values. Yet, these embodiments are also comprized by the scope of the present invention.

The term "hybridizing" as used in accordance with the present invention relates to stringent or non-stringent hybridization conditions. Preferably, it relates to stringent

conditions. Said hybridization conditions may be established according to conventional protocols described, for example, in Sambrook, "Molecular Cloning, A Laboratory Manual", Cold Spring Harbor Laboratory (1989) N.Y., Ausubel, "Current Protocols in Molecular Biology", Green Publishing Associates and Wiley Interscience, N.Y. (1989), or Higgins and Hames (eds) "Nucleic acid hybridization, a practical approach" IRL Press Oxford, Washington DC, (1985). Hybridizing molecules or molecules falling under alternative (d), supra, also comprise fragments of the molecules identified in (a) or (b) wherein the nucleotide sequence need not be identical to its counterpart in SEQ ID 13 or 14, said fragments having a function as indicated above.

An example of one such stringent hybridization condition is hybridization at 4XSSC at 65 °C, followed by a washing in 0.1XSSC at 65 °C for one hour. Alternatively, an exemplary stringent hybridization condition is in 50 % formamide, 4XSSC at 42 °C. Examples of such non-stringent hybridization conditions are 4XSSC at 50 °C or hybridization with 30-40 % formamide at 42 °C. Complementary strands of hybridizing molecules comprise those which encode fragments, analogues or derivatives of the polypeptide of the invention and differ, for example, by way of amino acid and/or nucleotide deletion(s), insertion(s), substitution(s), addition(s) and/or recombination(s) or any other modification(s) known in the art either alone or in combination from the above-described amino acid sequences or their underlying nucleotide sequence(s). Using the PESTFIND program (Rogers, Science 234 (1986), 364-368), PEST sequences (rich in proline, glutamic acid, serine, and threonine) can be identified, which are characteristically present in unstable proteins. Such sequences may be removed from the polypeptide of the invention in order to increase the stability and optionally the activity of the proteins. Methods for introducing such modifications in the nucleic acid molecules according to the invention are well-known to the person skilled in the art. The invention also relates to nucleic acid molecules the sequence of which differs from the nucleotide sequence of any of the above-described nucleic acid molecules due to the degeneracy of the genetic code. All such fragments, analogues and derivatives encoding the protein of the invention are included within the scope of the present invention, as long as the essential characteristic immunological and/or biological properties as defined above remain unaffected in kind, that is the novel nucleic acid molecules of the invention include all

nucleotide sequences encoding proteins or peptides which have at least a part of the primary structural conformation for one or more epitopes capable of reacting with antibodies to said polypeptide which are encoded by a nucleic acid molecule as set forth above and which have comparable or identical characteristics in terms of biological activity. Part of the invention is therefore also concerned with nucleic acid molecules encoding a polypeptide comprising at least a functional part of the above identified polypeptide encoded by a nucleic acid sequence comprised in a nucleic acid molecule according to the invention.

The present inventors have recently described a potassium channel (*reag*) which is strongly downregulated immediately after the activation of cyclin dependent kinases (key molecules in the cell cycle regulation), in both G1-S and G2-M transitions⁵. The K⁺ current is inhibited following activation of cyclin-dependent kinases due to a voltage-dependent sodium block, which is not apparent in all phases of the cell cycle. The experiments presented here are aimed to determine whether *eag*, in addition to being regulated by the cell cycle, is also able to directly influence cell proliferation and growth (20). In accordance with the present invention and with a view to the development of a suitable system for assessing (disease-related) proliferation in human cells, it was further attempted to study whether the implication of the channel in the cell cycle goes in both directions, such that it is not only *regulated by* but also *regulator of* the progression of the cell cycle.

The results obtained in this rat derived ion channel system show that in three different cell lines obtained from different species (Chinese hamster -CHO-, human -HEK293-, and mouse -NIH3T3-), the rate of proliferation is faster when the channel is overexpressed after transfection of the cells with a plasmid containing the channel DNA under the control of the cytomegalovirus promoter. Figure 1 and Figure 18a show the increase in metabolic activity in cultures of CHO cells in the presence of normal concentrations of fetal calf serum (10% FCS). Under these normal conditions, *reag* transfected cells grow several folds faster than untransfected cells (WT).

Figure 2 shows a comparable experiment at very low concentrations of fetal calf serum (0.5% FCS). These low serum concentrations do not allow wild-type cells to grow; after a few hours, the cells start to die. However, *reag* transfected cells are able to proliferate under the same conditions. The ability to overcome the growth arrest induced by the absence of growth factors is one of the typical properties of malignant transformation (cf Figure 18).

Not only the metabolic activity can be used to trace the proliferation in culture. The measurement of DNA synthesis is a more direct estimation of the rate of cell growth, since only cells entering S phase (committed to divide) synthesize DNA. Also DNA synthesis becomes serum-independent in *reag* transfected cells, i.e., the growth is maintained in the absence of growth factors (while it induces the programmed death of non-transfected cells). This is depicted in Figure 3, where the incorporation of 5-Bromo-2'-deoxyuridine⁷⁻¹⁰ (BrdU) was used to monitor DNA synthesis in the presence of 10 or 0.5% FCS in CHO cells. As opposed to wild-type or cells transfected with an inactivating voltage-dependent potassium channel from rat brain (Kv1.4), there are no significant differences in the amount of DNA synthesized in the presence of normal or low FCS concentrations in *reag* -expressing cells. Similar experiments were done using epidermal growth factor (EGF) in HEK-293 cells or platelet-derived growth factor (PDGF) in CHO cells, with essentially the same result. The pure growth factors were used to avoid the complexity introduced by the use of whole serum.

To test the effects of *eag* on cell proliferation more directly, DNA synthesis was measured through incorporation of 5-Bromo-deoxyuridine (BrdU) in cells synchronized in the S-phase of the cell cycle by means of thymidine arrest (23). Consistent with the above mentioned findings, when the S-phase of the cell cycle was allowed to proceed, *reag* expressing CHO cells (CHOrEAG) showed higher metabolic activity (Fig 18B) and increased BrdU incorporation (Fig 18C). These results suggest that more *eag*-transfected cells entered the S-phase during the arrested period and/or DNA synthesis was elevated, in any case indicating a faster proliferation rate in CHOrEAG cells. In the presence of low serum, BrdU incorporation was significantly higher in CHOrEAG than in wild type cells (Fig 18C).

Yet another cell line, NIH3T3, has been frequently used for tumor transformation assays, since these cells are very strongly contact-inhibited, (i.e., their growth is stopped when the culture reaches confluency). This results in a homogeneous monolayer in wild-type cells. The malignant transformation of the line (through oncogene expression) usually induces the loss of this property, and NIH3T3 cells start forming colonies composed of several layers of cells. This can be seen after the transfection with *reag* DNA, which induced the formation of such *foci* in several independent clones (Fig. 4A and B). Another standard test for transforming activity is the ability of NIH3T3 cells to grow in colonies when no substrate for attachment is available. To test this, cells are plated in an agar-containing medium, where the agar will prevent contacts between the cells and the surface of the plate. Under these conditions, wild-type NIH3T3 cells were unable to grow, while cells expressing *reag* formed large colonies even detectable by simple visual inspection of the plate. Table I shows that *reag*- (but not rKv1.4-) transfected cells formed colonies in a semisolid medium containing 0.3% agar (24,25), regardless of the vector used for transfection (Fig. 14). All of the above results indicate a transforming potential of *eag*.

Altogether, the results obtained from transfected cells indicate that *reag* can, at least under certain conditions, display oncogenic properties.

Once the transforming ability of *reag* was determined in accordance with the invention, the expression of the respective channel in human cancer cells was investigated. For this investigation, the cell line MCF-7 was used, which was initially obtained from a pleural effusion of a breast adenocarcinoma. The line is estrogen receptor positive as well as estrogen-sensitive and relatively well differentiated. The strategy followed was first to test electrophysiologically and pharmacologically for the presence of a functional current similar to *eag*, and then to try an identification of the corresponding channel at the molecular level. However, conventional approaches for such an identification failed.

Namely, in most cells, the current density was too low to allow reliable measurements of the whole cell current. Low current density precluded an accurate

measurement of channel properties using a whole cell configuration for the patch clamp. Therefore, due to said low current densities encountered, another approach was resorted to. Due to such a low number of channels per cell, it is only possible to characterize the functional properties of a channel by a special patch clamp method, excising patches of membranes containing one (or a few) channels and allowing characterization on a single molecule level. This approach relied on single-channel measurements in order to also compare properties at the single-molecule level such as single channel conductance, pharmacological properties, voltage dependence, and mean open times. Indeed, a channel with several properties compatible with *reag* in terms of kinetics, voltage-dependence, and pharmacology in most membrane patches could thus be identified. Figure 5 shows whole-cell currents obtained from a MCF7 cell under nystatin patch conditions and single channel currents, together with their current-voltage relationship. Despite differences in kinetics at very depolarized voltages, the voltage dependence of the channel in human cells is highly reminiscent to the voltage-dependence of the *reag* channel. Moreover, the single channel properties of the putative human-*eag* are also very similar to those of *reag*.

Furthermore, standard approaches to isolate the said channel on a molecular level also were not successful. Several other groups have attempted and/or are still attempting to isolate the gene coding for a human *eag* without success and this in spite of the fact that the rat *eag* channel has already been published in 1994. For example, Warmke and Ganetzky (Proc. Natl. Acad. Sci. USA 91 (1994), 3428-3442) specifically set out to clone the human *eag* gene using conventional technology. They were, however, unsuccessful and cloned a novel, *eag* related gene which they termed *h-erg* (also referred to as *HERG*). Further, Wymore et al., Circulation Res. 80 (1997), 261-268, reported that no *eag* specific clones could be detected in a cDNA library from human heart in spite of the fact that primers for amplification were used that were conserved across the entire *eag/erg* superfamily. Thus, the standard approach with degenerated oligonucleotides based on the sequence of members of the family revealed itself unsuccessful, although *HERG* was systematically detected by other researchers in the field. Significantly, most of these approaches to clone the human *eag* gene were made with brain libraries. The conclusion from these combined prior art data was that the human *eag* gene could not be

cloned by conventional technology using the most obvious source, namely brain tissue. The repeated isolation of *HERG* clones instead is most probably due to the relative abundance of *HERG* transcripts in brain libraries, and also to the high homology between the two channels. Consequently, a different strategy had to be devised to direct the screening more specifically to *eag* channels. First, as described herein above, a cell line expressing a channel functionally similar to *reag* was identified. Then degenerated oligonucleotides based on conserved sequences between rat, bovine and mouse *eag*, but divergent from *HERG* were designed. Using these primers, the cDNA obtained from MCF7 cells by PCR was amplified, and a band of the expected size was cloned in a suitable vector and sequenced. The amplified fragment corresponded to approximately 400 bp within the core region of the channel protein, and shared 90% identity to the *reag* sequence at the DNA level, and 99% at the amino acid level. However, at this stage it was still quite unclear what the thus identified clone corresponded to. For example, it was quite possible that a further member of the *eag* family had been identified. This is in particular true in view of the fact that despite of a number of attempts with brain libraries, nobody had been able to clone the human *eag* gene and that the MCF7 line is a breast cancer derived line.

Since MCF7 cells are immortal cells, it is assumed that a number of genes is mutated. Ab initio, it could have been expected that the human *eag* channel, if at all expressed in this cell line, was mutated. Under this assumption, it was quite uncertain whether this cell line could at all be used for the isolation of the desired gene.

Due to the prior art failures to clone human *eag* gene from brain libraries and the above recited uncertainties with immortalized cell lines, another source for a library was in need. The 400 bp fragment was therefore used to screen a normal human breast cDNA library. Due to the presence of *eag* in breast cancer cells, such a library was expected to comprise *heag* clones. Surprisingly, however, after screening 2×10^6 phages, no human-*eag* clones could be identified in said library. This rises the possibility that the channel is expressed only in tumor cells, and not in normal tissue. Specific oligonucleotides, namely 5'-CCAAACACACACACCAGC, 5'-CGTGGATGTTATCTTTTGG to check for *heag* fragments by PCR amplification directly from the above library were designed,

but no evidence for the presence of any *eag* clones in this library was found. In view of the above discussed prior art results, it came as a further surprise that the same primers detected *heag* in a normal human brain cDNA library, that was therefore screened. First, the probe obtained from MCF7 cells was used to check 10^6 phages. This procedure allowed to isolate a 1.6 kbp fragment from human *eag*. This fragment was then used as a probe for the screening of 2×10^6 phages from the same library. Several independent clones were isolated, but none of them was a full-length clone. Furthermore, only one clone contained the 5' end of the sequence, while two of them contained the 3' end and part of the 3' non-coding region. It is likely that the abundance of restriction sites in the nucleic acid sequence encoding the channel has induced this extensive fragmentation of the cDNA. For example, when EcoRI was used to extract the inserts of the library that was cloned in λ -gt10 phage at the EcoRI site, this conventional approach systematically failed to find the 5' end of the molecule (there is an EcoRI site at position 400 of the clone). The pooled positive clones were therefore screened again by PCR, trying to amplify the start codon, and only by this means it was possible to isolate one phage that contained this ATG. Two splice variants of *heag* were cloned, both expressed in brain tissue. The sequence obtained for *heag* 1 and *heag* 2 and their deduced amino acid sequence are shown in Figures 10 and 11, and compared to other members of the family.

The deduced amino acid sequence is identical to the sequence published after the priority date of the present invention by Occhidoro (27) and is 97,7% identical to *reag*. As mentioned, a second (81 bp longer) splice variant (*heag* 2) was also isolated analogous to that reported for bovine and mouse *eag* channels (28), the splice insertion being identical in all three species. The chromosomal localization of *heag* was determined by FISH detection (29) to map to chromosome lq32.1-32.3 (see also ref. 26).

To further check the possibility that *heag* is not expressed in normal mammary gland, as opposed to MCF-7 cancer cells, we performed single-tube RT-PCR experiments using total RNA from human brain, human mammary gland, and MCF-7 cells (Fig 12), using as primers two oligonucleotides designed to discriminate between the two splice variants of *heag*. In human brain, two splice variants were detected, while only the short one was expressed in MCF-7 cells (this, together with the lack of

amplification in the absence of reverse transcriptase, rules out a possible contamination by genomic DNA of the RNA preparation). No *heag* signal was detected in normal mammary gland RNA with this highly sensitive technique. This result was totally unexpected, because preliminary results had suggested that expression was present in tumor cells from the same organ. Further, after Southern blot analysis of the RT-PCR products a faint band hybridizing with a *heag* probe in mammary gland was identified. Accordingly, it is quite difficult to make a strong statement on the total absence of *heag* message in breast in view of these contradictory experimental data.

Furthermore, electrophysiological properties (21, 30) of *heag* were tested in *Xenopus* oocytes. As described above, they did not differ significantly from those of *reag* with the above mentioned exceptions, e.g. a shift in activation of 40 mV to more depolarized potentials when both channels were measured under identical conditions. The electrophysiological observations of *heag* channels expressed in *Xenopus* oocytes correlate well to those reported by Bijlenga et al. (31).

The present invention also relates to a nucleic acid molecule specifically hybridizing to the nucleic acid molecule of the invention which comprises the sequence 5'-GGGAGGATGACCATGGCT.

This embodiment of the present invention is particularly useful for specific antisense therapies for inhibiting cell proliferation as will be discussed in more detail herein below (e.g. in Example 5). In addition, this embodiment of the nucleic acid molecule of the invention can, naturally, also be used as a probe for specifically detecting *heag* mRNA in tissues, for example, by employing the Northern Blot technology. The analysis of *heag* mRNA expression in various tissues by Northern blot revealed a strong hybridization signal of approximately 9.2 kb in brain and a weak signal of similar size in placenta. Heart, lung, liver, skeletal muscle, kidney and pancreas were negative even following long exposures. In addition, total RNA from human brain, heart, trachea, adrenal gland, liver, kidney, skeletal muscle and mammary gland, and spinal cord poly(A)⁺ RNA, as well as total RNA from the adenovirus-transformed line 293 (a human non-tumoral cell line) were assayed by single-tube RT-PCR and Southern blot. Under

these experimental conditions, *heag* was detected in brain only, where both splice variants were identified (Fig. 15; Example 3).

The preferential expression of *heag* in brain was intriguing since the first cDNA had been isolated from an epithelial tumor cell line (MCF-7) and not from brain tissue (see above). To elucidate the presence of *heag* in other tumoral cell lines, total RNA was prepared from HeLa (cervix carcinoma), SHSY-5Y (neuroblastoma), and lines from mammary gland tumors: COLO-824 (carcinoma), EFM-19 (carcinoma), and BT-474 (ductal carcinoma). Total RNA from brain, MCF-7 cells, 293 cells and RNA from cultures of mammary gland epithelial cells (included to circumvent the mixed cell populations in whole mammary gland) served as controls. All cell lines were obtained from DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen) and maintained following the DSMZ catalog guidelines. Normal human mammary epithelial cells were purchased from BioWhittaker. The primers were designed to amplify different bands for *heag* 1 and *heag* 2, thus allowing us to rule out false positives due to genomic DNA contamination (controls in the absence of reverse transcriptase were also performed). HeLa, SHSY-5Y, EFM-19 and MCF-7 RNA exhibited an *heag* band, whereas COLO-824 and BT-474 signals were indistinguishable from background (Fig. 15B). Cultured epithelial cells and 293 cells (Fig. 15A) were negative. As discussed above, it could be shown in accordance with the present invention that *reag* transfected cells can display oncogenic properties. Thus, to determine whether the expression of *heag* is advantageous for tumor cells *in vivo*, subcutaneous implants of CHO cells expressing the channel (CHO*hEAG* cells) into the flank of female scid (severe combined immunodeficiency, 32) mice were performed and it could be shown that expression of *heag* represents an advantage for the proliferation of tumor cells *in vivo*, since CHO*hEAG* tumors grow faster and are more aggressive than CHO*Kv* tumors.

Thus, the embodiment of the nucleic acid molecule of the present invention may be employed in the quantitative and qualitative analysis of the expression level of human *eag* in various disease states detectable in a tissue that may be indicative of, for example, cancer (in particular mamma carcinoma, neuroblastoma), psoriasis, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, lateral amyotrophic sclerosis or multiple sclerosis.

In a preferred embodiment of the nucleic acid molecule of the invention, said nucleic acid molecule is DNA, such as genomic DNA. Whereas the present invention also comprises synthetic or semi-synthetic DNA molecules or derivatives thereof, such as peptide nucleic acid, the most preferred DNA molecule of the invention is cDNA.

In a further preferred embodiment of the present invention, said nucleic acid molecule is RNA, preferably mRNA.

Another preferred embodiment of the nucleic acid molecule of the invention encodes a fusion protein. For example, the nucleic acid molecule of the invention can be fused in frame to a detectable marker such as FLAG or GFP.

The invention further relates to a vector, particularly plasmid, cosmids, viruses and bacteriophages comprising the nucleic acid molecule of the invention. Such vectors may comprise further genes such as marker genes which allow for the selection of said vector in a suitable host cell and under suitable conditions. Thus the polynucleotide of the invention can be operatively linked in said vector to expression control sequences allowing expression in prokaryotic or eukaryotic cells. Expression of said polynucleotide comprises transcription of the polynucleotide into a translatable mRNA. Regulatory elements ensuring expression in eukaryotic cells, preferably mammalian cells, are well known to those skilled in the art. They usually comprise regulatory sequences ensuring initiation of transcription and optionally poly-A signals ensuring termination of transcription and stabilization of the transcript. Additional regulatory elements may include transcriptional as well as translational enhancers. Possible regulatory elements permitting expression in prokaryotic host cells comprise, e.g., the *lac*, *trp* or *tac* promoter in *E. coli*, and examples for regulatory elements permitting expression in eukaryotic host cells are the *AOXI* or *GALI* promoter in yeast or the CMV-, SV40-, RSV-promoter (Rous sarcoma virus), CMV-enhancer, SV40-enhancer or a globin intron in mammalian and other animal cells. Beside elements which are responsible for the initiation of transcription such regulatory elements may also comprise transcription termination signals, such as the SV40-poly-A site or the tk-poly-A site, downstream of the

polynucleotide. In this context, suitable expression vectors are known in the art such as Okayama-Berg cDNA expression vector pcDV1 (Pharmacia), pCDM8, pRc/CMV, pcDNA1, pcDNA3 (In-vitrogen), pSPORT1 (GIBCO BRL).

Preferably, said vector is an expression vector and/or a gene transfer or targeting vector. Expression vectors and gene targeting or transfer vectors are well-known in the art and can be adapted for specific purposes of the invention by the person skilled in the art. Thus, expression vectors derived from viruses such as retroviruses, vaccinia virus, adeno-associated virus, herpes viruses, or bovine papilloma virus, may be used for delivery of the polynucleotides or vectors of the invention into targeted cell populations. Methods which are well known to those skilled in the art can be used to construct recombinant viral vectors; see, for example, the techniques described in Sambrook, Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory (1989) N.Y. and Ausubel, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y. (1989). Alternatively, the polynucleotides and vectors of the invention can be reconstituted into liposomes for delivery to target cells.

The invention furthermore relates to a host transformed with the vector of the invention. Said host may be a prokaryotic or eukaryotic cell; see supra. The polynucleotide or vector of the invention which is present in the host cell may either be integrated into the genome of the host cell or it may be maintained extrachromosomally. In this respect, it is also to be understood that the recombinant DNA molecule of the invention can be used for "gene targeting" and/or "gene replacement", for restoring a mutant gene or for creating a mutant gene via homologous recombination; see for example Mouellic, Proc. Natl. Acad. Sci. USA, 87 (1990), 4712-4716; Joyner, Gene Targeting, A Practical Approach, Oxford University Press. Preferably, the host is a mammalian cell, a fungal cell, a plant cell, an insect cell or a bacterial cell. Preferred fungal cells are, for example, those of the genus *Saccharomyces*, in particular those of the species *S. cerevisiae*. The term "prokaryotic" is meant to include all bacteria which can be transformed or transfected with a polynucleotide for the expression of the protein of the present invention. Prokaryotic hosts may include gram negative as well as gram positive bacteria such as, for example, *E. coli*, *S. typhimurium*, *Serratia marcescens* and *Bacillus subtilis*. Methods for preparing fused, operably linked genes and expressing

them in bacteria or animal cells are well-known in the art (Maniatis, et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989). The genetic constructs and methods described therein can be utilized for expression the protein of the present invention in prokaryotic hosts. In general, expression vectors containing promoter sequences which facilitate the efficient transcription of the inserted polynucleotide are used in connection with the host. The expression vector typically contains an origin of replication, a promoter, and a terminator, as well as specific genes which are capable of providing phenotypic selection of the transformed cells. The transformed prokaryotic hosts can be grown in fermentors and cultured according to techniques known in the art to achieve optimal cell growth. The polypeptides of the invention can then be isolated from the grown medium, cellular lysates, or cellular membrane fractions. The isolation and purification of the microbially or otherwise expressed polypeptides of the invention may be by any conventional means such as, for example, preparative chromatographic separations and immunological separations such as those involving the use of monoclonal or polyclonal antibodies. As regards mammalian cells, HEK 293, CHO, HeLa and NIH 3T3 are preferred. As regards insect cells, it is most preferred to use Spodoptera frugiperda cells, whereas the most preferred bacterial cells are E.coli cells.

The invention also relates to a method of producing the (poly)peptide encoded by the nucleic acid molecule of the invention comprising culturing the host of the invention and isolating the produced (poly)peptide.

Depending on the vector constructing employed, the (poly)peptide of the invention may be exported to the culture medium or maintained within the host. Suitable protocols for obtaining the (poly)peptide produced are well-known in the art for both ways of (poly)peptide production.

The present invention furthermore relates to a (poly)peptide encoded by the nucleic acid molecule of the invention or produced by the method of the invention. The new channel is envisaged to show a structure having a short amino-terminal region, probably intracellular, five membrane-spanning segments, a hydrophobic hairpin

entering the membrane, a sixth transmembrane segment, and a long C-terminal cytoplasmic part comprising a cyclic-nucleotide binding consensus sequence, a nuclear localization consensus sequence, and a hydrophobic domain probably forming a coiled-coil structure. The polypeptide of the invention may also be a functional fragment of the human K^+ ion channel. By "functional fragment" polypeptides are meant that exhibit any of the activity of *heag* as described above. Using recombinant DNA technology, fragments of the (poly)peptide of the invention can be produced. These fragments can be tested for the desired function, for example, as indicated above, using a variety of assay systems such as those described in the present invention. Preferably, said fragments comprise the C-terminal portion of the novel ion channel.

The present invention also relates to an antibody specifically directed to the (poly)peptide of the invention. The antibody of the invention specifically discriminates between the human *eag* channel and the prior art channels such as mouse and rat *eag* and preferably binds to epitopes in the C-terminal part of the ion channel. The term "antibody", as used in accordance with the invention, also relates to antibody fragments or derivatives such as $F(ab)_2$, Fab', Fv or scFv fragments; see, for example, Harlow and Lane, "Antibodies, A Laboratory Manual", CSH Press 1988, Cold Spring Harbor, NY. Preferably, the antibody of the invention is a monoclonal antibody.

The invention also relates to a pharmaceutical composition comprising the nucleic acid molecule of the invention, the vector of the invention, the polypeptide of the invention and/or the antibody of the invention and a pharmaceutically acceptable carrier and/or diluent and/or excipient.

Examples of suitable pharmaceutical carriers and diluents as well as of excipients are well known in the art and include phosphate buffered saline solutions, water, emulsions, such as oil/water emulsions, various types of wetting agents, sterile solutions etc. Compositions comprising such carriers can be formulated by well known conventional methods. These pharmaceutical compositions can be administered to the patient in need thereof at a suitable dose. Administration of the suitable compositions may be effected by different ways, e.g., by oral, intravenous, intraperitoneal,

subcutaneous, intramuscular, topical or intradermal administration. The dosage regimen will be determined by the attending physician and clinical factors. As is well known in the medical arts, dosages for any one patient depend upon many factors, including the patient's size, body surface area, age, the particular compound to be administered, sex, time and route of administration, general health, and other drugs being administered concurrently. Generally, the regimen as a regular administration of the pharmaceutical composition should be in the range of 1 μ g to 10 mg units per day. If the regimen is a continuous infusion, it should also be in the range of 1 μ g to 10 mg units per kilogram of body weight per minute, respectively. Progress can be monitored by periodic assessment. Dosages will vary but a preferred dosage for intravenous administration of DNA is from approximately 10^6 to 10^{12} copies of the DNA molecule. The compositions of the invention may be administered locally or systemically. Administration will generally be parenterally, e.g., intravenously; DNA may also be administered directly to the target site, e.g., by biolistic delivery to an internal or external target site or by catheter to a site in an artery.

It is envisaged by the present invention that the various polynucleotides and vectors of the invention are administered either alone or in any combination using standard vectors and/or gene delivery systems, and optionally together with a pharmaceutically acceptable carrier or excipient. Subsequent to administration, said polynucleotides or vectors may be stably integrated into the genome of the subject. On the other hand, viral vectors may be used which are specific for certain cells or tissues and persist in said cells or tissues. Suitable pharmaceutical carriers and excipients are, as has been stated above, well known in the art. The pharmaceutical compositions prepared according to the invention can be used for the prevention or treatment or delaying of different kinds of diseases, which are related to the undesired (over)expression of the above identified nucleic acid molecule of the invention. In a preferred embodiment the pharmaceutical composition comprises antisense oligodesoxynucleotides, as for example described in example 5, capable of regulating, preferably decreasing heavy expression.

Furthermore, it is possible to use a pharmaceutical composition of the invention which comprises the polynucleotide or vector of the invention in gene therapy. Suitable

gene delivery systems may include liposomes, receptor-mediated delivery systems, naked DNA, and viral vectors such as herpes viruses, retroviruses, adenoviruses, and adeno-associated viruses, among others. Gene therapy, which is based on introducing therapeutic genes, for example for vaccination into cells by ex-vivo or in-vivo techniques is one of the most important applications of gene transfer. Suitable vectors, methods or gene-delivery systems for in-vitro or in-vivo gene therapy are described in the literature and are known to the person skilled in the art; see, e.g., Giordano, *Nature Medicine* 2 (1996), 534-539; Schaper, *Circ. Res.* 79 (1996), 911-919; Anderson, *Science* 256 (1992), 808-813; Isner, *Lancet* 348 (1996), 370-374; Muhlhauser, *Circ. Res.* 77 (1995), 1077-1086; Onodera, *Blood* 91 (1998), 30-36; Verzeletti, *Hum. Gene Ther.* 9 (1998), 2243-2251; Verma, *Nature* 389 (1997), 239-242; Anderson, *Nature* 392 (Supp. 1998), 25-30; Wang, *Gene Therapy* 4 (1997), 393-400; Wang, *Nature Medicine* 2 (1996), 714-716; WO 94/29469; WO 97/00957; US 5,580,859; US 5,589,466; US 4,394,448 or Schaper, *Current Opinion in Biotechnology* 7 (1996), 635-640, and references cited therein. The nucleic acid molecules and vectors of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) into the cell. Additionally, a baculoviral system can be used as eukaryotic expression system for the nucleic acid molecules of the invention. Delivery of nucleic acids to a specific site in the body for gene therapy may also be accomplished using a biolistic delivery system, such as that described by Williams (*Proc. Natl. Acad. Sci. USA* 88 (1991), 2726-2729).

Standard methods for transfecting cells with recombinant DNA are well known to those skilled in the art of molecular biology, see, e.g., WO 94/29469. Gene therapy may be carried out by directly administering the recombinant DNA molecule or vector of the invention to a patient or by transfecting cells with the polynucleotide or vector of the invention ex vivo and infusing the transfected cells into the patient. Furthermore, research pertaining to gene transfer into cells of the germ line is one of the fastest growing fields in reproductive biology. Gene therapy, which is based on introducing therapeutic genes into cells by ex vivo or in vivo techniques is one of the most important applications of gene transfer. Suitable vectors and methods for in vitro or in vivo gene therapy are described in the literature and are known to the person skilled in the art; see,

e.g., WO94/29469, WO 97/00957 or Schaper (Current Opinion in Biotechnology 7 (1996), 635-640) and references cited above. The polynucleotides and vectors comprised in the pharmaceutical composition of the invention may be designed for direct introduction or for introduction via liposomes, or viral vectors (e.g. adenoviral, retroviral) containing said recombinant DNA molecule into the cell. Preferably, said cell is a germ line cell, embryonic cell, stem cell or egg cell or derived therefrom. An embryonic cell can be for example an embryonic stem cell as described in, e.g., Nagy, Proc. Natl. Acad. Sci. USA 90 (1993) 8424-8428.

It is to be understood that the introduced polynucleotides and vectors of the invention express the (poly)peptide of the invention after introduction into said cell and preferably remain in this status during the lifetime of said cell. For example, cell lines which stably express the polynucleotide under the control of appropriate regulatory sequences may be engineered according to methods well known to those skilled in the art. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with the polynucleotide or vector of the invention and a selectable marker, either on the same or separate vectors. Following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective medium. The selectable marker in the recombinant plasmid confers resistance to the selection and allows for the selection of cells having stably integrated the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. Such engineered cell lines are particularly useful in screening methods or methods for identifying an inhibitor of the polypeptide of the present invention as described below.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, Cell 11(1977), 223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska, Proc. Natl. Acad. Sci. USA 48 (1962), 2026), and adenine phosphoribosyltransferase (Lowy, Cell 22 (1980), 817) in tk, hgp^rt or ap^rt cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, Proc. Natl. Acad. Sci. USA 77 (1980), 3567; O'Hare, Proc. Natl. Acad. Sci. USA 78 (1981), 1527), gpt,

which confers resistance to mycophenolic acid (Mulligan, Proc. Natl. Acad. Sci. USA 78 (1981), 2072), neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, J. Mol. Biol. 150 (1981), 1), hygromycin (Santerre, Gene 30 (1984), 147), Shble, which confers resistance to Zeocin® (Mulsant, Somat. Cell. Mol. Genet. 14 (1988), 243-252 or puromycin (pat, puromycin N-acetyl transferase). Additional selectable genes have been described, for example, trpB, which allows cells to utilize indole in place of tryptophan; hisD, which allows cells to utilize histinol in place of histidine (Hartman, Proc. Natl. Acad. Sci. USA 85 (1988), 8047); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue, 1987, In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory ed.). Cells to be used for *ex vivo* gene therapy are well known to those skilled in the art. For example, such cells include for example cancer cells present in blood or in a tissue or preferably the corresponding stem cells.

Furthermore, the invention relates to a diagnostic composition comprising the nucleic acid molecule of the invention, the vector of the invention, the polypeptide of the invention and/or the antibody of the invention.

The diagnostic composition of the invention is useful in detecting the onset or progress of diseases related to the undesired expression or overexpression of the nucleic acid molecule of the invention. As has been pointed out herein above, such diseases are interrelated or caused by an increased or ongoing cellular proliferation. Accordingly, the diagnostic composition of the invention may be used for assessing the onset or the disease status of cancer. Having thus an early criterium for tumor activity, suitable counter-measures can immediately be applied. Such an immediate action will, of course, significantly improve the prognosis of the patient. These considerations equally apply to the diagnosis of metastases and recurrent tumors.

On the other hand, not all types of tumors may be characterized by an undesired expression or overexpression of the nucleic acid molecule of the invention. Alternatively, said (over)expression may occur only in certain stages, such as early stages, of tumor

development. Therefore, the diagnostic composition of the invention may also or alternatively be employed as a means for the classification of tumors or of the developmental status of a tumor. Naturally, the or most of the applications of the composition of the invention described here for tumors also apply to other diseases interrelated with or caused by the undesired (over)expression of the nucleic acid molecule of the invention.

Furthermore, a disease as recited throughout this specification also could be caused by a malfunction of the polypeptide of the present invention. Said disease could be interrelated or caused by, for example, an increased or reduced gene dosis of the polypeptide of the present invention, an increased or reduced activity of said polypeptide e.g. due to a modification in the primary amino acid sequence as compared to the corresponding wild-type polypeptide in a cell or tissue or a loss of the regulation of the activity of said polypeptide. Said disease might further be caused by an incorrect expression of the polypeptide during cell cycle progression or cell development. For example, mutated binding sites to intracellular or extracellular compounds, e.g. ions or second messengers or regulatory proteins, might result in a malfunction of the polypeptide of the present invention as it changes the binding characteristics for said compounds regulating the activity of said polypeptide. Malfunction could also be caused by defective modifications sites, for example, phosphorylation or glycosylation sites. It also might be caused by incorrect splicing events and therefore by expression of a truncated or extended polypeptides, for example, if *heag* 1 is expressed instead of *heag* 2 or vice versa.

Thus, in a further embodiment the diagnostic composition described above could also be used to detect a malfunction of the polypeptide of the present invention.

In a further embodiment, the invention relates to a method for preventing or treating a disease which is caused by the malfunction of the polypeptide of the invention, comprising introducing an inhibitor of the expression of the nucleic acid molecule of the present invention or an inhibitor or a modifying agent of the malfunction of the (poly)peptide of the present invention or a nucleic acid molecule coding *heag* or a polypeptide having *heag* activity into a mammal affected by said disease or being

suspected of being susceptible to said disease. Methods for introduction of a nucleic acid molecule of the present invention encoding *heag* into a cell or subject, i.e. gene therapy, are described within this specification as well as methods for the identification of inhibitors of the expression of a nucleic acid molecule of the present invention. Furthermore, inhibitors or modifying agents of the malfunction of the polypeptide of the present invention can be identified according to methods for the identification of inhibitors of the polypeptide of the present invention known to a person skilled in the art (see below). For example, some genetic changes causing a malfunction of the polypeptide of the present invention lead to altered protein conformational states. Mutant proteins could possess a tertiary structure that renders them far less capable of facilitating ion transport. Restoring the normal or regulated conformation of mutated proteins is the most elegant and specific means to correct these molecular defects. Pharmacological manipulations thus may aim at restoration of wild-type conformation of the protein. Thus, the polynucleotides and encoded proteins of the present invention may also be used to design and/or identify molecules which are capable of activating the wild-type function of a derivative of the polypeptide of the present invention displaying said malfunction.

The doses and routes for the administration for the treatment of a patient in need thereof have already been discussed herein above in connection with the pharmaceutical composition of the invention. Diseases that may be treated using the method of the present invention comprise any diseases that are correlated with cellular proliferation. Preferred diseases that fall into this category are tumor diseases such as cancer (breast cancer, neuroblastoma etc.), psoriasis, and degenerative diseases, especially those of the nervous system such as Alzheimer's disease, multiple sclerosis, lateral amyotrophic sclerosis, and Parkinson's disease.

Preferably, said inhibitor of the expression or overexpression of said nucleic acid molecule is the nucleic acid molecule of the invention that hybridizes to the nucleic acid molecule encoding the ion channel of the invention or fragment thereof. For example, this nucleic acid molecule can be an antisense oligodesoxynucleotide (ODN). The inventors could show that antisense ODNs treatment significantly reduces DNA

synthesis of several tumor cells, e.g. EFM cells, SHSY-5Y cells and HeLa cells (Example 5). Thus, in a preferred embodiment the nucleic acid molecule comprises antisense ODNs.

In a further preferred embodiment, said inhibitor of polypeptide function is the antibody of the invention or a drug. Said drug can be histamine receptor H1 inhibitor. Preferably, said drug inhibits active *heag*, for example, acts as use-dependent, probably open-channel blocker, preferably said drug is astemizole or terfenadine. Further suitable drugs can be identified or designed by the person skilled in the art on the basis of the teachings of the present invention. Preferably, the drug will have an affinity to *heag* channel in the mM range, more preferable in the nM range or lower. Preferably, the drug has no effect on other channels, for example on cardiac channels.

In a further preferred embodiment of the invention, said method further comprises prior to the introduction step,

- (a) obtaining cells from the mammal infected by said disease and, after said introduction step, wherein said introduction is effected into said cells,
- (b) reintroducing said cells into said mammal or into a mammal of the same species.

This embodiment of the present invention is particularly useful for gene therapy purposes which will reduce the treatment duration largely and increase the effectivity and reduce (even eliminate) side effects. In addition, this embodiment of the method of the invention can also be employed in the context or in combination with conventional medical therapy. The removal from and the reintroduction into said mammal may be carried out according to standard procedures.

Preferably, the above referenced cell is a germ cell, an embryonic cell or an egg cell or a cell derived from any of these cells.

The invention further relates to a method of designing a drug for the treatment of a disease which is caused by the undesired expression or overexpression of the nucleic acid molecule of the invention comprising:

- (a) identification of a specific and potent drug;
- (b) identification of the binding site of said drug by site-directed mutagenesis and chimeric protein studies;
- (c) molecular modeling of both the binding site in the (poly)peptide and the structure of said drug; and
- (d) modifications of the drug to improve its binding specificity for the (poly)peptide.

The term "specific and potent drug" as used herein refers to a drug that potently and specifically blocks *heag* function.

All techniques employed in the various steps of the method of the invention are conventional or can be derived by the person skilled in the art from conventional techniques without further ado. Thus, biological assays based on the herein identified features of the ion channel of the invention may be employed to assess the specificity or potency of the drugs wherein the decrease of one or more activities of the ion channel may be used to monitor said specificity or potency. Steps (b) and (d) can be carried out according to conventional protocols described, for example, in K.L. Choi, C. Mossman, J. Aubé & G. Yellen. The International Quaternary Ammonium Receptor Site of *Shaker* Potassium Channels. *Neuron* 10, 533-541 (1993), C.-C. Shieh & G.E. Kirsch: Mutational Analysis of Ion Conduction and Drug Binding Sites in the Inner Mouth of Voltage-Gated K⁺-Channels. *Biophys. J.* 67, 2316-2325 (1994), or C. Miller: The Charybdotoxin Family of K⁺-Channel-Blocking Peptide. *Neuron* 15, 5-10 (1995).

For example, identification of the binding site of said drug by site-directed mutagenesis and chimerical protein studies can be achieved by modifications in the (poly)peptide primary sequence that affect the drug affinity; this usually allows to precisely map the binding pocket for the drug.

As regards step (c), the following protocols may be envisaged: Once the effector site for drugs has been mapped, the precise residues interacting with different parts of the

drug can be identified by combination of the information obtained from mutagenesis studies (step (b)) and computer simulations of the structure of the binding site (since a potassium channel has recently been crystallized in the art, this can now be done by the person skilled in the art without further ado) provided that the precise three-dimensional structure of the drug is known (if not, it can be predicted by computational simulation). If said drug is itself a peptide, it can be also mutated to determine which residues interact with other in the *heag* molecule.

Finally, in step (d) the drug can be modified to improve its binding affinity or its potency and specificity. If, for instance, there are electrostatic interactions between a particular residue of *heag* and some region of the drug molecule, the overall charge in that region can be modified to increase that particular interaction; additionally, if those interactions occur with a region of *heag* that is not conserved with other channel proteins, it is conceivable that an improvement of that interaction while other binding factors are weakened will improve the specificity of the drug.

Identification of binding sites may be assisted by computer programs. Thus, appropriate computer programs can be used for the identification of interactive sites of a putative inhibitor and the polypeptide of the invention by computer assisted searches for complementary structural motifs (Fassina, Immunomethods 5 (1994), 114-120). Further appropriate computer systems for the computer aided design of protein and peptides are described in the prior art, for example, in Berry, Biochem. Soc. Trans. 22 (1994), 1033-1036; Wodak, Ann. N. Y. Acad. Sci. 501 (1987), 1-13; Pabo, Biochemistry 25 (1986), 5987-5991. Modifications of the drug can be produced, for example, by peptidomimetics and other inhibitors can also be identified by the synthesis of peptidomimetic combinatorial libraries through successive chemical modification and testing the resulting compounds. Methods for the generation and use of peptidomimetic combinatorial libraries are described in the prior art, for example in Ostresh, Methods in Enzymology 267 (1996), 220-234 and Dorner, Bioorg. Med. Chem. 4 (1996), 709-715. Furthermore, the three-dimensional and/or crystallographic structure of inhibitors of the polypeptide of the invention can be used for the design of peptidomimetic inhibitors, e.g., in combination with the (poly)peptide of the invention (Rose, Biochemistry 35 (1996), 12933-12944; Rutenber, Bioorg. Med. Chem. 4 (1996), 1545-1558).

An exemplary strategy for identifying a specific inhibitor that may be used in accordance with the present invention is provided in the appended examples.

The invention also relates to a method of identifying an inhibitor of the expression of the nucleic acid of the invention or of a function of the (poly)peptide of the invention comprising:

- (a) testing a compound for the inhibition or reduction of translation wherein said compound is selected from antisense oligonucleotides and ribozymes; or
- (b) testing a compound for the inhibition of transcription wherein said compound binds to the promoter region of the gene encoding the (poly)peptide of the invention and preferably with transcription factor responsive elements thereof; or
- (c) testing peptides or antibodies suspected to block the proliferative activity of the (poly)peptide of the invention for said blocking activity.

As regards alternative (b) referred to above, it may be advantageous to first characterize the promoter region and locate transcription factor responsive sequences in it. Then it would be possible to genetically manipulate the promoter to render it more sensitive to repressors or less sensitive to enhancers. Turning now to alternative (c), it may be advantageous to first locate the part or parts of the ion channel of the invention implicated in the generation of proliferation disorders. Compounds that have been positive in one of the test systems are, *prima facie*, useful as inhibitors.

Peptidomimetics, phage display and combinatorial library techniques are well-known in the art and can be applied by the person skilled in the art without further ado to the improvement of the drug or inhibitor that is identified by the basic method referred to herein above.

In a further embodiment, the present invention relates to a method of inhibiting cell proliferation comprising applying an inhibitor to expression of the nucleic acid of the invention or the (poly)peptide of the invention. The method of the invention may be carried out *in vitro*, *ex vivo* or when application is to a subject, *in vivo*.

The present invention also relates to a method of prognosing cancer and/or neurodegenerative diseases and/or psoriasis comprising assessing the expression of the nucleic acid molecule of the invention or assessing the quantitative presence of the (poly)peptide of the invention. In a preferred embodiment said cancer is a mamma carcinoma or neuroblastoma, in a more preferred embodiment said cancer is breast adenocarcinoma, breast carcinoma ductal type, or cervix carcinoma. In a further embodiment said neurodegenerative diseases is Alzheimer's disease, Parkinson's disease, lateral amyotrophic sclerosis or multiple sclerosis.

The method of the invention may be carried out *in vitro*, *in vivo*, or *ex vivo*. Suitable protocols for carrying out the method of the invention are well-known in the art and include, as regards *in vitro* techniques, Northern blotting for the assessment of the level of mRNA or the analysis of tissue by microscopic techniques using, for example, antibodies that specifically recognize the (poly)peptide of the invention. One or more these techniques may be combined with PCR based techniques which may also or in combination with further (conventional) techniques be used for the above recited assessment.

In a preferred embodiment of the above-mentioned methods of the invention, said mammal is a human, rat or mouse.

The present invention further relates to the use of the nucleic acid molecules of the invention in gene therapy. As has been pointed out here above, gene therapy may be designed to inhibit cell proliferation and thus treat any disease affected thereby such as cancer or psoriasis in a specific way. The invention particularly envisages two independent lines carrying out such gene therapy protocols:

- (a) Mutagenesis of the channel together with chemical engineering of H1 antagonists (preferably of astemizole) in order to obtain a drug specific for human *eag*;
- (b) Quantitative and qualitative analysis of the expression levels of *eag* in cancer tissue, in order to design a diagnostic and/or prognostic method. This would also allow the design of genetic therapies against specific tumors.

For example, the nucleic acid molecule may be introduced in vivo into cells using a retroviral vector (Naldini et al., Science 272 (1996), 263-267; Mulligan, Science 260 (1993), 926-932) or another appropriate vector. Likewise, in accordance with the present invention cells from a patient can be isolated, modified in vitro using standard tissue culture techniques and reintroduced into the patient. Such methods comprise gene therapy or gene transfer methods which have been referred to herein above.

Finally, the present invention relates to a kit comprising the nucleic acid molecule specifically hybridizing to the nucleic acid molecule encoding the (poly)peptide of the invention, the vector of the invention, the polypeptide of the invention and/or the antibody of the invention.

The kit of the invention can, inter alia, be employed in a number of diagnostic methods referred to above. The kit of the invention may contain further ingredients such as selection markers and components for selective media suitable for the generation of transformed host cells and transgenic plant cells, plant tissue or plants. Furthermore, the kit may include buffers and substrates for reporter genes that may be present in the recombinant gene or vector of the invention. The kit of the invention may advantageously be used for carrying out the method of the invention and could be, inter alia, employed in a variety of applications referred to herein, e.g., in the diagnostic field or as research tool. The parts of the kit of the invention can be packaged individually in vials or in combination in containers or multicontainer units. Manufacture of the kit follows preferably standard procedures which are known to the person skilled in the art.

Several documents are cited throughout the text of this specification. Each of the documents cited herein (including any manufacturer's specifications, instructions, etc.) are hereby incorporated herein by reference; however, there is no admission that any document cited is indeed prior art as to the present invention.

The figures show:

Figure 1. Proliferation of wild-type (circles) and *reag*-expressing CHO cells as a function of time. Cells were plated in 96-well dishes and at the indicated times the tetrazolium salt MTT⁶ (50 µg/ml) was added to the plates. After four hours incubation in humidified atmosphere (37 C°, 5%CO₂), the reaction was stopped by addition of 2 volumes of 10% SDS in 1M HCl. The blue formazan crystals produced in living cells were solubilized overnight, and the resulting color was measured as optical density at the indicated wavelength. Possible non-specific effects of the transfection on the cell proliferation can be neglected, since a) the results were comparable in three independent cell lines from different species (rat, hamster and human); b) transfection with different independent clones gave the same results, and c) transfection with a different potassium channel (Kv1.4) in the same vector (thus with a tendency to recombine at the same site) gave results comparable to WT and did not reproduce the effects of the *reag* transfection.

Figure 2. Proliferation of wild type (circles) and *reag* expressing (triangles) CHO cells, in the presence of 0.5% FCS. This serum concentration is not able to sustain growth of normal cells, but transfected cells complete almost three cycles. Methods as for Figure 1.

Figure 3. DNA synthesis in CHO cells expressing different potassium channels, in the presence of normal (10%) or low (0.5%) concentrations of FCS. In control cells, WT or cells transfected with Kv1.4, the levels of DNA synthesis drop significantly in the presence of low serum concentration, whereas *reag* expressing cells maintain the same replication levels as in high serum concentrations.

Figure 4. (A) Photographs of plates with wild type, Kv1.4 transfected or *reag* transfected NIH3T3 cells. The cells were seeded at low density, and allowed to grow under standard conditions until wild-type cells reached confluence. The cells were then fixed with methanol and stained with Giemsa blue. Under those conditions, both wild type and Kv1.4-expressing cells grow in a monolayer, whereas *reag* expressing cells form *foci*. (B) Foci formation of *reag* -transfected NIH-3T3 cells compared to cells transfected with rKv1.4 and to wild type cells. The vector control (pcDNA3 transfected cells) yielded a similar phenotype as wild type cells (not shown). Transient transfection was carried out

using calcium phosphate (33). Cells were maintained in rich medium until control cells reached confluence, then fixed with methanol and stained with Giemsa blue.

Figure 5. Currents elicited by depolarizations in MCF7 cells under voltage clamp conditions. Left traces are whole cell currents, right traces have been obtained in an excised outside-out patch. Both the macroscopic currents and the I-V relationships (C and D) are reminiscent of *reag* currents.

Figure 6. Single channel activity in an outside-out membrane patch voltage-clamped at 0 mV, in the presence or the absence of 5 μ M astemizole. The pipette solution contained 140 mM KCl, 10 mM BAPTA, 10 mM HEPES pH 7.2; the bath solution contained 140 mM NaCl, 2 mM CaCl_2 , 2 mM MgCl_2 , 2.5 mM KCl, 10 HEPES pH 7.2.

Figure 7. A. DNA synthesis in MCF7 cells under different *eag* blockers. B. HEK293 DNA synthesis levels in the presence of astemizole, glibenclamide and terfenadine.

Figure 8. Dose-response curve for the effects of two H1 antagonists on DNA synthesis in MCF7 cells (IC_{50} 7 and 10 mM for LY 91241 and astemizole respectively).

Figure 9. Fluorescence images of control (untreated, A) and astemizole-treated (B) MCF7 cells, stained with Hoechst 33342. Notice in B the smaller surface of the nuclei, and a much lower cell density (due to cell death).

Figure 10. Nucleotide sequence of human-*eag* cDNA from human brain compared to the rat sequence and bovine sequences. Those positions showing a different nucleotide in any of the sequences are shaded.

Figure 11. Amino acid sequences of both splice variants obtained from human *eag* cDNA translation, compared to the corresponding bovine, mouse and rat sequences. The black boxes indicate a different residue in any of the sequences.

Figure 12. RT-PCR from human brain, human mammary gland and MCF-7 cells total RNA. The amplification produced two specific fragments corresponding to the expected sizes for *heag* 1 and 2 in brain, and the band corresponding to *heag* 1 in MCF-7 cells, while no amplification was detected in normal breast RNA.

Figure 13. Voltage-dependence of activation in high extracellular potassium, two-electrode voltage-clamp: In the conductance-voltage plot, the voltage for half-activation is shifted by 40 mV to the right in the *heag* channel with respect to the *reag* channel.

Figure 14. Colony formation in semisolid medium of NIH-3T3 cells transfected with the indicated DNAs. Cells were plated in regular medium containing 0.3% agar onto a layer of 0.55% agar medium. Colonies larger than 0.1 mm in diameter were scored 14 days after transfection. The average number of colonies in at least ten counted microscope fields is expressed per μ g DNA used in the transfection (except for the lanes "Transfection buffer" and "No treatment", where the numbers are absolute values). *reag* and Kv1.4 were transfected using either pcDNA3 or pTracer CMV vectors.

Figure 15. (A) Southern blot of RT-PCR products of RNAs from different human tissues and 293 cells. Transferrin receptor (TFR) signals are shown at the bottom. (B) Southern blot analysis of RT-PCR products of total RNAs from different human cell lines and mammary epithelial cells in primary culture (Epith. cells). TRF signals are shown at the bottom.

Figure 16. (A) Treatment of *heag* expressing tumor cell lines with antisense ODNs. (B) *heag* current in SHSY-5Y neuroblastoma cells (C) Current density in SHSY-5Y cells treated with antisense ODNs (D) Inhibition of DNA synthesis in human cancer cells (EFM-19, HeLa and SHSY-5Y) by antisense ODNs directed against *heag*.

Figure 17. (A) Subcutaneous implantation of CHO_hEAG cells induced aggressive tumors that grew rapidly and soon broke the skin of the carrier mice. The photograph was taken in the third week post-implantation of 2×10^6 cells. (B,C) The average mass of CHO_hEAG tumors was significantly greater than that of the CHO_Kv tumors both two

weeks (B; mean \pm S.E.M.; $p=0.002$) or three weeks post-implantation (C; mean \pm S.E.M.; $p=0.03$) (D) CHO_hEAG and (E) CHOK_v tumors photographed *in situ*. The main macroscopic differences are the darker color and the fixation to the skin of the CHO_hEAG tumor. (F, G) CHO_hEAG (F) and CHOK_v (G) tumors were cut open to show the great extent of necrosis (arrowheads) in the former. (H, I) The greater degree of necrosis and the fixation to the skin are also evident microscopically after paraffin embedding and hematoxylin-eosin staining. The histology is comparable in both micrographs, but in (H) a much bigger necrotic area is observed (arrowheads), and there is no border between the subcutaneous fat and the tumor. (Scale bars, 100 μ m) (J) As a quantitative measurement of these images, the average width of the vital area in CHOK_v tumors was significantly larger than that of CHO_hEAG tumors (mean \pm S.E.M.; $p<0.0005$).

Figure 18: Proliferation assays of rEAG-transfected CHO cells (A-C). Growth curves of CHO cells transfected with rEAG (circles) as compared to naive cells (triangles) in 10% (filled symbols) or 0.5% (open symbols) fetal calf serum. The values are referred to the ones measured after 12 h in culture (time 0 in the plot), and represent mean \pm S.E.M. of eight wells in the same plate. Cell lines were established by selection through the G-418 resistance encoded in the pcDNA3 vector. MTT hydrolysis (22) was used to measure metabolic activity of viable cells. Serum was carefully diluted 12 hours after plating. (B) Increase in metabolic activity during the first 12 hours after removal of S-phase block. For cell synchronization, 2 mM thymidine was added to the culture medium for 12 h. Thymidine was removed from the medium for additional 12 h, and then a second arresting pulse was applied for 12 h. Cells were then trypsinized and plated for metabolic activity and DNA synthesis determination. (C) BrdU incorporationⁱ during the first 12 hours after removal of S-phase block for 12h incubation in 10% FCS, or in the presence of 0.5% FCS (24 h incubation). BrdU incorporation was measured using the Boehringer-Mannheim "BrdU labeling and detection kit", following the indications of the manufacturer. The bars represent mean \pm S.D. for wild-type CHO cells (open bars), Kv1.4-transfected (shaded bars) and *eag*-transfected (solid bars). The incorporation of BrdU is quantified as optical density at 405 nm (reference 490 nm) produced on ABTSTM substrate by peroxidase coupled to the anti BrdU antibody.

The examples illustrate the invention.

Example 1: Cloning of the K⁺ ion channel

mRNA was purified from total RNA obtained from MCF-7 cells following standard procedures. Then, cDNA was prepared by reverse transcription with Superscript II reverse transcriptase; this cDNA was used as a template for PCR amplification using degenerate oligonucleotides designed to match highly conserved *eag* sequences. After amplification, a SacII/SacII fragment from rat *eag* was used as a probe for Southern blot analysis of the results. Those bands showing positive hybridization were subsequently cloned in pGEM-T vector (Promega) and sequenced. All of them gave sequences corresponding to HERG.

Specific oligonucleotides engineered to avoid HERG cDNA amplification were then designed, taking into account rat, mouse and bovine *eag*. We looked for sequences having high homology between the various *eag* clones but with maximal divergence to the HERG sequence.

The sequences of the oligonucleotides were the following:

5'-CAGAA(T,C)AA(T,C)GTGGC(A,C,T,G,)TGGCT

5'-TCACT(G,A)AAGATCTATA(A,G)TC

After PCR amplification, the band of the expected size was cloned into pGEMT and sequenced. The sequence obtained showed high homology to rat *eag* (nucleotides 942-1108).

This band was labeled and used as a probe to screen a mammary gland cDNA library. After screening of 2×10^6 phages, no positive clones were found.

We then used specific oligonucleotides to analyze cDNA using PCR from human heart and human brain (obtained from total RNA purchased from Clontech). Two PCR products from brain were sequenced, and the sequence corresponded to two alternatively spliced variants of *eag*. To further test the possibility of cloning the full length molecule from the human brain, we performed PCR analysis of a human cDNA library, and compared this result to the same experiment in the human mammary gland library (both from Clontech). Only the brain library gave positive results.

Subsequently, the amplified fragment was employed to screen the human brain library (2 rounds, 10^6 phages) and several clones that were cloned into the pBSK-vector were found and sequenced. All of them corresponded to the central part of the molecule, but were missing the 5' and 3' ends. The longest of these positive clones was used to prepare a probe and re-screen the library (again two rounds, 2×10^6 clones).

The sequences obtained in this case corresponded to part of the coding sequence (approximately 400 bp 5' were missing until the initiation codon) and a long 3' untranslated sequence. Since the fragment close to the 5' end of the molecule started in all cases with an EcoRI site, it was suspected that the site was actually present in the *heag* sequence, and that it was lost in the subcloning of the fragments into vectors for sequencing.

To obtain the full length sequence, we pooled those phages that carried fragments close to the 5' end and analyzed them by PCR amplification, using the sequence 3' to the mentioned EcoRI site and a sequence from lambda gt10 as primers for the PCR. After successive fractionation of the pools, two phages that carried the 5' end of the coding sequence were obtained, and one of them contained part of the 5' untranslated region.

Once we knew the complete sequence, we assembled the whole clone starting from two phages, one of them containing the 3' UTR and most of the coding sequence, and the other containing the 5' end. The first fragment was extracted from the phage by SphI/HindIII digestion, and subcloned into pBKS- to produce pBKSheag 1. In this was, a 1.2 kbp SphI-SphI fragment was also removed from the clone, and it was necessary to

reintroduce it afterwards. The fragment containing the 5' end was extracted by HindIII/MunI digestion. This fragment was ligated with a HindIII/MunI digest of pBKSheag 1. Only using this procedure were we able to obtain the full length clone in a single plasmid. We then needed to reintroduce the SphI-SphI fragment since we had deleted one of the SphI sites. Subsequently, an EagI/NotI fragment was subcloned into the NotI site of pCDNA3 vector, to eliminate the contaminating phage sequences and to obtain a vector suitable for functional expression of the channel. Finally obtained sequences are depicted in sequence listing as SEQ ID No. 1 and SEQ ID No. 2.

Example 2: Identification of inhibitors that specifically bloc the action of human *eag*.

Another member of the *eag* family, *HERG*¹¹⁻¹⁶, has been related to a familiar form of long QT syndrome (LQT). This has allowed to identify several blockers of *HERG* based on their ability to induce LQT-type arrhythmias. Thus, certain histamine H1 receptor blockers, such as astemizole and terfenadine, as well as class III antiarrhythmic drugs (dofetilide, E-4031) are potent and specific blockers of *HERG*^{15,17}. However, for *eag* channels, specific blockers have not yet been described. Due to the sequence similarity between *HERG* and *eag* channels, both groups of drugs on *reag* were tested in accordance with the present invention. The H1 blockers also affect *reag*, whereas the channel is rather insensitive to class III antiarrhythmics (dofetilide). This provides a useful tool to selectively block *eag*-type channels and to discard possible effects of *HERG* channels (which are also present in MCF7 cells). The effect of one of these drugs (astemizole 5 μ M) is shown on single putative human *eag* channels in Fig. 6.

It was further tested whether several *reag* and other potassium channel blockers are able to inhibit growth of MCF7 cells. As a "positive" control glibenclamide, a blocker of the ATP-sensitive potassium channel was also included, since it has been described to inhibit the proliferation of this cell line². To determine the rate of DNA synthesis, cells were plated on 96-well microtiter plates at a density of $\approx 10^5$ cells/ml and in the absence of growth factors. After 24 hours starvation, cells were stimulated by addition of 10% FCS in the presence of BrdU. The amount of BrdU incorporated into the

newly synthesized DNA was determined using a commercial antibody (Boehringer Mannheim). The drugs tested were added either at the same time or 12 hours prior to the stimulation. In a different human cell line, HEK293, the addition of 10 μ M astemizole or 100 μ M glibenclamide did not reduce significantly the DNA synthesis, while terfenadine (10 μ M) produced a strong inhibition. For this reason, only effects of astemizole (and its closely related analog LY91241) were considered, and those produced by terfenadine (although MCF7 cells are significantly more sensitive to growth inhibition by terfenadine than the control cells) discarded. In MCF7 cells, 5 μ M astemizole reduced the DNA synthesis by 40%, while the same concentration of the *HERG*-specific blocker dofetilide produced no significant effects. Ten times higher concentrations (50 μ M) of other potassium channel blockers (quinidine or glibenclamide) were required to induce a similar effect. A dose-response curve for astemizole effects on DNA synthesis in MCF7 cells is depicted in Figure 8. The half-maximal effect was obtained for 10 μ M astemizole.

In an attempt to clarify the mechanism underlying the proliferation inhibition in MCF7 cells, the nuclear morphology of cells treated with 5 μ M astemizole were checked, using the supravital nuclear stain Hoechst 33342. After 24 hours of treatment, most cells showed nuclear condensation and fragmentation, typical features of apoptotic cell death (Fig. 9).

In conclusion, a human counterpart of the *reag* channels are present in human cancer cells, and they have the ability to induce malignant transformation in several different cell types.

Example 3: Expression of *heag* in different human tissues

500 ng total RNA from different human tissues (or 5 ng polyA⁺ RNA, for spinal chord) were reverse transcribed and amplified using a pair of oligonucleotides of the sequences 5'-CGCATGAACTACCTGAAGACG (forward) and 5'-TCTGTGGATGGGGCGATGTTC (reverse). The amplified DNA was analyzed by Southern blot using a specific human *eag* probes (a 1.5 Kb EcoRI fragment from the core

of the channel). Among the RNAs tested, only brain total RNA gave positive signals. RNAs from spinal cord, adrenal gland, skeletal muscle, heart, trachea, liver, kidney and mammary gland were negative. The integrity of the RNA was checked using transferrin amplification. Using the same approach, the expression of *heag* in several tumoral human cell lines was checked, in: MCF-7 (breast adenocarcinoma), BT-474 (breast ductal carcinoma, from a solid tumor), EFM-19 (breast carcinoma, ductal type, from pleural fluid), COLO-824 (breast carcinoma, from pleural fluid), SHSY5Y (neuroblastoma).

In contrast to normal tissues, all the cancer cell lines tested were found positive for *heag* expression.

Further, Southern blot of RT-PCR products of RNAs from different human tissues and 293 cells show that only in RNA from brain the two bands corresponding to *heag* A and B could be amplified and identified. Transferrin receptor (TFR) signals are shown at the bottom (Fig. 15A). Furthermore, a Southern blot analysis of RT-PCR products of total RNAs from different human cell lines and mammary epithelial cells in primary culture (Epith. cells). TRF signals are shown at the bottom. RNAs from the different cell lines (34) and commercial RNAs from human tissues (Clontech) were subjected to single-tube RT-PCR (35). Total RNA was used with the exception of spinal cord, where poly(A)⁺ RNA was used (Primer sequences were: forward: 5'-CGCATGAACTACTGAAGACG, and reverse: 5'-TCTGTGGATGGGGCGATGTTC. 5'-TCAGCCCAGCAGAAGCATTAT and reverse: 5'-CTGGCAGCGTGTGAGAGC were used to control RNA and PCR performance.). Specific primers for TFR were used to control RNA and PCR performance. These ODNs were designed according to the published TFR sequence (36), starting at exon 11 and spanning to exon 19 (37). This, together with the amplification of two *heag* splice fragments and controls in the absence of reverse transcriptase, excludes a false positive due to genomic DNA contamination. 50 µl (*heag*) or 15 µl (TFR) of PCR reactions were analyzed in 2% agarose gels. DNA was transferred to membranes and consecutively hybridized at high stringency with [³²P]-dCTP labeled random primed probes consisting of a 980 bp *heag* fragment and the TFR fragment amplified from brain RNA.

Example 4: Expression of *heag* in vivo

To determine whether the expression of *heag* is advantageous for tumor cells *in vivo*, the inventors performed subcutaneous implants of CHO cells expressing the channel (CHO*hEAG* cells) into the flank of female scid (severe combined immunodeficiency, 33) mice. CHO*Kv* cells were used as a control. Therefore, 2×10^6 CHO*hEAG* or CHO-*Kv1.4* cells suspended in 100 μ l PBS were implanted subcutaneously on the flank of 6-8 week old female Fox Chase scid mice (*C.B-17/Icr scid/scid*) obtained from Bomholtgard, Ry, Denmark. The presence of tumors was checked every second day by tactile inspection of every mouse. After two or three weeks, the animals were sacrificed by cervical dislocation and the tumors dissected and fixed in paraformaldehyde for subsequent paraffin inclusion and staining. The identity of the CHO*hEAG* cells was established by UV illumination of the tumors to evoke fluorescence from the green fluorescence protein encoded in the pTracer vector (Invitrogen). One week after the implantation, all CHO*hEAG*-injected mice carried tumors detectable by palpation, while no mass greater than 1 mm was observed in the controls. During the second week post-implantation, the *heag*-expressing tumors reached in excess of 5 mm in diameter and visibly emerged through the skin in most cases (Fig. 17A); the mice were sacrificed after two (N=6) or three weeks (N=7). Only one of the 11 control animals used was free of visible tumors; all 13 CHO*hEAG*-injected animals showed tumors. The average mass (Fig. 17B, C) of the *heag*-expressing tumors was significantly larger than that of controls, especially two weeks following implantation (Fig. 17B). From macroscopic observation, the tumors appeared friable and hemorrhagic; the CHO*hEAG* tumors were darker than the controls and were adhered to the skin (Fig. 17D, E) in all CHO*hEAG*-injected mice at two weeks. Six of seven mice exhibited similar characteristics at three weeks. In contrast, the tumor could be easily dissected from the skin in all of the control mice after two weeks, and in five out of six mice at three weeks. The tissue below the tumor appeared unaffected in all cases. The dark color was due to great extent of intratumoral necrosis (Fig. 17 F, G, arrows), confirmed by histology (Fig. 17 H, I, arrowheads), indicating a faster growth of CHO*hEAG* tumors. The thickness of the vital area in the *EAG*-expressing tumors was significantly smaller than in the controls (Fig. 17J). The rapid growth of the tumor can account for the massive intratumoral necrosis in the CHO*hEAG* group. This could also

explain the enhanced difference found in the mass of the tumors two weeks after implantation, since CHO_hEAG tumors would cease growth due to massive necrosis. These data strongly suggest that expression of *heag* tumors grow faster and are more aggressive than CHOKv tumors.

Example 5: Inhibition of *heag*

It is assumed that expression of *heag* in some tumor cells is not the consequence of their abnormal growth, but that this K⁺ channel is necessary for their proliferation. Therefore, inhibition of *heag* expression with antisense oligodeoxynucleotides (ODNs) should decrease the proliferation rate in these tumor cells. Therefore, a 19-mer antisense phosphorothioate ODN (5'-CAGCCATGGTCATCCTCCC) spanning the putative initiation codon of *heag* was used to test inhibition of proliferation. The sense ODN and a scrambled sequence (gtcggtagcagtaggaggg) were used as controls. Data shown in Figure 16A confirms the efficiency of the antisense ODN treatment in reducing the *heag* mRNA content in EFM cells. A reduction in *heag* mediated K⁺ currents in SHSY-5Y cells by treatment with antisense ODN is shown in Fig. 16B and C.

Treatment of *heag* expressing tumor cell lines with antisense ODNs significantly reduced the yield of amplified PCR products. EFM-19 cells were treated with 10 µg/ml DAC30 (lanes "C") or 10 µg/ml DAC30 (Eurogentec) plus 1 µM antisense ODN (lanes "AS") overnight, total RNA was extracted and assayed under the same conditions as described in Example 3, with ODNs designed to either amplify *heag* or the transferrin receptor. The arrows in Fig. 16A mark the expected sizes of the amplified fragments. Further, to dissect the *heag* current in SHSY-5Y neuroblastoma cells, the inventors utilized the voltage-dependence of the activation of *eag* (30) in the presence of extracellular Mg²⁺. The current was measured after a depolarization to +60 mV from -120 mV (Fig. 16B, gray lines). The first part of the subtracted trace (Fig. 16B, black line) corresponds to *eag* current that has not yet activated when the holding potential is very negative (-120 mV), but becomes evident if the holding potential is -60 mV. The average current between 19 and 21 ms was chosen to determine the current density. The current density in SHSY-5Y cells treated with antisense ODNs was significantly reduced as compared to control cells

(The electrophysiological determinations were performed using standard protocols in the whole cell configuration of the patch-clamp technique (Hamill, O.P., Marty, A., Neher, E., Sakmann, B., Sigworth, F.J. Pflügers Arch- Eur. J. Physiol 391, 85 (1981)), with an extracellular solution containing (mM) 140 NaCl, 2.5 KCl, 2 CaCl₂, 2 MgCl₂, 10 Hepes/NaOH pH 7.2, 10 glucose. The pipette solution was (mM) 140 KCl, 10 BAPTA, 10 Hepes/ KOH pH 7.2.). The cells were treated overnight with antisense ODN 1 μ M containing fluorescein-labeled ODN. The currents were determined 1 to 3 days later in cells showing fluorescence in their nuclei. The bars in Fig. 16C represent mean \pm S.E.M. for 9 cells (control) or 25 cells (antisense). Only the outward currents were evaluated in the analysis. Furthermore, the inhibition of DNA synthesis in human cancer cells (EFM-19, HeLa and SHSY-5Y) by antisense ODNs directed against *heag* was investigated. DNA synthesis is expressed relative to BrdU incorporation in the absence of ODNs. The uptake conditions into cells using fluorescein labeled antisense ODN was optimized. Cells were seeded in 96-well plates at a density of 105 cells/ml. One day after plating, the cells were washed with culture medium and the ODN was added (final concentration 10 μ M). The ODN had previously been mixed with 20 μ g/ml of the transfection reagent DAC-30 (Eurogentec) in serum-free medium and allowed to incubate at room temperature for 20-30 min. The mixture was then added as a 1:1 dilution in culture medium and maintained in contact with cells overnight. After this incubation, the cells were washed and labeled with BrdU (100 μ M) for 2 h. Incorporation was detected using the kit from Boehringer Mannheim and measured as OD units at 405 nm (reference 490 nm) after subtraction of the non-specific background incorporation. (Fig. 16D). The bars indicate mean \pm S.D. for eight wells per condition in a representative experiment.

Glossary and List of Abbreviations

Cell lines:

CHO	CHO-K1 (ATCC CCL 61)	Chinese hamster <i>Cricetulus griseus</i> ovary
HEK293	293 (ATCC CRL 1573)	Transformed primary human embryonal kidney
NIH3T3	(ATCC CRL 1658)	Embryo Swiss mouse fibroblasts
MCF7	(ATCC HTB 22)	Human breast adenocarcinoma
WT	Wild-type cells	

Genes and gene products

<i>eag</i>	<i>ether-à-go-go</i> potassium channel
<i>HERG</i>	Human- <i>Eag</i> -Related Gene. Codes for an inwardly rectifying potassium channel mainly expressed in heart.
Kv1.4	Inactivating voltage-dependent potassium channel. Initially cloned from rat brain, it is present in many other tissues.

Others

EGF	Epidermal growth factor
-----	-------------------------

PDGF	Platelet-derived growth factor
FCS	Fetal calf serum
I-V relation	Current-Voltage relation
LQT	Long Q-T (interval between Q and T waves in the electrocardiogram). Induces severe arrhythmias due to repolarization defects.
BrdU	5-Bromo-2'-deoxyuridine. Structure analog of thymidine.
IC50	Concentration that produces 50% inhibition
RT-PCR. in	Polymerase Chain Reaction of cDNA produced by reverse transcription the same tube.

References

1. Moody, W. J. (1995). Critical periods of early development created by the coordinate modulation of ion channel properties. *Perspect Dev Neurobiol* **2**, 309-315.
2. Woodfork, K. A., Wonderlin, W. F., Peterson, V. A., and Strobl, J. S. (1995). Inhibition of ATP-sensitive potassium channels causes reversible cell-cycle arrest of human breast cancer cells in tissue culture. *J Cell Physiol* **162**, 163-71.
3. Lepple Wienhues, A., Berweck, S., Bohmig, M., Leo, C. P., Meyling, B., Garbe, C., and Wiederholt, M. (1996). K⁺ channels and the intracellular calcium signal in human melanoma cell proliferation. *J Membr Biol* **151**, 149-57.
4. Wonderlin, W. F., Woodfork, K. A., and Strobl, J. S. (1995). Changes in membrane potential during the progression of MCF-7 human mammary tumor cells through the cell cycle. *J Cell Physiol* **165**, 177-85.
5. Brüggemann, A., Stühmer, W., and Pardo, L. A. (1997). Mitosis-promoting factor-mediated suppression of a cloned delayed rectifier potassium channel expressed in *Xenopus* oocytes. *Proc Nat Acad Sci USA* **94**, 537-542.
6. Mosmann, T. (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *J. Immunol. Meth.* **65**, 55-63.
7. Muir, D., Varon, S., and Manthorpe, M. (1990). An enzyme-linked immunosorbent assay for bromodeoxyuridine incorporation using fixed microcultures. *Anal. Biochem.* **185**, 377-82.
8. Magaud, J. P., Sargent, I., and Mason, D. Y. (1988). Detection of human white cell proliferative responses by immunoenzymatic measurement of bromodeoxyuridine uptake. *J. Immunol. Meth.* **106**, 95-100.
9. Huong, P. L., Kolk, A. H., Eggelte, T. A., Verstijnen, C. P., Gilis, H., and Hendriks, J. T. (1991). Measurement of antigen specific lymphocyte proliferation using 5-bromo-deoxyuridine incorporation. An easy and low cost alternative to radioactive thymidine incorporation. *J. Immunol. Meth.* **140**, 243-8.
10. Ellwart, J., and Dormer, P. (1985). Effect of 5-fluoro-2'-deoxyuridine (FdUrd) on 5-bromo-2'-deoxyuridine (BrdUrd) incorporation into DNA measured with a monoclonal BrdUrd antibody and by the BrdUrd/Hoechst quenching effect. *Cytometry* **6**, 513-20.

11. Benson, D. W., MacRae, C. A., Vesely, M. R., Walsh, E. P., Seidman, J. G., Seidman, C. E., and Satler, C. A. (1996). Missense mutation in the pore region of *HERG* causes familial long QT syndrome. *Circulation* **93**, 1791-5.
12. Curran, M. E., Splawski, I., Timothy, K. W., Vincent, G. M., Green, E. D., and Keating, M. T. (1995). A molecular basis for cardiac arrhythmia: *HERG* mutations cause long QT syndrome. *Cell* **80**, 795-803.
13. Sanguinetti, M. C., Jiang, C., Curran, M. E., and Keating, M. T. (1995). A mechanistic link between an inherited and an acquired cardiac arrhythmia: *HERG* encodes the IKr potassium channel. *Cell* **81**, 299-307.
14. Spector, P. S., Curran, M. E., Keating, M. T., and Sanguinetti, M. C. (1996). Class III antiarrhythmic drugs block *HERG*, a human cardiac delayed rectifier K⁺ channel. Open-channel block by methanesulfonanilides. *Circ Res* **78**, 499-503.
15. Trudeau, M. C., Warmke, J. W., Ganetzky, B., and Robertson, G. A. (1995). *HERG*, a human inward rectifier in the voltage-gated potassium channel family. *Science* **269**, 92-5.
16. Suessbrich, H., Waldegger, S., Lang, F., and Busch, A. E. (1996). Blockade of *HERG* channels expressed in *Xenopus* oocytes by the histamine receptor antagonists terfenadine and astemizole. *FEBS Lett* **385**, 77-80.
17. For example, see: DeCoursey, T.E., Chandy, K.G., Gupta, S., Cahalan, M.D. *Nature* **307**, 465 (1984); Mauro, T., Dixon, D.B., Komuves, L., Hanley, K., Pappone, P.A. *J. Invest. Dermat.* **108**, 864 (1997).
18. Rouzair-Dubois, B. and Dubois, J.M. *J. Physiol.* **510**, 93 (1998).
19. Arcangeli, A., L. Bianchi, et al. *J. Physiol.* **489**, 455-471 (1995). Bianchi, L. et al., *Cancer Res.* **58**, 815-822 (1998).
20. Brüggemann, A., Stühmer, W., Pardo, L.A. *Proc. Natl. Acad. Sci. USA.* **94**, 537 (1997). Pardo, L.A., Brüggemann, A., Camacho, J., Stühmer, W. *J. Cell. Biol.* **143**, 767 (1998).
21. Ludwig, J., et al., *EMBO J.* **13**, 4451 (1994).
22. Mosmann, T. *J. Immunol. Meth.* **65**, 55 (1983). Cells were incubated with MTT (Thiazolyl blue) 50 µg/ml for 4h, and the formazan crystals were solubilized in 10% SDS, 10mM HCl for 12-14 h. The optical density at 570 nm was measured using an ELISA reader, with a reference wavelength of 650 nm.

23. Stein, G.S. et al., in Cell Growth and Apoptosis. A Practical Approach, G.P. Studzinski, Ed. (IRL Press, Oxford, 1995) pp.193-203.
24. Jainchill, J.L., Aaronson, S.A., Todaro, G.J. J. Virol. 4, 549 (1969).
25. Hermouet, S., Merendino, J.J., Jr., Gutkind, S., Spiegel, A.M. Proc. Natl. Acad. Sci. USA 88, 10455 (1991).
26. GenBank Accession Numbers for the sequences reported in this paper are AF078741 (*heag* A) and AF078742 (*heag* B).
27. Occhiodoro, T. et al., FEBS Lett. 434, 177 (1998).
28. Warmke, J.W. and Ganetzki, B. Proc. Natl. Acad. Sci. USA. 91, 3438 (1994). Frings, S., et al., J. Gen. Physiol. 111, 583 (1998).
29. Heng, H.H.Q., Squire, J., Tsui, L.-C. Proc. Natl. Acad. Sci. USA, 89, 9509 (1992); Heng, H.H.Q., and Tsui, L.-C. Chromosoma, 102, 325 (1993). We acknowledge Dr. Henry Heng (SeeDNA Biotech, Downsview, Ontario, Canada) for FISH analysis.
30. Terlau, H., et al., Pflügers Arch. - Eur. J. Physiol., 432, 301 (1996). Terlau, H., Heinemann, S.H., Stühmer, W., Pongs, O., Ludwig, J. J. Physiol., 502, 537-543 (1997). Meyer, R. and Heinemann, S.H. J. Physiol. 508, 49 (1998).
31. Bijlenga, P., et al. J. Physiol. 512, 317 (1998).
32. Bosma, G.C., et al. Nature 301, 527-530 (1987)
33. Chen, C. and Okayama, H. Mol. Cell Biol. 7, 2745 (1987).
34. Chomczynski, P. and Sacchi, N. Anal. Biochem. 162, 156 (1987).
35. Soto, F., et al., Proc. Natl. Acad. Sci. USA. 93, 3684 (1996).
36. McClelland, A., Kühn, L.C., Ruddle, F.H. Cell 39, 267 (1984). Schneider, C., Owen, M.J., Banville, D., Williams, J.G. Nature 311, 675 (1984).
37. Evans, P. and Kemp, J. Gene 199, 123 (1997).

This application incorporates by reference international application PCT/EP99/02695, filed April 21, 1999, which designated the United States.

Claims

1. A nucleic acid molecule comprising a nucleic acid molecule encoding a (poly)peptide having a function of the human K⁺ ion *eag* channel which is
 - (a) a nucleic acid molecule comprising a nucleic acid molecule encoding the polypeptide having the amino acid sequence of SEQ ID: No 3 or 4;
 - (b) a nucleic acid molecule comprising the nucleic acid molecule having the DNA sequence of SEQ ID: No 13 or 14;
 - (c) a nucleic acid molecule hybridizing to the complementary strand of a nucleic acid molecule of (a) or (b); or
 - (d) a nucleic acid molecule being degenerate to the sequence of the nucleic acid molecule of (c).
2. A nucleic acid molecule specifically hybridizing to the nucleic acid molecule of claim 1 which comprises the sequence 5'-GGGAGGATGACCATGGCT.
3. The nucleic acid molecule of claim 1 or 2 which is DNA.
4. The nucleic acid molecule of claim 1 or 2 which is RNA.
5. The nucleic acid molecule of any one of claims 1 to 4 encoding a fusion protein.
6. A vector comprising the nucleic acid molecule of any one of claims 1 to 5.
7. The vector of claim 6 which is an expression vector and/or a gene targeting or gene transfer vector.
8. A host transformed with a vector of claim 6 or 7.
9. The host of claim 8 which is a mammalian cell, a fungal cell, a plant cell, an insect cell or a bacterial cell.

10. A method of producing the (poly)peptide encoded by the nucleic acid molecule of any one of claims 1 or 3 to 5 comprising culturing the host of claim 8 or 9 and isolating the produced (poly)peptide.
11. A (poly)peptide encoded by the nucleic acid of any one of claims 1 or 3 to 5 or produced by the method of claim 10.
12. An antibody specifically directed to the (poly)peptide of claim 11.
13. The antibody of claim 12 which is a monoclonal antibody.
14. A pharmaceutical composition comprising the nucleic acid molecule of claim 2, the vector of claim 6, the polypeptide of claim 11 and/or the antibody of claim 12 or 13 and a pharmaceutically acceptable carrier and/or diluent and/or excipient.
15. A diagnostic composition comprising the nucleic acid molecule of any one of claims 1 to 5, the vector of claim 6, the polypeptide of claim 11 and/or the antibody of claim 12 or 13.
16. A method for preventing or treating a disease which is caused by the undesired expression or overexpression of the nucleic acid molecule of any one of claims 1 or 3 to 5, comprising introducing an inhibitor of the expression of the nucleic acid molecule of any one of claims 1 or 3 to 5 or an inhibitor of function of the (poly)peptide of claim 11 into a mammal affected by said disease or being suspected of being susceptible to said disease.
17. A method for preventing or treating a disease which is caused by the malfunction of the (poly)peptide of claim 11 comprising introducing an inhibitor of the expression of the nucleic acid molecule of any one of claims 1 or 3 to 5 or an inhibitor or modifying agent of the malfunction of the (poly)peptide of claim 11 or the nucleic acid molecule of any one of claims 1 or 3 to 5 encoding *heag* or the

polypeptide of claim 11 having heag activity into a mammal affected by said disease or being suspected of being susceptible to said disease.

18. The method of claim 16 wherein said inhibitor of the expression or overexpression of said nucleic acid molecule is a nucleic acid molecule of claim 2.
19. The method of claim 16 wherein said inhibitor of polypeptide function is the antibody of claim 12 or 13 or a drug, preferably astemizole or terfenadine.
20. The method of any one of claims 16 to 19 further comprising, prior to the introduction step,
 - (a) obtaining cells from the mammal infected by said disease and, after said introduction step, wherein said introduction is effected into said cells,
 - (b) reintroducing said cells into said mammal or into a mammal of the same species.
21. The method of any one of claims 16 to 20 wherein said cell is a germ cell, an embryonic cell or an egg cell or a cell derived therefrom.
22. A method of designing a drug for the treatment of a disease which is caused by the undesired expression or overexpression of the nucleic acid molecule of any one of claims 1 and 3 to 5 comprising
 - (a) identification of a specific and potent drugs;
 - (b) identification of the binding site of said drug by site-directed mutagenesis and chimeric protein studies;
 - (c) molecular modeling of both the binding site in the (poly)peptide and the structure of said drug; and
 - (c) modifications of the drug to improve its binding specificity for the (poly)peptide.

23. A method of identifying an inhibitor of the expression of the nucleic acid molecule of any one of claims 1 or 3 to 5 or an inhibitor of a function of the (poly)peptide of claim 11 comprising:
- (a) testing a compound for the inhibition or reduction of translation wherein said compound is selected from antisense oligonucleotides and/or ribozymes; or
 - (b) testing a compound for the inhibition of transcription wherein said compound binds to the promoter region of the gene encoding the (poly)peptide of claim 11 and preferably with transcription factor responsive elements thereof; or
 - (c) testing peptides or antibodies suspected to block the proliferative activity of the (poly)peptide of claim 11 for said blocking activity.
24. The method of claim 22 or 23 wherein said drug or inhibitor is further improved by peptidomimetics or by applying phage-display or combinatorial library techniques.
25. A method of inhibiting cell proliferation comprising applying an inhibitor to expression of the nucleic acid of any one of claims 1 or 3 to 5 or the (poly)peptide of claim 11.
26. A method of prognosing cancer and/or neurodegenerative diseases and/or psoriasis comprising assessing the expression of the nucleic acid molecule of any one of claims 1 and 3 to 5 or assessing the quantitative presence of the polypeptide of claim 11 in cells of a mammal.
27. The method of claim 26, wherein said cancer is mamma carcinoma or neuroblastoma or cervix carcinoma.
28. The method of claim 27, wherein said mamma carcinoma is breast adenocarcinoma, breast carcinoma ductal type.

29. The method of claim 26, wherein said neurodegenerative disease is Alzheimer's disease, Parkinson's disease, lateral amyotrophic sclerosis or multiple sclerosis.
30. The method of any one of claims 16 to 21 and 26 to 29 wherein said mammal is a human, rat or mouse.
31. Use of the nucleic acid molecule of any one of claims 1 to 5 in gene therapy.
32. Kit comprising the nucleic acid molecule of claim 2, the vector of claim 6, the polypeptide of claim 11 and/or the antibody of claim 12 or 13.

202504151510

ABSTRACT

The present invention relates to a novel human K⁺ ion channel, to nucleic acid molecules encoding the same and to vectors comprising said nucleic acid molecules. The invention additionally relates to antibodies specifically directed to the novel K⁺ ion channel and to pharmaceutical compositions and diagnostic kits containing at least one of the above-mentioned components. Furthermore, the present invention relates to methods of treating a disease caused by malfunction of the polypeptide of the present invention or by the (over)expression of the nucleic acid molecule of the invention comprising administering an inhibitor of said (over)expression or of ion channel function or an inhibitor abolishing said malfunction to a patient in need thereof. Methods of devising drugs for treating or preventing the above-mentioned disease, methods of inhibiting cell proliferation and methods of prognosing cancer are additional embodiments comprised by the present invention. The invention also envisages specific antisense or gene therapies on the basis of the nucleic acid molecule of the invention for inhibiting undesired cellular proliferation, for example, in connection with cancer or in neurodegenerative diseases.

10% FCS




Fig. 1

0.5% FCS





Fig. 2

**Fig. 3**

Foci formation in *r-eag*-transfected NIH-3T3 cells




Fig. 4a




Fig. 4b





Fig. 5

6/37




2 pA
100 ms

— 5 μ M Astemizole

Fig. 6

A



B




Fig. 7




Fig. 8





Figure 9

heag	-	A	A	T	T	C	C	G	G	-	G	C	-	-	-	-	-	-	-	-	-	C	C	G	C	C	C	C	G	A	G	C	26						
beag	-	G	T	G	C	C	G	G	A	C	G	C	-	-	-	-	-	-	-	-	-	C	C	C	C	C	C	C	G	A	G	C	187						
reag	T	G	C	G	G	T	G	A	G	A	C	A	C	G	G	C	C	C	C	C	C	C	C	C	C	C	C	C	A	G	C	199							
heag	T	G	C	T	G	G	A	G	A	T	G	A	C	C	A	T	G	G	C	T	G	G	G	G	C	A	G	G	A	C	T	A	66						
beag	T	G	C	C	G	G	A	G	A	T	G	A	C	C	A	T	G	G	C	T	G	G	G	G	C	A	G	A	A	G	G	A	C	T	227				
reag	A	G	T	A	G	G	A	G	A	T	G	A	C	C	A	T	G	G	C	T	G	G	C	C	G	G	C	A	T	A	C	T	A	239					
heag	G	T	G	G	C	C	C	T	C	A	A	A	C	A	C	G	T	T	C	T	G	G	A	G	A	A	T	A	T	T	G	T	C	G	C	106			
beag	G	T	G	G	C	C	C	G	C	A	A	A	C	A	C	G	T	T	C	T	G	G	A	G	A	A	T	A	T	T	G	T	C	G	C	267			
reag	G	T	G	G	C	C	C	G	C	A	G	A	C	A	C	A	T	T	C	T	G	G	A	G	A	A	C	A	T	C	G	T	G	C	279				
heag	G	G	T	C	C	A	A	T	G	A	T	A	C	T	A	T	T	T	G	T	G	T	G	G	A	A	T	G	C	T	C	A	G	A	T	146			
beag	G	G	T	C	C	A	A	T	G	A	T	A	C	T	A	A	C	T	T	T	G	T	T	G	G	A	A	T	G	C	C	A	G	A	T	307			
reag	G	G	T	C	C	A	A	C	G	A	C	A	T	T	T	T	T	T	G	T	G	T	G	G	A	A	T	G	C	C	A	G	A	T	319				
heag	A	G	T	G	A	C	T	G	G	C	C	T	A	T	T	T	T	T	A	C	A	G	C	A	A	T	G	A	T	T	T	T	G	C	186				
beag	A	G	T	G	A	C	T	G	G	C	C	T	A	T	C	G	T	G	T	A	C	A	G	C	A	A	T	G	A	T	T	T	T	G	C	347			
reag	C	G	T	G	A	C	T	G	G	C	C	C	A	T	C	G	T	G	T	A	C	A	G	C	A	A	T	G	A	T	T	C	T	T	G	C	359		
heag	A	A	G	C	T	G	T	C	T	G	G	C	T	A	T	C	A	G	G	C	A	G	A	A	G	T	G	A	T	G	C	A	A	A	A	226			
beag	A	A	G	C	T	G	T	C	T	G	G	C	T	A	T	C	A	G	G	C	G	A	A	G	T	G	A	T	G	C	A	A	A	A	A	387			
reag	A	A	G	C	T	G	T	C	T	G	G	C	T	A	T	C	A	C	A	G	G	C	G	A	A	G	T	G	A	T	G	C	A	A	A	G	A	399	
heag	G	C	A	G	C	A	C	C	T	G	C	A	G	T	T	T	A	T	G	T	A	T	G	G	A	G	C	T	G	A	C	T	G	A	T	A	A	266	
beag	G	C	A	G	T	A	C	A	T	G	C	A	G	T	T	T	T	A	T	G	T	A	T	G	G	G	A	G	C	T	G	A	C	C	G	A	T	A	427
reag	G	T	A	G	C	G	C	C	T	G	C	A	G	T	T	T	A	T	G	T	A	T	G	T	G	A	G	C	T	G	A	C	C	G	A	C	A	439	

Fig. 10

heag	A	G	A	C	A	C	G	A	T	T	G	A	A	A	A	G	T	G	C	G	C	A	A	A	C	A	T	T	T	G	A	A	C	T	A	T	306			
beag	A	G	A	T	A	C	A	T	T	G	A	A	A	A	A	G	T	G	C	G	C	A	A	A	C	T	T	T	T	G	A	A	C	T	A	T	467			
reag	G	G	A	C	A	C	G	G	T	T	G	A	A	A	G	T	T	C	G	C	C	A	G	A	C	T	T	T	T	G	A	A	C	T	A	C	479			
heag	G	A	G	A	T	G	A	A	T	T	C	C	T	T	T	G	A	A	T	T	C	T	G	A	T	G	T	A	C	A	A	G	A	A	C	A	346			
beag	G	A	G	A	T	G	A	A	T	T	C	C	T	T	T	G	A	T	T	C	T	G	A	T	G	T	A	C	A	A	G	A	A	C	A	A	507			
reag	G	A	G	A	T	G	A	C	T	C	C	T	T	C	G	A	A	T	T	C	T	G	A	T	G	T	A	C	A	A	G	A	A	C	A	A	519			
heag	G	G	A	C	A	C	C	T	G	T	G	T	G	T	T	C	T	T	T	G	T	G	A	A	A	A	T	T	G	C	T	C	C	A	A	T	C	G	386	
beag	G	G	A	C	A	C	C	T	G	T	G	T	G	T	T	C	T	T	T	G	T	G	A	A	A	A	T	T	G	C	T	C	C	A	A	T	C	G	547	
reag	G	G	A	C	A	C	C	T	G	T	G	T	G	T	T	T	T	T	T	G	T	G	A	A	G	A	T	C	G	C	T	C	C	A	A	T	C	A	G	559
heag	A	A	C	G	A	A	C	A	G	G	A	T	A	A	A	A	G	T	G	T	T	T	A	T	T	T	C	T	T	T	G	C	A	C	T	T	C	426		
beag	A	A	C	G	A	A	C	A	G	G	A	T	A	A	A	A	G	T	G	G	T	T	T	A	T	T	T	C	T	T	T	G	C	A	C	T	T	C	587	
reag	G	A	A	C	G	A	A	C	A	G	G	A	T	A	A	A	A	G	T	G	G	T	C	T	G	T	C	T	T	T	T	G	C	A	C	T	T	C	599	
heag	A	G	T	G	A	C	A	T	A	A	C	A	G	C	T	T	C	A	A	T	T	G	A	T	T	G	A	T	T	G	A	G	A	T	G	A	T	T	466	
beag	A	G	T	G	A	C	A	T	A	A	C	C	G	C	T	T	C	A	A	C	A	G	C	C	G	A	T	T	G	A	A	G	A	T	G	A	T	T	627	
reag	A	G	T	G	A	C	A	T	A	A	C	G	G	C	A	T	C	A	A	G	C	A	G	C	C	C	A	T	T	G	A	G	A	C	G	A	C	T	639	
heag	C	A	T	G	T	A	A	G	G	C	T	G	G	G	G	A	A	G	T	T	T	G	C	T	C	G	C	T	G	A	C	A	A	G	A	G	C	506		
beag	C	A	T	G	T	A	A	G	G	C	T	G	G	G	G	A	A	G	T	T	C	G	C	T	C	G	G	C	T	G	A	C	C	A	G	A	G	C	667	
reag	C	C	T	G	C	A	A	G	G	T	T	G	G	G	A	A	G	T	T	T	G	C	T	C	G	A	C	T	G	A	C	G	A	G	A	G	C	679		
heag	A	C	T	G	A	C	A	A	G	C	A	G	C	A	G	G	G	T	G	T	C	C	T	G	C	A	G	C	A	G	C	T	G	G	C	T	C	A	546	
beag	A	C	T	G	A	C	G	A	G	C	A	G	C	C	G	G	G	T	G	T	C	C	T	G	C	A	G	C	A	G	C	T	G	G	C	T	C	C	707	
reag	T	C	T	G	A	C	A	A	G	C	A	G	C	A	G	G	G	A	G	T	C	C	T	C	T	G	C	A	G	C	A	G	C	T	G	G	C	C	C	719

Fig. 10 cont.

heag	A	G	C	G	T	G	C	A	A	A	A	G	G	C	G	A	A	T	G	T	C	C	A	C	A	A	G	C	A	C	T	C	C	C	G	C	C	586	
beag	A	G	C	G	T	G	C	A	G	A	A	A	G	G	C	G	A	A	C	G	T	C	C	A	C	A	A	G	C	A	C	T	C	C	T	C	C	747	
reag	A	G	T	G	T	G	C	A	G	A	G	G	T	G	A	A	T	G	T	C	A	C	A	A	G	C	A	C	T	C	G	C	G	C	C	C	759		
heag	T	G	G	C	A	G	A	G	T	C	C	T	A	C	A	G	C	T	G	G	G	C	T	C	A	G	A	C	A	T	C	C	T	C	C	C	A	626	
beag	T	G	G	C	C	G	A	G	G	T	C	T	G	C	A	G	C	T	C	G	G	C	T	C	A	G	A	C	A	T	C	C	T	C	C	C	A	787	
reag	T	G	G	C	A	G	A	G	T	C	C	T	G	C	A	G	C	T	G	G	T	T	C	A	G	A	C	A	T	C	C	T	C	C	C	C	A	799	
heag	G	T	A	C	A	A	G	C	A	A	G	A	G	G	C	A	C	T	C	C	C	C	C	T	C	A	C	A	T	C	A	T	C	A	T	C	A	666	
beag	G	T	A	C	A	A	G	C	A	A	G	G	C	A	C	C	A	A	G	A	C	T	C	C	C	C	C	G	C	A	C	A	T	C	A	T	C	827	
reag	G	T	A	C	A	A	G	C	A	A	G	A	G	C	G	C	C	A	A	A	G	A	C	A	C	C	C	C	T	C	A	C	A	T	C	A	T	C	839
heag	T	T	A	C	A	T	T	A	T	T	G	T	G	T	T	T	T	A	A	G	A	C	C	G	T	G	G	A	T	T	G	G	A	T	C	A	T	C	706
beag	T	T	A	C	A	C	T	A	C	T	G	C	G	T	T	T	T	A	A	G	A	C	C	A	C	G	T	G	G	A	C	T	G	G	A	T	C	A	867
reag	C	T	A	C	A	C	T	A	C	T	G	T	G	T	C	T	T	A	A	G	A	C	C	A	A	T	G	G	A	T	T	G	G	A	T	C	A	879	
heag	T	C	T	T	G	A	T	C	T	T	G	A	C	C	T	T	A	T	A	C	A	G	C	C	A	T	C	T	T	G	T	C	C	T	C	T	A	746	
beag	T	C	C	T	G	A	T	C	C	T	A	C	C	T	T	C	T	A	C	A	C	A	G	C	C	A	T	C	C	T	G	G	T	T	C	C	T	A	907
reag	T	C	T	T	G	A	T	C	C	T	G	A	C	C	T	T	C	T	A	C	A	C	A	G	C	C	A	T	C	C	T	G	G	T	C	C	T	A	919
heag	T	A	A	T	G	T	C	T	C	C	T	T	C	A	A	A	C	C	A	G	G	C	A	G	A	T	A	T	G	T	G	C	C	T	G	G	C	786	
beag	C	A	A	C	G	T	C	T	C	C	T	T	T	A	A	A	C	C	A	G	G	C	A	G	A	C	A	A	C	G	T	G	C	C	T	G	G	947	
reag	C	A	A	C	G	T	C	T	C	C	T	T	T	A	A	A	C	C	A	G	C	C	A	G	A	T	A	C	G	T	G	C	C	T	G	C	959		
heag	C	T	G	G	T	T	G	T	T	G	A	T	A	G	C	A	T	C	G	T	G	G	A	T	C	T	T	T	T	T	T	T	T	T	T	T	G	826	
beag	C	T	G	G	T	T	G	T	G	A	C	A	G	C	A	T	C	G	T	G	G	A	T	G	T	C	A	T	T	T	T	T	T	T	T	T	G	987	
reag	C	T	G	G	T	G	T	G	G	A	C	A	G	C	A	T	C	G	T	G	G	A	T	G	T	C	A	T	C	T	T	T	T	T	T	T	G	999	

Fig. 10 cont.

heag	A	C	A	T	T	G	T	G	C	T	C	A	A	T	T	T	C	A	T	A	C	C	A	C	C	T	T	T	G	T	T	G	G	A	C	C	A	G	C	866	
beag	A	C	A	T	T	G	T	G	C	T	G	A	A	T	T	T	C	A	C	A	C	C	A	C	T	T	T	T	G	T	T	G	G	A	C	C	G	C	1027		
reag	A	C	A	T	T	G	T	C	T	T	G	A	A	T	T	T	C	A	C	A	C	C	A	C	C	T	T	T	G	T	C	G	G	C	C	A	G	C	1039		
heag	A	G	G	G	A	G	G	T	G	A	T	T	T	C	T	G	A	C	C	C	C	A	A	A	C	T	T	A	T	C	C	G	C	A	T	G	A	C	906		
beag	T	G	G	G	A	G	G	T	G	A	T	T	T	C	T	G	A	C	C	C	C	A	A	A	C	T	C	A	T	T	C	G	C	A	T	G	A	C	1067		
reag	G	G	G	G	A	A	G	T	G	A	T	C	T	C	T	G	A	C	C	C	C	A	A	A	C	T	T	A	T	C	C	G	C	A	T	G	A	C	1079		
heag	T	A	C	C	T	G	A	A	G	A	C	G	T	G	G	T	T	T	G	T	G	A	T	T	G	A	C	C	T	T	C	T	G	T	C	C	T	G	T	946	
beag	T	A	C	C	T	G	A	A	G	A	C	G	T	G	G	T	T	T	G	T	G	A	T	T	G	A	C	C	T	T	C	T	G	T	C	C	T	G	T	1107	
reag	T	A	C	C	T	G	A	A	G	A	C	G	T	G	G	T	T	T	G	T	G	A	T	C	G	A	C	C	T	T	C	T	C	T	C	C	T	G	T	1119	
heag	T	G	C	C	A	T	A	T	G	A	T	G	T	C	A	T	C	A	A	C	G	C	T	T	T	T	G	A	G	A	C	G	T	G	A	T	G	A	986		
beag	T	G	C	C	C	T	A	T	G	A	C	G	T	C	A	T	C	A	A	C	G	C	T	T	T	T	T	G	A	G	A	A	C	G	T	G	G	A	T	G	1147
reag	T	G	C	C	A	T	A	T	G	A	C	G	T	C	A	T	C	A	A	C	G	C	T	T	T	T	T	G	A	G	A	A	C	G	T	G	A	T	G	1159	
heag	G	G	G	C	A	T	C	A	G	C	A	G	C	C	T	G	T	T	C	A	G	C	T	C	T	C	T	A	A	A	A	G	T	T	G	T	C	C	G	1026	
beag	G	G	G	C	A	T	C	A	G	C	A	G	C	C	T	G	T	T	C	A	G	C	T	C	T	C	T	G	A	A	A	G	T	T	G	T	C	C	G	1187	
reag	G	G	G	C	A	T	C	A	G	C	A	G	C	C	T	G	T	T	C	A	G	T	T	C	T	C	T	G	A	A	A	G	T	C	G	T	G	C	G	1199	
heag	C	T	G	C	T	C	C	G	T	C	T	T	G	G	G	C	C	G	A	G	T	G	G	C	C	C	G	T	A	A	G	C	T	G	G	A	C	C	A	C	1066
beag	C	T	G	C	T	C	C	G	C	C	T	G	G	A	C	G	A	C	C	G	G	A	C	C	G	G	A	A	G	C	T	G	G	A	C	C	A	C	1227		
reag	C	T	G	C	T	C	C	G	T	C	T	C	T	C	G	A	C	G	A	G	T	G	G	C	C	G	C	A	A	G	C	T	G	G	A	C	A	T	1239		
heag	A	C	A	T	T	G	A	A	T	A	T	G	G	A	G	C	T	G	C	T	G	C	T	G	G	T	C	C	T	G	C	T	G	C	T	G	T	G	1106		
beag	A	C	A	T	C	G	A	G	T	A	T	G	G	A	G	C	T	G	C	C	G	G	T	G	C	T	C	C	T	G	C	T	G	G	T	G	1267				
reag	A	T	A	T	C	G	A	G	T	A	C	G	G	A	G	C	G	G	C	G	C	T	G	C	T	C	C	T	G	C	T	G	C	T	G	T	1279				

Fig. 10 cont.

heag	T	G	T	G	T	T	T	G	G	C	T	G	G	C	A	C	A	C	T	G	G	A	T	G	G	C	C	T	G	C	A	T	C	T	G	G	1146			
beag	T	G	T	G	T	C	G	G	G	C	T	G	G	C	C	G	C	T	G	G	A	T	G	G	C	C	T	G	C	A	T	T	G	C	A	T	G	G	1307	
reag	C	G	T	G	T	C	G	G	G	C	T	G	G	C	C	A	C	T	G	G	A	T	G	G	C	C	T	G	C	A	T	C	T	G	G	1319				
heag	T	A	C	A	G	C	A	T	T	G	G	G	A	C	T	A	T	G	A	C	G	A	T	T	T	G	A	C	A	C	A	C	A	C	A	1186				
beag	T	A	C	A	G	C	A	T	C	G	G	G	A	C	T	A	T	G	A	C	G	A	T	C	T	C	G	A	C	G	A	C	A	C	A	1347				
reag	T	A	C	A	G	C	A	T	T	G	G	G	A	T	T	A	T	G	A	T	G	A	A	G	A	A	G	A	C	A	C	A	1359							
heag	A	G	A	C	A	T	C	C	G	C	A	A	C	A	A	C	A	G	C	T	G	G	C	T	G	T	A	C	C	A	A	C	T	A	G	C	G	A	T	1226
beag	A	G	A	C	C	A	T	C	C	G	C	A	A	C	A	A	C	A	G	C	T	G	G	C	T	C	T	A	C	C	A	G	C	T	G	C	C	A	T	1387
reag	A	G	A	C	C	A	T	C	C	G	T	A	A	C	A	A	C	A	G	C	T	G	G	C	T	C	T	A	C	C	A	A	C	T	G	C	A	T	1399	
heag	G	G	A	C	A	T	T	G	G	C	A	C	C	C	C	T	T	A	C	A	G	T	T	A	A	C	G	G	G	T	C	T	G	C	T	C	A	1266		
beag	G	G	A	C	A	T	T	G	G	C	A	C	C	C	C	T	T	A	C	C	A	G	T	T	A	A	C	G	G	G	T	C	T	G	C	T	C	A	1427	
reag	G	G	A	C	A	T	T	G	G	C	A	C	T	C	C	A	T	A	C	C	A	G	T	T	A	A	T	G	G	T	C	T	G	T	T	C	G	1439		
heag	G	G	A	A	G	T	G	G	G	A	A	G	G	T	G	G	T	C	C	A	G	C	A	A	G	A	A	T	T	C	T	G	T	C	T	A	C	A	1306	
beag	G	G	A	A	G	T	G	G	G	A	A	G	G	G	G	G	T	C	C	C	A	G	C	A	A	G	A	A	T	T	C	C	G	T	C	T	A	C	A	1467
reag	G	G	A	A	G	T	G	G	G	A	A	G	G	C	G	G	G	C	C	A	A	G	C	A	A	G	A	A	C	T	C	C	G	T	A	T	A	C	A	1479
heag	T	C	T	C	C	T	C	G	T	T	G	T	A	T	T	C	A	A	T	G	A	C	C	A	G	C	C	T	C	A	C	C	A	G	T	G	T	1346		
beag	T	C	T	C	C	T	C	G	T	T	G	T	A	T	T	T	C	A	T	G	A	C	C	A	G	C	C	T	C	A	C	C	A	G	C	G	T	1507		
reag	T	T	C	C	T	C	G	C	T	G	T	A	C	T	T	C	A	C	A	A	G	T	C	T	C	A	C	C	A	G	T	G	T	1519						
heag	G	G	G	C	T	T	T	G	G	G	A	A	C	A	T	C	C	A	C	A	G	A	C	A	T	T	G	A	C	A	T	T	G	A	G	A	G	1386		
beag	G	G	G	C	T	T	T	G	G	G	A	A	C	A	T	C	G	C	C	G	T	C	C	A	C	A	G	A	C	A	T	T	G	A	G	A	G	1547		
reag	G	G	G	C	T	T	T	G	G	T	A	A	C	A	T	C	G	C	C	C	A	T	C	C	A	C	A	G	A	C	A	T	C	G	A	G	A	G	1559	

Fig. 10 cont.

heag	A	T	C	T	T	T	G	C	A	G	T	G	G	C	C	A	T	C	A	T	G	A	T	G	A	T	T	G	G	C	T	C	A	T	T	C	T	C	T	1426	
beag	A	T	C	T	T	T	G	C	C	C	G	T	G	G	C	C	A	T	C	A	T	G	A	T	G	A	T	T	G	G	C	T	C	C	T	C	T	C	T	1587	
reag	A	T	C	T	T	C	G	C	C	G	T	A	G	C	C	A	T	C	A	T	G	A	T	G	A	T	T	G	G	C	T	C	C	T	C	T	G	T	1599		
heag	A	T	G	C	C	A	C	C	A	T	C	T	T	C	T	T	G	G	A	A	T	G	T	G	A	C	T	A	T	T	T	T	T	C	C	A	A	C	A	1466	
beag	A	T	G	C	C	A	C	C	A	T	C	T	T	T	G	G	A	A	T	G	T	G	A	C	G	A	C	C	A	T	T	T	T	C	C	A	A	C	A	1627	
reag	A	T	G	C	C	A	C	C	A	T	C	T	T	T	G	G	A	A	T	G	T	G	A	C	G	A	C	C	A	T	T	T	T	C	C	A	G	C	A	1639	
heag	G	A	T	G	T	A	T	G	C	C	A	A	C	A	C	C	A	A	C	A	G	A	T	A	C	C	A	T	G	A	G	A	T	G	C	T	C	A	A	C	1506
beag	G	A	T	G	T	A	C	G	C	C	A	A	C	A	C	A	C	A	G	G	T	A	C	C	A	T	G	A	G	A	T	G	C	T	C	A	A	C	1667		
reag	G	A	T	G	T	A	T	G	C	C	A	A	C	A	C	A	C	A	G	G	T	A	T	C	A	T	G	A	G	A	T	G	C	T	C	A	A	C	1679		
heag	A	G	T	G	T	T	C	G	G	A	C	T	T	C	C	T	G	A	A	G	C	T	C	T	A	C	C	A	G	G	T	G	C	C	A	A	A	G	1546		
beag	A	G	T	G	T	C	C	G	G	A	C	T	T	C	T	T	C	T	G	A	A	G	C	T	C	T	A	C	C	A	G	T	G	C	C	A	A	G	1707		
reag	A	G	C	G	T	C	C	G	G	A	T	T	T	C	C	T	G	A	A	G	C	T	C	T	A	C	C	A	G	G	T	G	C	C	A	A	G	G	1719		
heag	G	A	T	T	G	A	G	T	G	A	C	C	G	A	T	A	T	G	G	A	T	T	G	T	G	T	T	G	T	G	T	C	C	A	C	T	T	G	1586		
beag	G	G	C	T	G	A	G	C	C	G	A	G	T	C	A	T	G	G	A	T	T	A	C	A	T	C	A	T	C	G	T	C	C	A	C	C	T	G	1747		
reag	G	G	C	T	G	A	G	C	C	G	A	G	G	T	C	A	T	G	G	A	C	T	A	C	A	T	T	G	T	G	T	C	T	A	C	C	T	G	1759		
heag	G	T	C	C	A	T	G	T	C	C	A	G	A	G	G	C	A	T	T	G	A	C	A	G	A	C	T	G	A	A	G	T	C	C	T	G	C	A	G	1626	
beag	G	T	C	C	A	T	G	T	C	C	A	G	A	G	G	C	A	T	T	G	A	C	A	C	A	G	A	A	G	G	T	C	C	T	G	C	A	G	1787		
reag	G	T	C	C	A	T	G	T	C	C	C	G	C	A	T	C	G	A	C	A	C	G	A	C	A	G	A	A	G	G	T	C	C	T	G	C	A	A	1799		
heag	A	T	C	T	G	C	C	C	A	A	G	G	A	C	A	T	G	A	G	C	C	G	A	C	C	A	T	C	T	G	C	G	T	G	C	A	C	C	1666		
beag	A	T	C	T	G	C	C	C	C	A	A	G	G	A	C	A	T	G	A	G	C	G	A	C	A	T	C	T	G	C	G	T	G	C	A	C	C	1827			
reag	A	T	C	T	G	C	C	C	C	A	A	G	G	A	C	A	T	G	C	C	T	G	A	C	A	T	T	G	C	G	T	A	C	C	A	C	C	1839			

Fig. 10 cont.

heag	T	G	A	A	C	C	G	C	A	A	G	G	A	G	C	A	C	C	C	G	G	C	C	T	T	C	C	G	G	C	T	1706					
beag	T	A	A	A	C	C	G	C	A	A	G	G	A	G	C	A	C	C	C	A	G	C	C	T	T	T	C	G	G	C	T	1867					
reag	T	G	A	A	C	C	G	A	A	A	A	G	A	A	G	A	A	C	C	C	G	C	C	T	T	C	C	G	G	C	T	1879					
heag	G	G	C	C	A	G	T	G	A	T	G	G	C	T	C	C	G	G	C	A	T	G	G	C	C	A	T	G	G	A	T	C	1746				
beag	G	G	C	C	A	G	C	G	A	C	G	G	C	T	G	C	G	C	A	C	T	G	G	C	C	A	T	G	G	A	T	C	1907				
reag	G	G	C	C	A	G	C	G	A	T	G	G	T	G	A	G	G	C	C	T	T	G	G	C	C	A	T	G	G	A	T	C	1919				
heag	C	A	G	A	C	G	G	T	G	C	A	C	T	G	T	G	C	C	C	A	G	G	G	A	C	C	T	C	A	C	C	A	T	G	1786		
beag	C	A	G	A	C	G	G	T	G	C	A	C	T	G	C	C	C	C	C	T	G	G	G	A	C	C	T	C	A	C	C	A	C	G	1947		
reag	C	A	G	A	C	A	G	T	A	C	A	C	T	G	C	C	C	C	C	A	G	G	G	A	C	C	T	C	A	T	C	A	C	G	1959		
heag	C	A	G	G	A	G	A	G	C	G	T	T	G	A	C	A	G	C	C	T	T	G	T	G	T	C	T	T	C	T	C	T	G	G	1826		
beag	C	A	G	G	A	G	A	G	C	G	T	C	G	A	C	A	G	C	C	T	G	C	T	T	C	T	T	C	T	C	C	A	T	T	1987		
reag	C	C	G	G	A	G	A	G	T	G	T	G	A	C	A	G	C	C	T	C	T	C	T	C	T	C	T	C	T	C	C	A	T	G	1999		
heag	C	T	C	C	C	T	G	G	A	G	G	T	G	A	T	C	C	A	A	G	A	T	G	G	T	G	G	C	C	A	T	T	1866				
beag	C	T	C	C	C	T	G	G	A	G	G	T	G	A	T	C	C	A	G	A	T	G	A	C	G	A	G	G	T	G	C	C	A	T	2027		
reag	C	T	C	C	C	T	G	G	A	G	G	T	G	A	T	C	C	A	G	A	T	G	A	T	G	G	T	G	C	C	A	T	C	2039			
heag	C	T	A	G	G	A	A	A	G	G	A	G	A	C	G	T	G	T	T	G	G	A	G	A	T	G	T	T	C	T	G	G	A	A	G	1906	
beag	C	T	A	G	G	A	A	A	G	G	A	G	A	C	G	T	G	T	T	T	G	G	A	G	A	C	G	T	T	C	T	G	A	A	G	2067	
reag	C	T	A	G	G	A	A	A	G	G	A	G	A	T	G	T	T	T	T	T	G	G	G	G	A	T	T	C	T	G	G	A	A	G	2079		
heag	A	A	G	C	C	A	C	C	C	T	T	G	C	C	A	G	T	C	C	A	A	T	G	T	T	A	G	G	C	C	T	T	1946				
beag	A	A	G	C	C	A	C	C	C	T	T	G	C	C	C	A	G	T	G	T	G	C	C	A	A	T	G	T	G	A	G	G	C	C	T	2107	
reag	A	G	G	C	T	A	C	C	C	T	T	G	C	C	A	G	T	C	C	T	G	C	C	T	A	A	T	G	T	C	C	G	G	C	C	T	2119

Fig. 10 cont.

heag	G	A	C	C	T	A	C	T	G	T	G	A	T	C	T	G	C	A	T	G	T	G	A	T	G	C	C	T	G	1986				
beag	G	A	C	C	T	A	C	T	G	T	G	A	C	C	C	A	T	G	T	G	A	C	G	C	C	C	T	G	2147					
reag	G	A	C	C	T	A	C	T	G	T	G	A	C	C	T	G	C	A	T	G	T	G	A	A	G	G	C	C	T	G	2159			
heag	C	A	G	A	A	G	T	G	C	T	G	A	T	T	C	T	A	C	A	C	G	G	C	C	T	T	C	C	T	2026				
beag	C	A	G	A	A	G	T	G	C	T	G	A	T	T	C	T	A	C	A	A	G	C	C	T	T	C	C	C	T	2187				
reag	C	A	G	A	A	G	T	G	C	T	A	G	A	A	T	T	C	T	A	C	A	A	G	C	C	T	T	C	C	T	2199			
heag	T	C	T	C	C	G	G	A	A	C	C	T	G	A	T	T	C	T	G	A	C	T	T	G	A	G	A	G	A	2066				
beag	T	C	T	C	C	G	G	A	A	C	C	T	C	A	T	T	C	T	T	G	A	C	T	T	G	A	G	C	G	2227				
reag	T	C	T	C	C	G	G	A	A	C	C	T	G	A	T	T	C	T	T	C	A	T	C	T	G	A	G	A	G	2239				
heag	G	A	T	T	G	T	T	C	C	G	G	A	T	C	A	G	C	G	A	T	G	T	G	A	A	C	G	T	G	A	2106			
beag	G	A	T	C	G	T	G	T	T	C	C	G	G	A	T	C	A	G	T	G	A	C	G	T	G	A	A	G	G	A	2267			
reag	G	A	T	T	G	T	T	C	C	G	G	A	T	C	A	G	C	G	A	C	G	T	G	A	A	C	G	A	G	A	A	2279		
heag	G	A	A	G	A	C	G	C	A	T	G	A	A	C	G	A	T	G	A	G	C	C	C	C	C	C	C	T	G	A	T	2146		
beag	G	A	G	G	A	G	C	C	A	T	G	A	A	G	C	G	A	A	T	G	A	G	C	C	C	C	C	T	G	A	T	2307		
reag	G	A	G	G	A	G	A	G	A	T	G	A	A	C	G	A	A	C	G	A	G	A	C	C	C	C	C	T	A	T	C	2319		
heag	T	G	C	C	C	G	A	C	C	T	G	T	C	C	T	G	T	C	C	A	G	A	T	T	C	C	C	C	C	T	G	A	T	2186
beag	T	G	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	2347	
reag	T	G	C	C	C	C	T	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	2359	
heag	C	C	G	A	C	A	G	C	A	G	A	G	C	T	G	C	C	A	G	C	T	G	A	G	A	G	A	G	G	G	2226			
beag	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	2387	
reag	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	C	2399	

Fig. 10 cont.

heag	G	G	C	C	G	G	A	C	C	T	G	G	A	T	G	A	C	C	T	A	G	A	T	G	T	G	G	A	G	G	C	A	A	T	G	2266				
beag	G	G	G	C	G	G	A	C	T	T	G	G	A	C	G	A	C	C	T	G	G	A	C	G	C	A	G	G	C	A	G	C	A	G	C	2427				
reag	G	G	C	C	G	G	A	C	C	T	G	G	A	T	G	A	T	G	T	G	A	G	A	G	G	C	A	A	T	G	C	A	A	T	G	2439				
heag	T	C	C	T	A	C	A	G	C	A	T	G	C	C	T	C	C	A	A	C	C	A	C	A	G	C	C	T	C	G	T	G	A	A	2306					
beag	T	C	C	T	C	A	C	G	A	G	C	A	-	-	-	-	G	C	C	A	-	C	C	A	C	G	C	C	T	G	C	G	A	A	2461					
reag	C	C	C	T	C	A	C	G	A	C	A	T	A	C	C	T	C	A	G	C	C	A	C	C	A	C	A	G	C	C	T	G	G	T	G	A	2479			
heag	G	G	C	C	A	G	C	G	T	G	T	C	A	C	C	G	T	G	A	G	T	C	C	T	G	C	C	A	C	G	C	C	C	C	C	2346				
beag	G	G	C	C	A	G	C	G	T	C	G	T	C	A	C	C	G	T	C	G	A	G	A	G	C	C	T	G	C	C	A	C	G	C	C	2501				
reag	G	G	C	C	A	G	T	G	T	G	T	C	A	C	G	G	T	G	A	G	T	C	C	C	G	C	C	A	C	G	C	C	T	G	C	2519				
heag	G	T	A	T	C	C	T	T	C	C	A	G	G	C	A	C	C	T	C	C	G	G	G	T	G	C	C	A	G	A	C	C	C	C	2386					
beag	G	T	G	G	C	C	T	T	C	C	G	G	C	G	C	C	T	G	C	C	C	G	G	G	C	T	G	C	T	G	A	T	C	C	2541					
reag	G	T	G	T	C	C	T	T	C	C	A	G	G	C	A	G	C	C	T	C	C	A	C	A	G	T	G	T	C	A	G	A	C	C	2559					
heag	A	C	G	C	A	A	G	C	T	A	C	A	G	G	C	C	A	G	G	T	C	C	G	A	G	T	G	C	C	T	G	G	C	C	C	2426				
beag	A	C	G	C	C	C	G	C	T	G	C	A	G	G	C	C	T	G	G	G	C	C	G	A	G	G	C	C	T	G	C	C	C	C	2581					
reag	A	C	G	C	C	A	A	G	C	T	G	C	A	T	G	C	A	C	C	G	G	A	T	C	T	G	A	G	T	G	C	T	A	G	T	C	2599			
heag	C	A	A	G	G	G	G	G	C	C	G	G	C	C	A	T	T	G	T	G	C	C	A	A	G	C	C	A	A	A	A	A	G	C	T	G	G	2466		
beag	C	A	A	G	C	C	G	C	G	G	G	C	C	G	A	C	T	G	C	C	A	A	G	C	C	A	A	G	G	C	A	A	G	G	C	T	G	2621		
reag	C	A	A	G	C	A	G	C	G	G	T	G	C	C	A	C	C	C	T	G	C	C	A	A	G	C	C	A	A	G	C	A	A	G	C	T	G	2639		
heag	G	C	C	C	G	C	T	T	C	A	A	A	G	A	T	G	C	G	G	A	A	G	T	G	A	G	A	C	T	G	G	A	C	T	G	G	A	2506		
beag	G	C	C	C	G	C	T	T	C	A	A	G	G	A	T	G	C	C	G	G	C	A	G	G	C	T	G	A	G	A	C	T	G	G	A	C	T	G	A	2661
reag	G	C	C	C	G	T	T	C	A	A	A	G	A	T	G	C	T	G	T	G	C	C	T	G	T	G	A	G	A	T	T	G	A	G	A	T	T	G	A	2679

Fig. 10 cont.

heag	A	C	A	A	G	G	T	G	T	C	C	A	A	G	G	C	T	G	A	G	T	C	G	A	G	A	C	T	T	C	C	G	A	2546							
beag	G	C	A	A	G	G	T	C	C	A	A	G	G	C	G	A	G	T	C	C	A	T	G	G	A	A	C	G	C	T	C	C	C	G	A	2701					
reag	A	C	A	A	G	G	T	G	T	C	C	A	A	G	G	C	A	G	A	G	T	C	C	A	T	G	G	A	G	A	C	G	C	T	T	C	C	G	A	2719	
heag	G	A	G	A	C	A	A	A	G	C	G	T	C	A	G	G	C	G	A	G	C	C	A	C	T	G	A	A	G	A	C	A	G	A	C	A	2586				
beag	G	A	G	A	C	G	A	A	G	G	C	C	G	C	C	G	G	C	G	A	G	C	C	A	C	T	C	A	A	G	A	A	C	G	A	C	2741				
reag	G	A	G	A	C	A	A	G	G	C	A	T	C	G	G	C	G	A	G	G	C	C	A	C	G	C	T	G	A	A	G	A	C	A	2759						
heag	G	A	C	T	C	G	T	G	T	G	A	C	A	G	T	G	G	C	A	T	C	A	C	C	A	A	G	A	G	C	G	A	C	T	T	G	C	C	2626		
beag	G	A	C	T	C	G	T	C	G	A	C	A	G	C	G	G	C	A	T	C	A	C	C	A	A	G	A	G	C	G	A	C	C	T	T	G	C	T	C	2781	
reag	G	A	C	T	C	C	T	G	T	G	A	C	A	G	T	G	G	A	A	T	C	A	C	C	A	A	G	A	T	G	A	C	C	T	T	G	C	T	2799		
heag	T	G	G	A	C	A	A	C	G	T	G	G	G	T	G	A	G	C	C	A	G	T	C	C	C	C	A	G	A	T	C	G	G	A	G	2666					
beag	T	G	G	A	C	A	A	C	G	T	G	G	G	C	G	A	G	C	C	A	G	A	G	C	C	C	C	A	G	A	C	C	G	G	A	G	2821				
reag	T	G	G	A	C	A	T	G	T	G	G	G	T	G	A	G	C	C	A	G	A	G	T	C	C	C	C	A	G	A	C	C	G	G	A	G	2839				
heag	T	C	C	C	A	T	C	C	T	G	G	C	A	G	A	G	G	T	C	A	A	G	C	A	T	T	C	T	C	T	A	C	C	C	A	T	C	2706			
beag	C	C	C	C	A	T	C	T	G	G	C	G	G	A	G	G	T	C	A	A	G	C	C	T	T	C	C	T	T	C	T	A	C	C	C	A	T	C	2861		
reag	C	C	C	C	A	T	C	T	T	G	G	C	C	G	A	G	G	T	C	A	A	G	C	A	T	T	T	C	T	A	C	C	C	C	A	T	C	2879			
heag	C	C	T	G	A	G	C	A	G	C	C	T	G	C	A	G	C	C	A	C	A	G	T	C	C	T	G	G	A	G	T	G	A	G	C	2746					
beag	C	C	C	G	A	G	C	A	G	C	G	C	T	G	C	A	G	C	C	G	C	C	G	C	C	T	G	G	A	G	G	T	G	A	A	G	C	2901			
reag	C	C	C	G	A	G	C	A	G	A	A	C	T	G	C	A	G	C	C	A	C	A	G	T	G	C	T	G	G	A	G	T	G	A	A	G	C	2919			
heag	A	C	G	A	G	C	T	G	A	A	G	G	A	G	A	C	A	T	C	A	A	G	C	C	T	T	A	A	A	C	G	C	C	A	A	A	T	2786			
beag	A	C	G	A	G	C	T	C	A	A	G	G	A	G	A	C	A	T	C	A	A	G	G	C	C	T	T	G	A	G	C	A	C	C	A	A	G	A	T	2941	
reag	A	T	G	A	G	C	T	G	A	A	G	G	A	A	G	A	C	A	T	C	A	A	G	G	C	T	T	G	A	T	G	A	A	T	G	C	C	A	A	T	2959

Fig. 10 cont.

heag	G	A	C	C	A	A	T	A	T	T	G	A	G	A	A	C	A	G	C	T	C	T	C	T	G	A	G	A	T	A	C	T	C	A	G	A	T	A	2826	
beag	G	A	C	G	A	G	C	A	T	T	G	A	G	A	A	C	A	G	C	T	C	T	C	T	G	A	G	A	T	A	C	T	C	A	G	A	T	A	2981	
reag	G	A	C	C	T	C	C	A	T	T	G	A	G	A	G	C	A	G	C	T	G	A	C	T	G	A	G	A	C	T	C	A	G	A	T	A	2999			
heag	T	T	A	A	C	T	T	C	C	A	G	A	A	G	A	T	C	C	T	C	C	A	G	T	C	C	T	C	C	T	C	A	G	A	G	T	T	G	T	2866
beag	T	T	A	A	C	C	T	C	C	A	G	A	A	G	A	T	C	C	T	C	G	C	C	T	C	A	G	A	C	T	A	C	T	A	C	T	A	T	3021	
reag	C	T	C	A	T	G	T	C	C	A	G	A	G	G	T	C	C	A	G	T	C	C	C	C	G	C	A	G	A	C	A	C	G	A	C	A	T	3039		
heag	T	T	G	A	A	T	A	T	C	G	A	G	G	C	C	A	C	A	G	T	C	C	C	A	G	A	T	C	A	G	A	G	A	G	A	G	A	2906		
beag	T	T	G	A	A	T	A	T	C	G	A	G	G	C	C	C	C	C	C	C	C	C	C	C	A	G	T	C	A	G	A	G	A	G	A	3061				
reag	G	T	G	A	G	G	T	C	C	A	G	G	C	C	C	C	C	C	C	C	C	C	C	A	G	T	C	A	G	A	C	A	G	A	G	A	3079			
heag	C	A	T	T	T	T	G	G	A	G	C	C	A	G	C	T	G	A	G	A	G	G	T	C	T	A	T	T	-	T	A	A	A	A	A	A	A	2945		
beag	C	A	T	T	T	T	G	G	C	G	C	A	A	G	C	T	G	A	G	A	G	T	C	T	G	T	T	G	T	A	A	A	A	A	A	A	3101			
reag	C	A	T	T	T	T	G	G	G	G	C	A	A	G	C	T	G	A	G	A	G	A	T	C	A	T	T	T	C	A	A	A	C	A	A	C	3119			
heag	G	-	-	-	-	-	-	-	-	T	C	-	-	A	G	A	-	G	A	C	A	G	A	T	A	C	C	T	C	C	A	A	C	C	T	G	C	C	2973	
beag	G	A	-	A	A	A	A	T	C	C	A	A	G	A	T	G	A	C	A	A	A	C	C	T	A	C	C	G	T	C	C	T	G	C	C	C	3140			
reag	A	A	C	A	A	A	A	T	C	A	A	-	-	G	A	C	A	-	G	A	C	A	A	A	G	C	T	G	C	C	-	C	C	T	G	C	C	3156		
heag	-	-	-	-	-	-	-	-	-	-	-	-	-	G	T	C	A	C	C	A	C	-	T	A	C	-	-	-	-	-	-	-	-	-	-	-	-	2992		
beag	C	T	A	G	A	C	A	C	C	A	C	A	C	A	C	A	C	C	A	C	C	A	T	G	A	C	C	A	A	C	A	A	C	C	C	C	3179			
reag	C	C	T	G	A	C	A	C	T	C	C	T	A	C	C	C	C	C	C	A	A	C	A	T	G	A	C	C	A	A	C	A	A	C	A	C	T	3196		
heag	C	C	C	G	G	A	T	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3002		
beag	T	T	C	A	A	G	T	A	G	G	C	T	T	T	C	C	C	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	A	3200			
reag	T	T	C	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3200		

Fig. 10 cont.

heag1 M T M A G G R R G L V A P Q N T F L E N 20
 heag2 M T M A G G R R G L V A P Q N T F L E N 20
 beag1 M T M A G G R **K** G L V A P Q N T F L E N 20
 beag2 M T M A G G R **K** G L V A P Q N T F L E N 20
 meag M T M A G G R R G L V A P Q N T F L E N 20
 reag M T M A G G R R G L V A P Q N T F L E N 20

heag1 I V R R S N D T N F V L G N A Q I V D W 40
 heag2 I V R R S N D T N F V L G N A Q I V D W 40
 beag1 I V R R S N D T N F V L G N A Q I V D W 40
 beag2 I V R R S N D T N F V L G N A Q I V D W 40
 meag I V R R S N D T N F V L G N A Q I V D W 40
 reag I V R R S N D T N F V L G N A Q I V D W 40

heag1 P I V Y S N D G F C K L S G Y H R A E V 60
 heag2 P I V Y S N D G F C K L S G Y H R A E V 60
 beag1 P I V Y S N D G F C K L S G Y H R A E V 60
 beag2 P I V Y S N D G F C K L S G Y H R A E V 60
 meag P I V Y S N D G F C K L S G Y H R A E V 60
 reag P I V Y S N D G F C K L S G Y H R A E V 60

heag1 M Q K S S T C S F M Y G E L T D K D T I 80
 heag2 M Q K S S T C S F M Y G E L T D K D T I 80
 beag1 M Q K S S T C S F M Y G E L T D K D T I 80
 beag2 M Q K S S T C S F M Y G E L T D K D T I 80
 meag M Q K S S **A** C S F M Y G E L T D K D T **V** 80
 reag M Q K S S **A** C S F M Y G E L T D K D T **V** 80

heag1 E K V R Q T F E N Y E M N S F E I L M Y 100
 heag2 E K V R Q T F E N Y E M N S F E I L M Y 100
 beag1 E K V R Q T F E N Y E M N S F E I L M Y 100
 beag2 E K V R Q T F E N Y E M N S F E I L M Y 100
 meag E K V R Q T F E N Y E M N S F E I L M Y 100
 reag E K V R Q T F E N Y E M N S F E I L M Y 100

Fig. 11

heag1	K K N R T P V W F F V K I A P I R N E Q	120
heag2	K K N R T P V W F F V K I A P I R N E Q	120
beag1	K K N R T P V W F F V K I A P I R N E Q	120
beag2	K K N R T P V W F F V K I A P I R N E Q	120
meag	K K N R T P V W F F V K I A P I R N E Q	120
reag	K K N R T P V W F F V K I A P I R N E Q	120
heag1	D K V V L F L C T F S D I T A F K Q P I	140
heag2	D K V V L F L C T F S D I T A F K Q P I	140
beag1	D K V V L F L C T F S D I T A F K Q P I	140
beag2	D K V V L F L C T F S D I T A F K Q P I	140
meag	D K V V L F L C T F S D I T A F K Q P I	140
reag	D K V V L F L C T F S D I T A F K Q P I	140
heag1	E D D S C K G W G K F A R L T R A L T S	160
heag2	E D D S C K G W G K F A R L T R A L T S	160
beag1	E D D S C K G W G K F A R L T R A L T S	160
beag2	E D D S C K G W G K F A R L T R A L T S	160
meag	E D D S C K G W G K F A R L T R A L T S	160
reag	E D D S C K G W G K F A R L T R A L T S	160
heag1	S R G V L Q Q L A P S V Q K G E N V H K	180
heag2	S R G V L Q Q L A P S V Q K G E N V H K	180
beag1	S R G V L Q Q L A P S V Q K G E N V H K	180
beag2	S R G V L Q Q L A P S V Q K G E N V H K	180
meag	S R G V L Q Q L A P S V Q K G E N V H K	180
reag	S R G V L Q Q L A P S V Q K G E N V H K	180
heag1	H S R L A E V L Q L G S D I L P Q Y K Q	200
heag2	H S R L A E V L Q L G S D I L P Q Y K Q	200
beag1	H S R L A E V L Q L G S D I L P Q Y K Q	200
beag2	H S R L A E V L Q L G S D I L P Q Y K Q	200
meag	H S R L A E V L Q L G S D I L P Q Y K Q	200
reag	H S R L A E V L Q L G S D I L P Q Y K Q	200

Fig. 11 cont.

heag1 E A P K T P P H I I L H Y C V F K T T W 220
 heag2 E A P K T P P H I I L H Y C V F K T T W 220
 beag1 E A P K T P P H I I L H Y C V F K T T W 220
 beag2 E A P K T P P H I I L H Y C V F K T T W 220
 meag E A P K T P P H I I L H Y C V F K T T W 220
 reag E A P K T P P H I I L H Y C V F K T T W 220

heag1 D W I I L I L T F Y T A I L V P Y N V S 240
 heag2 D W I I L I L T F Y T A I L V P Y N V S 240
 beag1 D W I I L I L T F Y T A I L V P Y N V S 240
 beag2 D W I I L I L T F Y T A I L V P Y N V S 240
 meag D W I I L I L T F Y T A I L V P Y N V S 240
 reag D W I I L I L T F Y T A I L V P Y N V S 240

heag1 F K T R Q N N V A W L V V D S I V D V I 260
 heag2 F K T R Q N N V A W L V V D S I V D V I 260
 beag1 F K T R Q N N V A W L V V D S I V D V I 260
 beag2 F K T R Q N N V A W L V V D S I V D V I 260
 meag F K T R Q N N V A W L V V D S I V D V I 260
 reag F K T R Q N N V A W L V V D S I V D V I 260

heag1 F L V D I V L N F H T T F V G P A G E V 280
 heag2 F L V D I V L N F H T T F V G P A G E V 280
 beag1 F L V D I V L N F H T T F V G P A G E V 280
 beag2 F L V D I V L N F H T T F V G P A G E V 280
 meag F L V D I V L N F H T T F V G P A G E V 280
 reag F L V D I V L N F H T T F V G P A G E V 280

heag1 I S D P K L I R M N Y L K T W F V I D L 300
 heag2 I S D P K L I R M N Y L K T W F V I D L 300
 beag1 I S D P K L I R M N Y L K T W F V I D L 300
 beag2 I S D P K L I R M N Y L K T W F V I D L 300
 meag I S D P K L I R M N Y L K T W F V I D L 300
 reag I S D P K L I R M N Y L K T W F V I D L 300

Fig. 11 cont.

heag1	L S C L P Y D V I N A F E N V D E	---	317
heag2	L S C L P Y D V I N A F E N V D E V S A		320
beag1	L S C L P Y D V I N A F E N V D E	---	317
beag2	L S C L P Y D V I N A F E N V D E V S A		320
meag	L S C L P Y D V I N A F E N V D E V S A		320
reag	L S C L P Y D V I N A F E N V D E	---	317
heag1	-----		317
heag2	F M G D P G K I G F A D Q I P P P L E G		340
beag1	-----		317
beag2	F M G D P G K I G F A D Q I P P P L E G		340
meag	F M G D P G K I G F A D Q I P P P L E G		340
reag	-----		317
heag1	---- G I S S L F S S L K V V R L L R		333
heag2	R E S Q G I S S L F S S L K V V R L L R		360
beag1	---- G I S S L F S S L K V V R L L R		333
beag2	R E S Q G I S S L F S S L K V V R L L R		360
meag	R E S Q G I S S L F S S L K V V R L L R		360
reag	---- G I S S L F S S L K V V R L L R		333
heag1	L G R V A R K L D H Y I E Y G A A V L V		353
heag2	L G R V A R K L D H Y I E Y G A A V L V		380
beag1	L G R V A R K L D H Y I E Y G A A V L V		353
beag2	L G R V A R K L D H Y I E Y G A A V L V		380
meag	L G R V A R K L D H Y I E Y G A A V L V		380
reag	L G R V A R K L D H Y I E Y G A A V L V		353
heag1	L L V C V F G L A A H W M A C I W Y S I		373
heag2	L L V C V F G L A A H W M A C I W Y S I		400
beag1	L L V C V F G L A A H W M A C I W Y S I		373
beag2	L L V C V F G L A A H W M A C I W Y S I		400
meag	L L V C V F G L A A H W M A C I W Y S I		400
reag	L L V C V F G L A A H W M A C I W Y S I		373

Fig. 11 cont.

heag1 G D Y E I F D E D T K T I R N N S W L Y 393
 heag2 G D Y E I F D E D T K T I R N N S W L Y 420
 beag1 G D Y E I F D E D T K T I R N N S W L Y 393
 beag2 G D Y E I F D E D T K T I R N N S W L Y 420
 meag G D Y E I F D E D T K T I R N N S W L Y 420
 reag G D Y E I F D E D T K T I R N N S W L Y 393

heag1 Q L A M D I G T P Y Q F N G S G S G K W 413
 heag2 Q L A M D I G T P Y Q F N G S G S G K W 440
 beag1 Q L A M D I G T P Y Q F N G S G S G K W 413
 beag2 Q L A M D I G T P Y Q F N G S G S G K W 440
 meag Q L A **L** D I G T P Y Q F N G S G S G K W 440
 reag Q L A **L** D I G T P Y Q F N G S G S G K W 413

heag1 E G G P S K N S V Y I S S L Y F T M T S 433
 heag2 E G G P S K N S V Y I S S L Y F T M T S 460
 beag1 E G G P S K N S V Y I S S L Y F T M T S 433
 beag2 E G G P S K N S V Y I S S L Y F T M T S 460
 meag E G G P S K N S V Y I S S L Y F T M T S 460
 reag E G G P S K N S V Y I S S L Y F T M T S 433

heag1 L T S V G F G N I A P S T D I E K I F A 453
 heag2 L T S V G F G N I A P S T D I E K I F A 480
 beag1 L T S V G F G N I A P S T D I E K I F A 453
 beag2 L T S V G F G N I A P S T D I E K I F A 480
 meag L T S V G F G N I A P S T D I E K I F A 480
 reag L T S V G F G N I A P S T D I E K I F A 453

heag1 V A I M M I G S L L Y A T I F G N V T T 473
 heag2 V A I M M I G S L L Y A T I F G N V T T 500
 beag1 V A I M M I G S L L Y A T I F G N V T T 473
 beag2 V A I M M I G S L L Y A T I F G N V T T 500
 meag V A I M M I G S L L Y A T I F G N V T T 500
 reag V A I M M I G S L L Y A T I F G N V T T 473

Fig. 11 cont.

heag1 I F Q Q M Y A N T N R Y H E M L N S V R 493
 heag2 I F Q Q M Y A N T N R Y H E M L N S V R 520
 beag1 I F Q Q M Y A N T N R Y H E M L N S V R 493
 beag2 I F Q Q M Y A N T N R Y H E M L N S V R 520
 meag I F Q Q M Y A N T N R Y H E M L N S V R 520
 reag I F Q Q M Y A N T N R Y H E M L N S V R 493

heag1 D F L K L Y Q V P K G L S E R V M D Y I 513
 heag2 D F L K L Y Q V P K G L S E R V M D Y I 540
 beag1 D F L K L Y Q V P K G L S E R V M D Y I 513
 beag2 D F L K L Y Q V P K G L S E R V M D Y I 540
 meag D F L K L Y Q V P K G L S E R V M D Y I 540
 reag D F L K L Y Q V P K G L S E R V M D Y I 513

heag1 V S T W S M S R G I D T E K V L Q I C P 533
 heag2 V S T W S M S R G I D T E K V L Q I C P 560
 beag1 V S T W S M S R G I D T E K V L Q I C P 533
 beag2 V S T W S M S R G I D T E K V L Q I C P 560
 meag V S T W S M S R G I D T E K V L Q I C P 560
 reag V S T W S M S R G I D T E K V L Q I C P 533

heag1 K D M R A D I C V H L N R K V F K E H P 553
 heag2 K D M R A D I C V H L N R K V F K E H P 580
 beag1 K D M R A D I C V H L N R K V F K E H P 553
 beag2 K D M R A D I C V H L N R K V F K E H P 580
 meag K D M R A D I C V H L N R K V F K E H P 580
 reag K D M R A D I C V H L N R K V F K E H P 553

heag1 A F R L A S D G C L R A L A M E F Q T V 573
 heag2 A F R L A S D G C L R A L A M E F Q T V 600
 beag1 A F R L A S D G C L R A L A M E F Q T V 573
 beag2 A F R L A S D G C L R A L A M E F Q T V 600
 meag A F R L A S D G C L R A L A M E F Q T V 600
 reag A F R L A S D G C L R A L A M E F Q T V 573

Fig. 11 cont.

heag1	H C A P G D L I Y H A G E S V D S L C F	593
heag2	H C A P G D L I Y H A G E S V D S L C F	620
beag1	H C A P G D L I Y H A G E S V D S L C F	593
beag2	H C A P G D L I Y H A G E S V D S L C F	620
meag	H C A P G D L I Y H A G E S V D S L C F	620
reag	H C A P G D L I Y H A G E S V D S L C F	593
heag1	V V S G S L E V I Q D D E V V A I L G K	613
heag2	V V S G S L E V I Q D D E V V A I L G K	640
beag1	V V S G S L E V I Q D D E V V A I L G K	613
beag2	V V S G S L E V I Q D D E V V A I L G K	640
meag	V V S G S L E V I Q D D E V V A I L G K	640
reag	V V S G S L E V I Q D D E V V A I L G K	613
heag1	G D V F G D V F W K E A T L A Q S C A N	633
heag2	G D V F G D V F W K E A T L A Q S C A N	660
beag1	G D V F G D V F W K E A T L A Q S C A N	633
beag2	G D V F G D V F W K E A T L A Q S C A N	660
meag	G D V F G D V F W K E A T L A Q S C A N	660
reag	G D V F G D V F W K E A T L A Q S C A N	633
heag1	V R A L T Y C D L H V I K R D A L Q K V	653
heag2	V R A L T Y C D L H V I K R D A L Q K V	680
beag1	V R A L T Y C D L H V I K R D A L Q K V	653
beag2	V R A L T Y C D L H V I K R D A L Q K V	680
meag	V R A L T Y C D L H V I K R D A L Q K V	680
reag	V R A L T Y C D L H V I K R D A L Q K V	653
heag1	L E F Y T A F S H S F S R N L I L T Y N	673
heag2	L E F Y T A F S H S F S R N L I L T Y N	700
beag1	L E F Y T A F S H S F S R N L I L T Y N	673
beag2	L E F Y T A F S H S F S R N L I L T Y N	700
meag	L E F Y T A F S H S F S R N L I L T Y N	700
reag	L E F Y T A F S H S F S R N L I L T Y N	673

Fig. 11 cont.

heag1	L R K R I V F R K I S D V K R E E E E R	693
heag2	L R K R I V F R K I S D V K R E E E E R	720
beag1	L R K R I V F R K I S D V K R E E E E R	693
beag2	L R K R I V F R K I S D V K R E E E E R	720
meag	L R K R I V F R K I S D V K R E E E E R	720
reag	L R K R I V F R K I S D V K R E E E E R	693
heag1	M K R K N E A P L I L P P D H P V R R L	713
heag2	M K R K N E A P L I L P P D H P V R R L	740
beag1	M K R K N E A P L I L P P D H P V R R L	713
beag2	M K R K N E A P L I L P P D H P V R R L	740
meag	M K R K N E A P L I L P P D H P V R R L	740
reag	M K R K N E A P L I L P P D H P V R R L	713
heag1	F Q R F R Q Q K E A R L A A E R G G R D	733
heag2	F Q R F R Q Q K E A R L A A E R G G R D	760
beag1	F Q R F R Q Q K E A R L A A E R G G R D	733
beag2	F Q R F R Q Q K E A R L A A E R G G R D	760
meag	F Q R F R Q Q K E A R L A A E R G G R D	760
reag	F Q R F R Q Q K E A R L A A E R G G R D	733
heag1	L D D L D V E K G N V L T E H A S A N H	753
heag2	L D D L D V E K G N V L T E H A S A N H	780
beag1	L D D L D V E K G S V L T E H - - S H H	751
beag2	L D D L D V E K G S V L T E H - - S H H	778
meag	L D D L D V E K G N A L T D H T S A N H	780
reag	L D D L D V E K G N A L T D H T S A N H	753
heag1	S L V K A S V V T V R E S P A T P V S F	773
heag2	S L V K A S V V T V R E S P A T P V S F	800
beag1	G L A K A S V V T V R E S P A T P V A F	771
beag2	G L A K A S V V T V R E S P A T P V A F	798
meag	S L V K A S V V T V R E S P A T P V S F	800
reag	S L V K A S V V T V R E S P A T P V S F	773

Fig. 11 cont.

heag1	Q	A	A	S	T	S	G	V	P	D	H	A	K	L	Q	A	P	G	S	E	793
heag2	Q	A	A	S	T	S	G	V	P	D	H	A	K	L	Q	A	P	G	S	E	820
beag1	P	A	A	A	A	P	A	G	L	D	H	A	R	L	Q	A	P	G	A	E	791
beag2	P	A	A	A	A	P	A	G	L	D	H	A	R	L	Q	A	P	G	A	E	818
meag	Q	A	A	T	T	S	T	M	S	D	H	A	K	L	H	A	P	G	S	E	820
reag	Q	A	A	S	T	S	T	V	S	D	H	A	K	L	H	A	P	G	S	E	793
heag1	C	L	G	P	K	G	G	G	G	D	C	A	K	R	K	S	W	A	R	F	813
heag2	C	L	G	P	K	G	G	G	G	D	C	A	K	R	K	S	W	A	R	F	840
beag1	G	L	G	P	K	A	G	G	A	D	C	A	K	R	K	G	W	A	R	F	811
beag2	G	L	G	P	K	A	G	G	A	D	C	A	K	R	K	G	W	A	R	F	838
meag	C	L	G	P	K	A	V	S	C	D	P	A	K	R	K	G	W	A	R	F	840
reag	C	L	G	P	K	A	G	G	G	D	P	A	K	R	K	G	W	A	R	F	813
heag1	K	D	A	C	G	K	S	E	D	W	N	K	V	S	K	A	E	S	M	E	833
heag2	K	D	A	C	G	K	S	E	D	W	N	K	V	S	K	A	E	S	M	E	860
beag1	K	D	A	C	G	Q	A	E	D	W	S	K	V	S	K	A	E	S	M	E	831
beag2	K	D	A	C	G	Q	A	E	D	W	S	K	V	S	K	A	E	S	M	E	858
meag	K	D	A	C	G	K	G	E	D	W	N	K	V	S	K	A	E	S	M	E	860
reag	K	D	A	C	G	K	G	E	D	W	N	K	V	S	K	A	E	S	M	E	833
heag1	T	L	P	E	R	T	K	A	S	G	E	A	T	L	K	K	T	D	S	C	853
heag2	T	L	P	E	R	T	K	A	S	G	E	A	T	L	K	K	T	D	S	C	880
beag1	T	L	P	E	R	T	K	A	A	G	E	A	T	L	K	K	T	D	S	C	851
beag2	T	L	P	E	R	T	K	A	A	G	E	A	T	L	K	K	T	D	S	C	878
meag	T	L	P	E	R	T	K	A	P	G	E	A	T	L	K	K	T	D	S	C	880
reag	T	L	P	E	R	T	K	A	S	G	E	A	T	L	K	K	T	D	S	C	853
heag1	D	S	G	I	T	K	S	D	L	R	L	D	N	V	G	E	A	R	S	P	873
heag2	D	S	G	I	T	K	S	D	L	R	L	D	N	V	G	E	A	R	S	P	900
beag1	D	S	G	I	T	K	S	D	L	R	L	D	N	V	G	E	A	R	S	P	871
beag2	D	S	G	I	T	K	S	D	L	R	L	D	N	V	G	E	A	R	S	P	898
meag	D	S	G	I	T	K	S	D	L	R	L	D	N	V	G	E	T	R	S	P	900
reag	D	S	G	I	T	K	S	D	L	R	L	D	N	V	G	E	A	R	S	P	873

Fig. 11 cont.

heag1 Q D R S P I L A E V K H S F Y P I P E Q 893
 heag2 Q D R S P I L A E V K H S F Y P I P E Q 920
 beag1 Q D R S P I L A E V K H S F Y P I P E Q 891
 beag2 Q D R S P I L A E V K H S F Y P I P E Q 918
 meag Q D R S P I L A E V K H S F Y P I P E Q 920
 reag Q D R S P I L A E V K H S F Y P I P E Q 893

heag1 T L Q A T V L E V **R** H E L K E D I K A L 913
 heag2 T L Q A T V L E V **R** H E L K E D I K A L 940
 beag1 T L Q A **A** V L E V K H E L K E D I K A L 911
 beag2 T L Q A **A** V L E V K H E L K E D I K A L 938
 meag T L Q A T V L E V K **Y** E L K E D I K A L 940
 reag T L Q A T V L E V K H E L K E D I K A L 913

heag1 N A K M T **N** I E K Q L S E I L R I L T S 933
 heag2 N A K M T **N** I E K Q L S E I L R I L T S 960
 beag1 **S T** K M T S I E K Q L S E I L R I L T S 931
 beag2 **S T** K M T S I E K Q L S E I L R I L T S 958
 meag N A K M T S I E K Q L S E I L R I L **M** S 960
 reag N A K M T S I E K Q L S E I L R I L **M** S 933

heag1 R R S S Q S P Q E L F E I S R P Q S P E 953
 heag2 R R S S Q S P Q E L F E I S R P Q S P E 980
 beag1 R R S S Q S P Q E L F E I S R P Q S P E 951
 beag2 R R S S Q S P Q E L F E I S R P Q S P E 978
 meag R **G** S **A** Q S P Q E **T G** E I S R P Q S P E 980
 reag R **G** S S Q S P Q **D T C** E **V** S R P Q S P E 953

heag1 S E R D I F G A S 962
 heag2 S E R D I F G A S 989
 beag1 S E R D I F G A S 960
 beag2 S E R D I F G A S 987
 meag S **D** R D I F G A S 989
 reag S **D** R D I F G A S 962

Fig. 11 cont.

31/37




Fig. 12




Fig. 13

DNA	Colonies ≥ 0.1 mm
rEAG-pTracer	9.9 ± 2.4
rEAG-pcDNA3	8.5 ± 3.2
rKv1.4-pTracer	0
rKv1.4-pcDNA3	1.4 ± 0.7
GFP-pcDNA3	0.8 ± 0.5
Transfection buffer	0.6 ± 0.2
No treatment	0

Fig. 14




Fig. 15




Fig. 16




Fig. 17





Fig. 17 cont.




Fig. 18

**DECLARATION AND POWER OF ATTORNEY
FOR PATENT APPLICATION**

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name;

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

NOVEL HUMAN K⁺ ION CHANNEL AND THERAPEUTIC APPLICATIONS THEREOF

the specification of which

(check one) ☒ is attached hereto

☐ was filed on _____ as Application Serial No. _____ and was amended on _____
(if applicable)

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I do not know and do not believe that the invention was ever patented or described in any printed publication in any country before my or our invention thereof or more than one year prior to this application.

I do not know and do not believe that the invention was in public use or on sale in the United States of America more than one year prior to this application.

I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known by me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

EXPRESS MAIL
EK170574511US

Prior Foreign Application(s)

Priority
Claimed

<u>EP 98 10 7268.9</u>	<u>EPO</u>	<u>April 21, 1998</u>	<u>[X]</u>	<u>[]</u>
(Number)	(Country)	(Day/Month/Year Filed)	Yes	No

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or under § 120 and § 365(c) of the same Title to the international application(s) designating the United States listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose to the United States Patent and Trademark Office all information known by me to be material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application:

<u>PCT/EP99/02695</u>	<u>21 April 1999</u>	<u>pending</u>
(Application Serial No.)	(Filing Date)	(Status) (patented, pending, abandoned)

As a named inventor, I hereby appoint the following attorneys or agents to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

<u>Jane A. Massaro (Reg. No. 34,218)</u>
<u>Margaret A. Pierri, (Reg. No. 30,709)</u>
<u>Lisa A. Dixon (Reg. No. 40,995)</u>
<u>Elinor K. Shin, (Reg. No. 43,117)</u>
<u>Karen E. Brown (Reg. No. 43,866)</u>

Send correspondence to: Jane A. Massaro
FISH & NEAVE
1251 Avenue of the Americas
New York, New York 10020-1104

Direct telephone calls to: Jane A. Massaro
(212) 596-9000

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are

punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first joint inventor Luis Angel Pardo-Fernández

First Inventor's signature _____ Date _____

Residence Düstere-Eichen-Weg 14a, 37073, Göttingen, Germany

Citizenship Spanish

Post Office Address Düstere-Eichen-Weg 14a, 37073, Göttingen, Germany

Full name of Second Inventor Walter Stühmer

Second Inventor's signature _____ Date _____

Residence Stiegbreite 13, 37077 Göttingen, Germany

Citizenship German

Post Office Address Stiegbreite 13, 37077 Göttingen, Germany

Full name of Third Inventor Synnöve Beckh

Third Inventor's signature _____ Date _____

Residence Stiegbreite 13, 37077 Göttingen, Germany

Citizenship German

Post Office Address Stiegbreite 13, 37077 Göttingen, Germany

Full name of Fourth Inventor Andrea Brüggemann

Fourth Inventor's signature _____ Date _____

Residence Hoechst-Marion-Roussel, DG, Cardiovascular, H821, 65926, Frankfurt, Germany

Citizenship German

Post Office Address Hoechst-Marion-Roussel, DG, Cardiovascular, H821, 65926, Frankfurt, Germany

Full name of Fifth Inventor Donato Del Camino Fernandez-Miranda

Fifth Inventor's signature _____ Date _____

Residence Neurobiology Department, Harvard Medical School, Boston, MA 02115, USA

Citizenship Spanish

Post Office Address Neurobiology Department, Harvard Medical School, Boston, MA 02115, USA

Full name of Sixth Inventor Araceli Sánchez Pérez

Sixth Inventor's signature _____ Date _____

Residence Düstere-Eichen-Weg 14a, 37073, Göttingen, Germany

Citizenship Spanish

Post Office Address Düstere-Eichen-Weg 14a, 37073, Göttingen, Germany

Full name of Seventh Inventor Rüdiger Weseloh

Seventh Inventor's signature _____ Date _____

Residence Immanuel-Kant-Strasse 32, 37083, Göttingen, Germany

Citizenship German

Post Office Address Immanuel-Kant-Strasse 32, 37083, Göttingen, Germany

SEQUENCE LISTING

<110> Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.

<120> Novel human K⁺ ion channel and therapeutic applications thereof

<130> B1790PCT

<140> PCT/EP99/02695

<141> 1999-04-21

<160> 15

<170> PatentIn Ver. 2.1

<210> 1

<211> 3002

<212> DNA

<213> Homo sapiens

<400> 1

```

aattccgggc cgcgcggacc ccgagctgct gggaggatga ccatggctgg gggcaggagg 60
ggactagtgg cccctcaaaa cactgttctg gagaatattg ttcggcggtc caatgatact 120
aatttttgtgt tggggaatgc tcagatagtg gactggccta ttgtgtacag caatgatgga 180
ttttgcaagc tgtctggcta tcacagggca gaagtgatgc aaaaaagcag cacctgcagt 240
tttatgtatg gggagctgac tgataaaagc acgattgaaa aagtgcggca aacatttgag 300
aactatgaga tgaattcctt tgaaattctg atgtacaaga agaacaggac acctgtgtgg 360
ttcttttgtga aaattgctcc aattcgaaac gaacaggata aagtggtttt atttctttgc 420
actttcagtg acataacagc tttcaaacag ccaattgagg atgattcatg taaaggctgg 480
gggaagtttg ctcggtgac aagagcactg acaagcagca ggggtgtcct gcagcagctg 540
gtccaagcg tgcaaaaagg cgagaatgtc cacaagcact cccgcctggc agaggctcta 600
cagctgggct cagacatcct tcccagtagc aagcaagagg caccaaagac tccccctcac 660
atcatcttac attattgtgt ttttaagacc acgtgggatt ggatcatctt gatcttgacc 720
ttctatacag ccatcttggt cccttataat gtctccttca aaaccaggca gaataatgtg 780
gctggctgg ttgttgatag catcgtggat gttatctttt tgggtggacat tgtgctcaat 840
tttcatacca cctttgttg accagcaggg gaggtgattt ctgaccccaa acttatccgc 900
atgaactacc tgaagacgtg gtttgtgatt gaccttctgt cctgtttgcc atatgatgtc 960
atcaacgctt ttgagaacgt ggatgagggc atcagcagcc tggttcagctc tctaaaagtt 1020
gtccggctgc ttcgtcttgg gcgagtggcc cgtaagctgg accactacat tgaatatgga 1080
gctgctgtgc tggctctgct ggtgtgtgtg tttgggctgg ctgcacactg gatggcctgc 1140
atctggtaca gcattgggga ctatgagatc tttgacgagg acaccaagac aatccgcaac 1200
aacagctggc tgtaccaact agcgatggac attggcacc cttaccagtt taatgggtct 1260
ggctcaggga agtggaagg tggctccagc aagaattctg tctacatctc ctctgtgtat 1320
ttcacaatga ccagcctcac cagtgtgggc tttgggaaca tcgccccatc cacagacatt 1380
gagaagatct ttgcagtggc catcatgatg attggctcac ttctctatgc caccatcttc 1440
gggaatgtga cgactatttt ccaacagatg tatgccaaca ccaacagata ccatgagatg 1500
ctcaacagtg ttcgggactt cctgaagctc taccaggtgc caaaaggatt gagtgaagca 1560
gtaatggatt atattgtgtc cacttggtcc atgtccagag gcattgacac agagaaggtc 1620
ctgcagatct gccccaaagga catgagagcc gacatctgcy tgcacctgaa ccgcaaggty 1680
ttcaaggaga acccgccctt ccgctggc agtgatggct gcctccgggc actggccatg 1740
gagttccaga cgggtgactg tgcccaggg gacctcatct accatgcagg agagagcggt 1800
gacagcctct gottttgtgtt ttctggctcc ctggagggtg tccaagatga tgagggtgtg 1860
gccattctag gaaaaggaga cgtgtttgga gatgtgttct ggaaggaagc cacccttgcc 1920
cagtcctgtg ccaatgttag ggccttgacc tactgtgatc tgcattgat caagcgggat 1980
gcctgcaga aagtgtctga attctacacg gccttctccc attccttctc ccggaacctg 2040
attctgacgt acaacttgag gaagaggatt gtgttccgga agatcagcga tgtgaaacgt 2100
gaagaggaag aacgcataaa acgaaaagaa gaggccccc tgatcttgcc cccggaaccac 2160

```

```

cctgtccggc gcctcttcca gagattccga cagcagaaaaggccaggct ggcagctgag 2220
agagggggcc gggacctgga tgacctagat gtggagaagg gcaatgtcct tacagagcat 2280
gcctccgcc accacagcct cgtgaaggcc agcgtgggtca ccgtgctga gactcctgcc 2340
acgccgtat ccttccaggc agcctccacc tccgggggtgc cagaccacgc aaagctacag 2400
gcgccagggt ccgagtgcct gggccccaag gggggcgggg gcgattgtgc caagcgcaa 2460
agctgggcc gcttcaaaga tgcttgctgg aagagtggagg actggaacaa ggtgtccaag 2520
gctgagtcga tggagacact tcccagagg acaaaagcgt caggcgaggc cacactgaag 2580
aagacagact cgtgtgacag tggcatcacc aagagcgact tgcgcctgga caacgtgggt 2640
gaggccagga tggagtcacc tcggagtcac atcctggcag aggtcaagca ttcgtttctac 2700
cccatccctg agcagacgct gcaggccaca gtcctggagg tgaggcacga gctgaaggag 2760
gacatcaagg ccttaaaccg caaaatgacc aatattgaga aacagctctc tgagatactc 2820
aggatattaa cttccagaag atcctctcag tctcctcagg agttgtttga aatctcgagg 2880
ccacagtccc cagaatcaga gagagacatt tttggagcca gctgagagg ctatttataa 2940
aaaaagtcag agacagatac ctccaacctt gccgtcacca ccaccctac caccgcgaat 3000
tc 3002

```

<210> 2

<211> 3083

<212> DNA

<213> Homo sapiens

<400> 2

```

aattccgggc ccgccggacc ccgagctgct gggaggatga ccatggctgg gggcaggagg 60
ggactagtgg cccctcaaaa cacgtttctg gagaatattg ttcggcggtc caatgatact 120
aatttttgtg tggggaatgc tcagatagtg gactggccta ttgtgtacag caatgatgga 180
ttttgcaagc tgtctggcta tcacagggca gaagtgatgc aaaaaagcag cacctgcagt 240
tttatgtatg gggagctgac tgataaagac acgattgaaa aagtgcggca aacatttgag 300
aactatgaga tgaattcctt tgaaattctg atgtacaaga agaacaggac acctgtgtgg 360
ttcttttgtg aaattgctcc aattcgaaac gaacaggata aagtggtttt atttctttgc 420
actttcagtg acataacagc tttcaaacag ccaattgagg atgattcatg taaaggctgg 480
gggaagtttg ctcggtgac aagagcactg acaagcagca ggggtgtcct gcagcagctg 540
gtccaagcg tgcaaaaagg cgagaatgtc cacaagcact cccgcctggc agaggctcta 600
cagctgggct cagacatcct tcccagtag aagcaagagg caccaaagac tcccctcac 660
atcatcttac attatttgtt ttttaagacc acgtgggatt ggatcatctt gatcttgacc 720
ttctatacag ccatcttggt cccttataat gtctccttca aaaccaggca gaataatgtg 780
gcctggctgg ttgttgatag catcgtggat gttatctttt tgggtggacat tgtgtcaat 840
tttcatacca cctttgttgg accagcaggg gaggtgattt ctgaccccaa acttatccgc 900
atgaactacc tgaagacgtg gtttgtgatt gaccttctgt cctgtttgcc atatgatgtc 960
atcaacgctt ttgagaacgt ggatgaggtt agtgccctta tgggtgatcc agggaagatt 1020
ggttttgtc atcagattcc accaccactg gaggggagag agagtcaggg catcagcagc 1080
ctgttcagct ctctaaaagt tgtccggctg ctccgtcttg ggcgagtggc ccgtaagctg 1140
gaccactaca ttgaatatgg agctgctgtg ctggtcctgc tgggtgtgtg gtttgggctg 1200
gctgcacact ggatggcctg catctggtac agcattgggg actatgagat ctttgacgag 1260
gacaccaaga caatccgcaa caacagctgg ctgtaccaac tagcatgga cattggcacc 1320
ccttaccagt ttaatgggtc tggctcaggg aagtgggaag gtgtcccag caagaattct 1380
gtctacatct cctcgttgta tttcacaatg accagcctca ccagtgtggg ctttgggaac 1440
atcgcccat ccacagacat tgagaagatc tttgcagtgg ccatcatgat gattggctca 1500
cttctctatg ccaccatctt cgggaatgtg acgactatct tccaacagat gtatgccaac 1560
accaacagat accatgagat gctcaacagt gttcgggact tcctgaagct ctaccagggtg 1620
ccaaaaggat tgagtgaagc agtaatggat tatatttgtt ccacttggtc catgtccaga 1680
ggcattgaca cagagaaggc cctgcagatc tcccccaagg acatgagagc cgacatctgc 1740
gtgcacctga accgcaagg gttcaaggag caccggcct tccggctggc cagtgatggc 1800
tgctccggg cactggccat ggagttccag acggtgcact gtgcccagg ggacctcatc 1860
taccatgcag gagagagcgt tgacagcctc tgctttgtgg tttctggctc cctggagggtg 1920
atccaagatg atgaggtggt ggccattcta ggaaaaggag acgtgtttgg agatgtgttc 1980
tggaaggaag ccaccttgc ccagtcctgt gccaatgtta gggccttgac ctactgtgat 2040
ctgcatgtga tcaagcggga tgcctgcag aaagtgtgg aattctacac ggccttctcc 2100
cattccttct cccggaacct gattctgacg tacaacttga ggaagaggat tgtgttccgg 2160

```



```

aagatcagcg atgtgaaacg tgaagaggaa gaacgcatga aacgaaagaa tgaggccccc 2220
ctgatcttgc ccccgaccac ccctgtccgg cgcctcttcc agagattccg acagcagaaa 2280
gaggccaggc tggcagctga gagagggggc cgggacctgg atgacctaga tgtggagaag 2340
ggcaatgtcc ttacagagca tgccctccgc aaccacagcc tcgtgaaggc cagcgtggtc 2400
accgtgcgtg agagtccctg cagcggcgta tccttccagg cagcctccac ctccgggggtg 2460
ccagaccacg caaagctaca ggcgccaggg tccgagtgcc tgggccccaa ggggggaggg 2520
ggcgattgtg ccaagcgcaa aagctggggc cgcttcaaag atgcttgagg gaagagtgag 2580
gactggaaca aggtgtccaa ggctgagtcg atggagacac ttcccgagag gacaaaagcg 2640
tcaggcgagg ccacactgaa gaagacagac tcgtgtgaca gtggcatcac caagagcgac 2700
ttgcgcctgg acaacgtggg tgaggccagg agtccccagg atcggagtc cctcctggca 2760
gagggtcaagc attcgttcta ccccatccct gagcagacgc tgcaggccac agtcctggag 2820
gtgaggcacg agctgaagga ggacatcaag gccttaaacy ccaaaatgac caatattgag 2880
aaacagctct ctgagatact caggatatta acttccagaa gatcctctca gtctcctcag 2940
gagttgtttg aaatatcgag gccacagtcc ccagaatcag agagagacat ttttgaggcc 3000
agctgagagg tctattttaa aaaaaagtca gagacagata cctccaacc tgccgtcacc 3060
accacccta ccaccggaa ttc 3083

```

<210> 3

<211> 962

<212> PRT

<213> Homo sapiens

<400> 3

```

Met Thr Met Ala Gly Gly Arg Arg Gly Leu Val Ala Pro Gln Asn Thr
  1             5             10             15

Phe Leu Glu Asn Ile Val Arg Arg Ser Asn Asp Thr Asn Phe Val Leu
          20             25             30

Gly Asn Ala Gln Ile Val Asp Trp Pro Ile Val Tyr Ser Asn Asp Gly
          35             40             45

Phe Cys Lys Leu Ser Gly Tyr His Arg Ala Glu Val Met Gln Lys Ser
          50             55             60

Ser Thr Cys Ser Phe Met Tyr Gly Glu Leu Thr Asp Lys Asp Thr Ile
          65             70             75             80

Glu Lys Val Arg Gln Thr Phe Glu Asn Tyr Glu Met Asn Ser Phe Glu
          85             90             95

Ile Leu Met Tyr Lys Lys Asn Arg Thr Pro Val Trp Phe Phe Val Lys
          100            105            110

Ile Ala Pro Ile Arg Asn Glu Gln Asp Lys Val Val Leu Phe Leu Cys
          115            120            125

Thr Phe Ser Asp Ile Thr Ala Phe Lys Gln Pro Ile Glu Asp Asp Ser
          130            135            140

Cys Lys Gly Trp Gly Lys Phe Ala Arg Leu Thr Arg Ala Leu Thr Ser
          145            150            155            160

Ser Arg Gly Val Leu Gln Gln Leu Ala Pro Ser Val Gln Lys Gly Glu
          165            170            175

Asn Val His Lys His Ser Arg Leu Ala Glu Val Leu Gln Leu Gly Ser
          180            185            190

```

Asp	Ile	Leu 195	Pro	Gln	Tyr	Lys	Gln 200	Glu	Ala	Pro	Lys	Thr 205	Pro	Pro	His
Ile	Ile 210	Leu	His	Tyr	Cys	Val 215	Phe	Lys	Thr	Thr	Trp 220	Asp	Trp	Ile	Ile
Leu 225	Ile	Leu	Thr	Phe	Tyr 230	Thr	Ala	Ile	Leu	Val 235	Pro	Tyr	Asn	Val	Ser 240
Phe	Lys	Thr	Arg	Gln 245	Asn	Asn	Val	Ala	Trp 250	Leu	Val	Val	Asp	Ser 255	Ile
Val	Asp	Val	Ile 260	Phe	Leu	Val	Asp	Ile 265	Val	Leu	Asn	Phe	His 270	Thr	Thr
Phe	Val	Gly 275	Pro	Ala	Gly	Glu	Val 280	Ile	Ser	Asp	Pro	Lys 285	Leu	Ile	Arg
Met	Asn 290	Tyr	Leu	Lys	Thr	Trp 295	Phe	Val	Ile	Asp	Leu 300	Leu	Ser	Cys	Leu
Pro 305	Tyr	Asp	Val	Ile	Asn 310	Ala	Phe	Glu	Asn	Val 315	Asp	Glu	Gly	Ile	Ser 320
Ser	Leu	Phe	Ser	Ser 325	Leu	Lys	Val	Val	Arg 330	Leu	Leu	Arg	Leu	Gly 335	Arg
Val	Ala	Arg	Lys 340	Leu	Asp	His	Tyr	Ile 345	Glu	Tyr	Gly	Ala 350	Ala	Val	Leu
Val	Leu	Leu 355	Val	Cys	Val	Phe	Gly 360	Leu	Ala	Ala	His	Trp 365	Met	Ala	Cys
Ile	Trp 370	Tyr	Ser	Ile	Gly	Asp 375	Tyr	Glu	Ile	Phe	Asp 380	Glu	Asp	Thr	Lys
Thr 385	Ile	Arg	Asn	Asn 390	Ser	Trp	Leu	Tyr	Gln	Leu 395	Ala	Met	Asp	Ile	Gly 400
Thr	Pro	Tyr	Gln 405	Phe	Asn	Gly	Ser	Gly	Ser 410	Gly	Lys	Trp	Glu	Gly 415	Gly
Pro	Ser	Lys	Asn 420	Ser	Val	Tyr	Ile	Ser 425	Ser	Leu	Tyr	Phe	Thr 430	Met	Thr
Ser	Leu	Thr 435	Ser	Val	Gly	Phe	Gly 440	Asn	Ile	Ala	Pro	Ser 445	Thr	Asp	Ile
Glu	Lys 450	Ile	Phe	Ala	Val	Ala 455	Ile	Met	Met	Ile	Gly 460	Ser	Leu	Leu	Tyr
Ala 465	Thr	Ile	Phe	Gly 470	Asn	Val	Thr	Thr	Ile	Phe 475	Gln	Gln	Met	Tyr	Ala 480
Asn	Thr	Asn	Arg	Tyr 485	His	Glu	Met	Leu	Asn 490	Ser	Val	Arg	Asp	Phe 495	Leu
Lys	Leu	Tyr	Gln 500	Val	Pro	Lys	Gly	Leu 505	Ser	Glu	Arg	Val 510	Met	Asp	Tyr

Ile	Val	Ser	Thr	Trp	Ser	Met	Ser	Arg	Gly	Ile	Asp	Thr	Glu	Lys	Val
		515					520					525			
Leu	Gln	Ile	Cys	Pro	Lys	Asp	Met	Arg	Ala	Asp	Ile	Cys	Val	His	Leu
	530					535					540				
Asn	Arg	Lys	Val	Phe	Lys	Glu	His	Pro	Ala	Phe	Arg	Leu	Ala	Ser	Asp
545					550					555					560
Gly	Cys	Leu	Arg	Ala	Leu	Ala	Met	Glu	Phe	Gln	Thr	Val	His	Cys	Ala
				565					570					575	
Pro	Gly	Asp	Leu	Ile	Tyr	His	Ala	Gly	Glu	Ser	Val	Asp	Ser	Leu	Cys
			580					585					590		
Phe	Val	Val	Ser	Gly	Ser	Leu	Glu	Val	Ile	Gln	Asp	Asp	Glu	Val	Val
		595					600					605			
Ala	Ile	Leu	Gly	Lys	Gly	Asp	Val	Phe	Gly	Asp	Val	Phe	Trp	Lys	Glu
	610					615					620				
Ala	Thr	Leu	Ala	Gln	Ser	Cys	Ala	Asn	Val	Arg	Ala	Leu	Thr	Tyr	Cys
625					630					635					640
Asp	Leu	His	Val	Ile	Lys	Arg	Asp	Ala	Leu	Gln	Lys	Val	Leu	Glu	Phe
				645					650					655	
Tyr	Thr	Ala	Phe	Ser	His	Ser	Phe	Ser	Arg	Asn	Leu	Ile	Leu	Thr	Tyr
			660					665					670		
Asn	Leu	Arg	Lys	Arg	Ile	Val	Phe	Arg	Lys	Ile	Ser	Asp	Val	Lys	Arg
		675					680					685			
Glu	Glu	Glu	Glu	Arg	Met	Lys	Arg	Lys	Asn	Glu	Ala	Pro	Leu	Ile	Leu
	690					695					700				
Pro	Pro	Asp	His	Pro	Val	Arg	Arg	Leu	Phe	Gln	Arg	Phe	Arg	Gln	Gln
705				710					715					720	
Lys	Glu	Ala	Arg	Leu	Ala	Ala	Glu	Arg	Gly	Gly	Arg	Asp	Leu	Asp	Asp
				725					730					735	
Leu	Asp	Val	Glu	Lys	Gly	Asn	Val	Leu	Thr	Glu	His	Ala	Ser	Ala	Asn
			740					745				750			
His	Ser	Leu	Val	Lys	Ala	Ser	Val	Val	Thr	Val	Arg	Glu	Ser	Pro	Ala
		755					760					765			
Thr	Pro	Val	Ser	Phe	Gln	Ala	Ala	Ser	Thr	Ser	Gly	Val	Pro	Asp	His
	770				775						780				
Ala	Lys	Leu	Gln	Ala	Pro	Gly	Ser	Glu	Cys	Leu	Gly	Pro	Lys	Gly	Gly
785					790				795					800	
Gly	Gly	Asp	Cys	Ala	Lys	Arg	Lys	Ser	Trp	Ala	Arg	Phe	Lys	Asp	Ala
				805					810					815	
Cys	Gly	Lys	Ser	Glu	Asp	Trp	Asn	Lys	Val	Ser	Lys	Ala	Glu	Ser	Met
			820				825						830		

Glu Thr Leu Pro Glu Arg Thr Lys Ala Ser Gly Glu Ala Thr Leu Lys
 835 840 845
 Lys Thr Asp Ser Cys Asp Ser Gly Ile Thr Lys Ser Asp Leu Arg Leu
 850 855 860
 Asp Asn Val Gly Glu Ala Arg Ser Pro Gln Asp Arg Ser Pro Ile Leu
 865 870 875 880
 Ala Glu Val Lys His Ser Phe Tyr Pro Ile Pro Glu Gln Thr Leu Gln
 885 890 895
 Ala Thr Val Leu Glu Val Arg His Glu Leu Lys Glu Asp Ile Lys Ala
 900 905 910
 Leu Asn Ala Lys Met Thr Asn Ile Glu Lys Gln Leu Ser Glu Ile Leu
 915 920 925
 Arg Ile Leu Thr Ser Arg Arg Ser Ser Gln Ser Pro Gln Glu Leu Phe
 930 935 940
 Glu Ile Ser Arg Pro Gln Ser Pro Glu Ser Glu Arg Asp Ile Phe Gly
 945 950 955 960
 Ala Ser

<210> 4
 <211> 989
 <212> PRT
 <213> Homo sapiens

<400> 4
 Met Thr Met Ala Gly Gly Arg Arg Gly Leu Val Ala Pro Gln Asn Thr
 1 5 10 15
 Phe Leu Glu Asn Ile Val Arg Arg Ser Asn Asp Thr Asn Phe Val Leu
 20 25 30
 Gly Asn Ala Gln Ile Val Asp Trp Pro Ile Val Tyr Ser Asn Asp Gly
 35 40 45
 Phe Cys Lys Leu Ser Gly Tyr His Arg Ala Glu Val Met Gln Lys Ser
 50 55 60
 Ser Thr Cys Ser Phe Met Tyr Gly Glu Leu Thr Asp Lys Asp Thr Ile
 65 70 75 80
 Glu Lys Val Arg Gln Thr Phe Glu Asn Tyr Glu Met Asn Ser Phe Glu
 85 90 95
 Ile Leu Met Tyr Lys Lys Asn Arg Thr Pro Val Trp Phe Phe Val Lys
 100 105 110
 Ile Ala Pro Ile Arg Asn Glu Gln Asp Lys Val Val Leu Phe Leu Cys
 115 120 125

Thr	Phe	Ser	Asp	Ile	Thr	Ala	Phe	Lys	Gln	Pro	Ile	Glu	Asp	Asp	Ser
130						135					140				
Cys	Lys	Gly	Trp	Gly	Lys	Phe	Ala	Arg	Leu	Thr	Arg	Ala	Leu	Thr	Ser
145					150					155					160
Ser	Arg	Gly	Val	Leu	Gln	Gln	Leu	Ala	Pro	Ser	Val	Gln	Lys	Gly	Glu
				165					170					175	
Asn	Val	His	Lys	His	Ser	Arg	Leu	Ala	Glu	Val	Leu	Gln	Leu	Gly	Ser
			180					185					190		
Asp	Ile	Leu	Pro	Gln	Tyr	Lys	Gln	Glu	Ala	Pro	Lys	Thr	Pro	Pro	His
		195					200					205			
Ile	Ile	Leu	His	Tyr	Cys	Val	Phe	Lys	Thr	Thr	Trp	Asp	Trp	Ile	Ile
210					215						220				
Leu	Ile	Leu	Thr	Phe	Tyr	Thr	Ala	Ile	Leu	Val	Pro	Tyr	Asn	Val	Ser
225					230					235					240
Phe	Lys	Thr	Arg	Gln	Asn	Asn	Val	Ala	Trp	Leu	Val	Val	Asp	Ser	Ile
				245					250					255	
Val	Asp	Val	Ile	Phe	Leu	Val	Asp	Ile	Val	Leu	Asn	Phe	His	Thr	Thr
			260					265					270		
Phe	Val	Gly	Pro	Ala	Gly	Glu	Val	Ile	Ser	Asp	Pro	Lys	Leu	Ile	Arg
		275					280					285			
Met	Asn	Tyr	Leu	Lys	Thr	Trp	Phe	Val	Ile	Asp	Leu	Leu	Ser	Cys	Leu
290						295					300				
Pro	Tyr	Asp	Val	Ile	Asn	Ala	Phe	Glu	Asn	Val	Asp	Glu	Val	Ser	Ala
305					310					315					320
Phe	Met	Gly	Asp	Pro	Gly	Lys	Ile	Gly	Phe	Ala	Asp	Gln	Ile	Pro	Pro
				325					330					335	
Pro	Leu	Glu	Gly	Arg	Glu	Ser	Gln	Gly	Ile	Ser	Ser	Leu	Phe	Ser	Ser
			340					345					350		
Leu	Lys	Val	Val	Arg	Leu	Leu	Arg	Leu	Gly	Arg	Val	Ala	Arg	Lys	Leu
		355					360					365			
Asp	His	Tyr	Ile	Glu	Tyr	Gly	Ala	Ala	Val	Leu	Val	Leu	Leu	Val	Cys
370						375					380				
Val	Phe	Gly	Leu	Ala	Ala	His	Trp	Met	Ala	Cys	Ile	Trp	Tyr	Ser	Ile
385					390					395					400
Gly	Asp	Tyr	Glu	Ile	Phe	Asp	Glu	Asp	Thr	Lys	Thr	Ile	Arg	Asn	Asn
				405					410					415	
Ser	Trp	Leu	Tyr	Gln	Leu	Ala	Met	Asp	Ile	Gly	Thr	Pro	Tyr	Gln	Phe
			420					425					430		
Asn	Gly	Ser	Gly	Ser	Gly	Lys	Trp	Glu	Gly	Gly	Pro	Ser	Lys	Asn	Ser
		435					440					445			

Val Tyr Ile Ser Ser Leu Tyr Phe Thr Met Thr Ser Leu Thr Ser Val
 450 455 460
 Gly Phe Gly Asn Ile Ala Pro Ser Thr Asp Ile Glu Lys Ile Phe Ala
 465 470 475 480
 Val Ala Ile Met Met Ile Gly Ser Leu Leu Tyr Ala Thr Ile Phe Gly
 485 490 495
 Asn Val Thr Thr Ile Phe Gln Gln Met Tyr Ala Asn Thr Asn Arg Tyr
 500 505 510
 His Glu Met Leu Asn Ser Val Arg Asp Phe Leu Lys Leu Tyr Gln Val
 515 520 525
 Pro Lys Gly Leu Ser Glu Arg Val Met Asp Tyr Ile Val Ser Thr Trp
 530 535 540
 Ser Met Ser Arg Gly Ile Asp Thr Glu Lys Val Leu Gln Ile Cys Pro
 545 550 555 560
 Lys Asp Met Arg Ala Asp Ile Cys Val His Leu Asn Arg Lys Val Phe
 565 570 575
 Lys Glu His Pro Ala Phe Arg Leu Ala Ser Asp Gly Cys Leu Arg Ala
 580 585 590
 Leu Ala Met Glu Phe Gln Thr Val His Cys Ala Pro Gly Asp Leu Ile
 595 600 605
 Tyr His Ala Gly Glu Ser Val Asp Ser Leu Cys Phe Val Val Ser Gly
 610 615 620
 Ser Leu Glu Val Ile Gln Asp Asp Glu Val Val Ala Ile Leu Gly Lys
 625 630 635 640
 Gly Asp Val Phe Gly Asp Val Phe Trp Lys Glu Ala Thr Leu Ala Gln
 645 650 655
 Ser Cys Ala Asn Val Arg Ala Leu Thr Tyr Cys Asp Leu His Val Ile
 660 665 670
 Lys Arg Asp Ala Leu Gln Lys Val Leu Glu Phe Tyr Thr Ala Phe Ser
 675 680 685
 His Ser Phe Ser Arg Asn Leu Ile Leu Thr Tyr Asn Leu Arg Lys Arg
 690 695 700
 Ile Val Phe Arg Lys Ile Ser Asp Val Lys Arg Glu Glu Glu Glu Arg
 705 710 715 720
 Met Lys Arg Lys Asn Glu Ala Pro Leu Ile Leu Pro Pro Asp His Pro
 725 730 735
 Val Arg Arg Leu Phe Gln Arg Phe Arg Gln Gln Lys Glu Ala Arg Leu
 740 745 750
 Ala Ala Glu Arg Gly Gly Arg Asp Leu Asp Asp Leu Asp Val Glu Lys
 755 760 765

Gly Asn Val Leu Thr Glu His Ala Ser Ala Asn His Ser Leu Val Lys
 770 775 780
 Ala Ser Val Val Thr Val Arg Glu Ser Pro Ala Thr Pro Val Ser Phe
 785 790 795 800
 Gln Ala Ala Ser Thr Ser Gly Val Pro Asp His Ala Lys Leu Gln Ala
 805 810 815
 Pro Gly Ser Glu Cys Leu Gly Pro Lys Gly Gly Gly Asp Cys Ala
 820 825 830
 Lys Arg Lys Ser Trp Ala Arg Phe Lys Asp Ala Cys Gly Lys Ser Glu
 835 840 845
 Asp Trp Asn Lys Val Ser Lys Ala Glu Ser Met Glu Thr Leu Pro Glu
 850 855 860
 Arg Thr Lys Ala Ser Gly Glu Ala Thr Leu Lys Lys Thr Asp Ser Cys
 865 870 875 880
 Asp Ser Gly Ile Thr Lys Ser Asp Leu Arg Leu Asp Asn Val Gly Glu
 885 890 895
 Ala Arg Ser Pro Gln Asp Arg Ser Pro Ile Leu Ala Glu Val Lys His
 900 905 910
 Ser Phe Tyr Pro Ile Pro Glu Gln Thr Leu Gln Ala Thr Val Leu Glu
 915 920 925
 Val Arg His Glu Leu Lys Glu Asp Ile Lys Ala Leu Asn Ala Lys Met
 930 935 940
 Thr Asn Ile Glu Lys Gln Leu Ser Glu Ile Leu Arg Ile Leu Thr Ser
 945 950 955 960
 Arg Arg Ser Ser Gln Ser Pro Gln Glu Leu Phe Glu Ile Ser Arg Pro
 965 970 975
 Gln Ser Pro Glu Ser Glu Arg Asp Ile Phe Gly Ala Ser
 980 985

<210> 5

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 5

ccaaacacac acaccagc

18

<210> 6

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 6

cgtggatggtt atcttttttg

20

<210> 7

<211> 18

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 7

gggaggatga ccatggct

18

<210> 8

<211> 25

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 8

cagaa(t, c)aa(t, c)gtggc(a, c, t, g) tggct
25

<210> 9

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 9

tcact(g, a)aag atctata(a, g)t c
21

<210> 10

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 10

cgcatgaact acctgaagac g

21

114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 129 130 131 132 133 134 135 136 137 138 139 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202 203 204 205 206 207 208 209 210 211 212 213 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 279 280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 340 341 342 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 388 389 390 391 392 393 394 395 396 397 398 399 400 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 419 420 421 422 423 424 425 426 427 428 429 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485 486 487 488 489 490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 525 526 527 528 529 530 531 532 533 534 535 536 537 538 539 540 541 542 543 544 545 546 547 548 549 550 551 552 553 554 555 556 557 558 559 560 561 562 563 564 565 566 567 568 569 570 571 572 573 574 575 576 577 578 579 580 581 582 583 584 585 586 587 588 589 590 591 592 593 594 595 596 597 598 599 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 621 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638 639 640 641 642 643 644 645 646 647 648 649 650 651 652 653 654 655 656 657 658 659 660 661 662 663 664 665 666 667 668 669 670 671 672 673 674 675 676 677 678 679 680 681 682 683 684 685 686 687 688 689 690 691 692 693 694 695 696 697 698 699 700 701 702 703 704 705 706 707 708 709 710 711 712 713 714 715 716 717 718 719 720 721 722 723 724 725 726 727 728 729 730 731 732 733 734 735 736 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 771 772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 828 829 830 831 832 833 834 835 836 837 838 839 840 841 842 843 844 845 846 847 848 849 850 851 852 853 854 855 856 857 858 859 860 861 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 883 884 885 886 887 888 889 890 891 892 893 894 895 896 897 898 899 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 921 922 923 924 925 926 927 928 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952 953 954 955 956 957 958 959 960 961 962 963 964 965 966 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 987 988 989 990 991 992 993 994 995 996 997 998 999 1000

<210> 11
 <211> 21
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: synthetic

<400> 11
 tctgtggatg gggcgatgtt c 21

<210> 12
 <211> 18
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Description of Artificial Sequence: synthetic

<400> 12
 gggaggatga ccatggct 18

<210> 13
 <211> 2886
 <212> DNA
 <213> Homo sapiens

<400> 13
 atgaccatgg ctggggggcag gagggggacta gtggcccctc aaaacacggt tctggagaat 60
 attgttcggc ggtccaatga tactaatttt gtgttgggga atgctcagat agtggactgg 120
 cctatttgtt acagcaatga tggattttgc aagctgtctg gctatcacag ggcagaagtg 180
 atgcaaaaaa gcagcacctg cagtttttatg tatggggagc tgactgataa agacacgatt 240
 gaaaaagtgc ggcaaacatt tgagaactat gagatgaatt cctttgaaat tctgatgtac 300
 aagaagaaca ggacacctgt gtggttcttt gtgaaaattg ctccaattcg aaacgaacag 360
 gataaagtgg ttttattttct ttgcactttc agtgacataa cagctttcaa acagccaatt 420
 gaggatgatt catgtaaagg ctggggggaag tttgctcggc tgacaagagc actgacaagc 480
 agcaggggtg tcttgacagca gctggctcca agcgtgcaaa aaggcgagaa tgtccacaag 540
 cactcccgcg tggcagaggt cctacagctg ggctcagaca tccttcccca gtacaagcaa 600
 gaggcaccaa agactcccc tcacatcatc ttacattatt gtgtttttaa gaccacgtgg 660
 gattggatca tcttgatctt gaccttctat acagccatct tgggccctta taatgtctcc 720
 ttcaaaacca ggcagaataa tgtggcctgg ctggttggtg atagcatcgt ggatgttatc 780
 tttttggtgg acattgtgct caattttcat accacctttg ttggaccagc aggggaggtg 840
 atttctgacc ccaaacttat ccgcatgaac tacctgaaga cgtggtttgt gattgacctt 900
 ctgtcctggt tgccatatga tgtcatcaac gcttttgaga acgtggatga gggcatcagc 960
 agcctgttca gctctctaaa agttgtccgg ctgctccgtc ttggggcgagt ggcccgtaag 1020
 ctggaccact acattgaata tggagctgct gtgctggtcc tgcctggtgtg tgtgtttggg 1080
 ctggctgcac actggatggc ctgcatctgg tacagcattg gggactatga gatctttgac 1140
 gaggacacca agacaatccg caacaacagc tggctgtacc aactagcgat ggacattggc 1200
 accccttacc agtttaattg gtctggctca gggaagtggg aagggtggtcc cagcaagaat 1260
 tctgtctaca tctcctcggt gtatttcaca atgaccagcc tcaccagtgt gggctttggg 1320
 aacatcgccc catccacaga cattgagaag atctttgcag tggccatcat gatgattggc 1380
 tcacttctct atgccaccat cttcggaat gtgacgacta ttttccaaca gatgtatgcc 1440
 aacaccaaca gataccatga gatgctcaac agtggttcggg acttcctgaa gctctaccag 1500
 gtgccaaaag gattgagtga gcgagtaat gattatattg tgtccacttg gtccatgtcc 1560
 agaggcattg acacagagaa ggtcctgcag atctgcccc aaggacatgag agccgacatc 1620
 tgcgtgcacc tgaaccgcaa ggtgttcaag gagcaccggg ccttccggct ggccagtgat 1680
 ggctgcctcc gggcactggc catggagttc cagacggtgc actgtgcccc aggggacctc 1740

atctaccatg	caggagagag	cgttgacagc	ctctgctttg	tggtttctgg	ctccctggag	1800
gtgatccaag	atgatgaggt	ggtggccatt	ctaggaaaag	gagacgtgtt	tggagatgtg	1860
ttctggaagg	aagccaccct	tgcccagtc	tgtgccaatg	ttagggcctt	gacctactgt	1920
gatctgcatg	tgatcaagcg	ggatgccctg	cagaaagtgc	tggaattcta	cacggccttc	1980
tcccattcct	tctcccggaa	cctgattctg	acgtacaact	tgaggaagag	gattgtgttc	2040
cggaagatca	gcgatgtgaa	acgtgaagag	gaagaacgca	tgaaacgaaa	gaatgaggcc	2100
cccctgatct	tgcccccgga	ccaccctgtc	cggcgctct	tccagagatt	ccgacagcag	2160
aaagaggcca	ggctggcagc	tgagagaggg	ggccgggacc	tggatgacct	agatgtggag	2220
aagggcaatg	tccttacaga	gcattgcctcc	gccaccaca	gcctcgtgaa	ggccagcgtg	2280
gtcaccgtgc	gtgagagtcc	tgccacgccc	gtatccttcc	aggcagcctc	cacctccggg	2340
gtgccagacc	acgcaaagct	acaggcgcca	gggtccgagt	gcctgggccc	caaggggggc	2400
gggggcgatt	gtgccaaagc	caaaagctgg	gcccgcctca	aagatgcttg	cgggaagagt	2460
gaggactgga	acaaggtgtc	caaggctgag	tcgatggaga	cacttcccga	gaggacaaaa	2520
gcgtcaggcg	aggccacact	gaagaagaca	gactcgtgtg	acagtggcat	caccaagcagc	2580
gacttgcgcc	tggaacaagc	gggtgaggcc	aggagtcccc	aggatcgag	tcccatcctg	2640
gcagaggtca	agcattcggt	ctaccccatc	cctgagcaga	cgctgcaggc	cacagtccctg	2700
gaggtgaggc	acgagctgaa	ggaggacatc	aaggccttaa	acgccaaaat	gaccaatatt	2760
gagaaacagc	tctctgagat	actcaggata	taaacttcca	gaagatcctc	tcagtctcct	2820
caggagttgt	ttgaaatata	gaggccacag	tcccagaat	cagagagaga	cattttttgga	2880
gccagc						2886

<210> 14
 <211> 2967
 <212> DNA
 <213> Homo sapiens

<400> 14						
atgaccatgg	ctggggggcag	gaggggacta	gtggcccctc	aaaacacggt	tctggagaat	60
attgttccgc	ggtccaatga	tactaatttt	gtgttgggga	atgctcagat	agtggactgg	120
cctattgtgt	acagcaatga	tggattttgc	aagctgtctg	gctatcacag	ggcagaagtg	180
atgcaaaaaa	gcagcacctg	cagtttttatg	tatggggagc	tgactgataa	agacacgatt	240
gaaaaagtgc	ggcaaacatt	tgagaactat	gagatgaatt	cctttgaaat	tctgatgtac	300
aagaagaaca	ggacacctgt	gtggttcttt	gtgaaaattg	ctccaattcg	aaacgaacag	360
gataaagtgg	ttttatttct	ttgcactttc	agtgcataaa	cagctttcaa	acagccaatt	420
gaggatgatt	catgtaaagg	ctgggggaag	tttgcctggc	tgacaagagc	actgacaagc	480
agcaggggtg	tcctgcagca	gctggctcca	agcgtgcaaa	aaggcgagaa	tgtccacaag	540
cactcccgcc	tggcagaggt	cctacagctg	ggctcagaca	tccttcccc	gtacaagcaa	600
gaggcaccaa	agactcccc	tcacatcatc	ttacattatt	gtgtttttta	gaccacgtgg	660
gattggatca	tcttgatctt	gaccttctat	acagccatct	tggtccctta	taatgtctcc	720
ttcaaaacca	ggcagaataa	tgtggcctgg	ctggttgttg	atagcatcgt	ggatgttatc	780
tttttgggtg	acattgtgct	caattttcat	accacctttg	ttggaccagc	aggggaggtg	840
atctctgacc	ccaaacttat	ccgcatgaac	tacctgaaga	cgtgggtttg	gattgacctt	900
ctgtcctgtt	tgccatatga	tgtcatcaac	gcttttgaga	acgtggatga	ggttagtgcc	960
tttatgggtg	atccagggaa	gattggtttt	gctgatcaga	ttccaccacc	actggagggg	1020
agagagagtc	agggcatcag	cagcctgttc	agctctctaa	aagttgtccg	gctgctccgt	1080
cttggggcag	tggcccgtaa	gctggaccac	tacattgaat	atggagctgc	tgtgctggtc	1140
ctgctggtgt	gtgtgttttg	gctggctgca	cactggatgg	cctgcatctg	gtacagcatt	1200
ggggactatg	agatctttga	cgaggacacc	aagacaatcc	gcaacaacag	ctggctgtac	1260
caactagcga	tggacattgg	caccctttac	cagtttaatg	ggtctggctc	aggggaagtgg	1320
gaaggtggtc	ccagcaagaa	ttctgtctac	atctcctcgt	tgtattttcac	aatgaccagc	1380
ctcaccagtg	tgggcttttg	gaacatcgcc	ccatccacag	acattgagaa	gatcttttga	1440
gtggccatca	tgatgattgg	ctcacttctc	tatgccacca	tcttcgggaa	tgtgacgact	1500
atcttccaac	agatgtatgc	caacaccaac	agataccatg	agatgctcaa	cagtgttcgg	1560
gacttcctga	agcttaccca	ggtgccaaaa	ggattgagtg	agcgagtaat	ggattatatt	1620
gtgtccactt	ggtccatgtc	cagaggcatt	gacacagaga	aggtcctgca	gatctgcccc	1680
aaggacatga	gagccgacat	ctgctgtcac	ctgaaccgca	aggtgttcaa	ggagcaccgc	1740
gccttcgggc	tggccagtg	tggctgcctc	cgggcactgg	ccatggagtt	ccagacgggtg	1800
cactgtgccc	caggggacct	catctaccat	gcaggagaga	gcgttgacag	cctctgcttt	1860

```

gtggttttctg gctccctgga ggtgatccaa gatgatgagg tgggtggccat tctaggaaaa 1920
ggagacgtgt ttggagatgt gttctggaag gaagccaccc ttgcccagtc ctgtgccaat 1980
gttagggcct tgacctactg tgatctgcat gtgatcaagc gggatgccct gcagaaagtg 2040
ctggaattct acacggcctt ctcccattcc ttctcccgga acctgattct gacgtacaac 2100
ttgaggaaga ggattgtgtt ccggaagatc agcgatgtga aacgtgaaga ggaagaacgc 2160
atgaaacgaa agaatgaggc ccccctgatc ttgcccccg accaccctgt ccggcgcctc 2220
ttccagagat tccgacagca gaaagaggcc aggtggcag ctgagagagg gggccgggac 2280
ctggatgacc tagatgtgga gaagggaat gtcttacag agcatgcctc cgccaaccac 2340
agcctcgtga aggccagcgt ggtcaccgtg cgtgagagtc ctgccacgcc cgtatccttc 2400
caggcagcct ccacctccgg ggtgccagac cagcgaagc tacaggcgcc aggtccgag 2460
tgctggggcc ccaagggggg cgggggcat tgtgccaagc gcaaaagctg ggcccgcctc 2520
aaagatgctt gcggaagag tgaggactgg aacaagggtg ccaaggctga gtcgatggag 2580
acacttcccg agaggacaaa agcgtcaggc gaggccacac tgaagaagac agactcgtgt 2640
gacagtggca tcaccaagag cgacttgccg ctggacaacg tgggtgaggc caggagtccc 2700
caggatcgga gtccatcct ggcagagtc aagcattcgt tctaccccat ccctgagcag 2760
acgctgcagg ccacagtcct ggaggtgagg cagcagctga aggaggacat caaggcctta 2820
aacgccaaaa tgaccaatat tgagaaacag ctctctgaga tactcaggat attaaacttc 2880
agaagatcct ctcatgtctc tcaggagtgt tttgaaatat cgaggccaca gtccccagaa 2940
tcagagagag acatttttgg agccagc 2967

```

<210> 15

<211> 19

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: antisense
phosphorothioate ODN

<400> 15

cagccatggg catcctccc